MXPA06007565A - Piperazines useful for treating pain - Google Patents
Piperazines useful for treating painInfo
- Publication number
- MXPA06007565A MXPA06007565A MXPA/A/2006/007565A MXPA06007565A MXPA06007565A MX PA06007565 A MXPA06007565 A MX PA06007565A MX PA06007565 A MXPA06007565 A MX PA06007565A MX PA06007565 A MXPA06007565 A MX PA06007565A
- Authority
- MX
- Mexico
- Prior art keywords
- group
- halo
- another embodiment
- alkyl
- compound
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 54
- 230000036407 pain Effects 0.000 title claims abstract description 46
- 150000004885 piperazines Chemical class 0.000 title 1
- -1 Nitro(cyano)vinylpiperazine Compound Chemical class 0.000 claims abstract description 240
- 150000001875 compounds Chemical class 0.000 claims abstract description 201
- 239000000203 mixture Substances 0.000 claims abstract description 59
- 239000011780 sodium chloride Substances 0.000 claims abstract description 38
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 125000001475 halogen functional group Chemical group 0.000 claims description 231
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 177
- 125000000217 alkyl group Chemical group 0.000 claims description 163
- 229910052799 carbon Inorganic materials 0.000 claims description 125
- 239000003814 drug Substances 0.000 claims description 96
- 125000005843 halogen group Chemical group 0.000 claims description 59
- 201000010099 disease Diseases 0.000 claims description 58
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 54
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 48
- 229940079593 drugs Drugs 0.000 claims description 44
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 43
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 208000002551 Irritable Bowel Syndrome Diseases 0.000 claims description 29
- 206010068760 Ulcers Diseases 0.000 claims description 28
- 231100000397 ulcer Toxicity 0.000 claims description 28
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000006370 trihalo methyl group Chemical group 0.000 claims description 19
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims description 14
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 239000003937 drug carrier Substances 0.000 claims description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 11
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 9
- 125000006375 C2-C10 alkynyl group Chemical group 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 7
- 229910014585 C2-Ce Inorganic materials 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract description 39
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 172
- OTYHQQJKLCPSNV-UHFFFAOYSA-N C(#N)C1N(CCNC1)C=C Chemical compound C(#N)C1N(CCNC1)C=C OTYHQQJKLCPSNV-UHFFFAOYSA-N 0.000 description 121
- 125000004432 carbon atoms Chemical group C* 0.000 description 95
- 210000004027 cells Anatomy 0.000 description 83
- 125000001113 thiadiazolyl group Chemical group 0.000 description 80
- 125000004076 pyridyl group Chemical group 0.000 description 79
- 125000002098 pyridazinyl group Chemical group 0.000 description 76
- 125000000714 pyrimidinyl group Chemical group 0.000 description 76
- 125000003373 pyrazinyl group Chemical group 0.000 description 75
- 241000700159 Rattus Species 0.000 description 57
- UFJAPRDCXLVOTN-UHFFFAOYSA-N 1-ethenyl-2-nitropiperazine-2-carbonitrile Chemical class [O-][N+](=O)C1(C#N)CNCCN1C=C UFJAPRDCXLVOTN-UHFFFAOYSA-N 0.000 description 52
- 230000002401 inhibitory effect Effects 0.000 description 50
- 229910052757 nitrogen Inorganic materials 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 102100006612 GRM5 Human genes 0.000 description 30
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 30
- 239000003795 chemical substances by application Substances 0.000 description 30
- 150000002829 nitrogen Chemical group 0.000 description 30
- 235000002639 sodium chloride Nutrition 0.000 description 30
- 108060008565 TRPV1 Proteins 0.000 description 27
- 239000003112 inhibitor Substances 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 230000003042 antagnostic Effects 0.000 description 26
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 26
- 206010057666 Anxiety disease Diseases 0.000 description 25
- 206010061920 Psychotic disease Diseases 0.000 description 25
- 239000005557 antagonist Substances 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 25
- 239000002253 acid Substances 0.000 description 24
- 125000005872 benzooxazolyl group Chemical group 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- 206010002855 Anxiety Diseases 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 230000002459 sustained Effects 0.000 description 20
- 206010011401 Crohn's disease Diseases 0.000 description 19
- 230000036506 anxiety Effects 0.000 description 19
- 238000004166 bioassay Methods 0.000 description 18
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-MZCSYVLQSA-N cd3od Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 206010012735 Diarrhoea Diseases 0.000 description 15
- 241000282414 Homo sapiens Species 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 206010061536 Parkinson's disease Diseases 0.000 description 14
- 239000000969 carrier Substances 0.000 description 14
- 201000008286 diarrhea Diseases 0.000 description 14
- 150000002828 nitro derivatives Chemical class 0.000 description 13
- 230000001225 therapeutic Effects 0.000 description 13
- 206010015037 Epilepsy Diseases 0.000 description 12
- 208000004454 Hyperalgesia Diseases 0.000 description 12
- 208000007999 Hyperesthesia Diseases 0.000 description 12
- 210000002414 Leg Anatomy 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 208000005374 Poisoning Diseases 0.000 description 12
- 238000001356 surgical procedure Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 206010012218 Delirium Diseases 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 11
- 206010027599 Migraine Diseases 0.000 description 11
- 208000008085 Migraine Disorders Diseases 0.000 description 11
- 208000003715 Parkinsonian Disorders Diseases 0.000 description 11
- 206010034010 Parkinsonism Diseases 0.000 description 11
- 229940083542 Sodium Drugs 0.000 description 11
- 206010047700 Vomiting Diseases 0.000 description 11
- 230000006399 behavior Effects 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 230000001684 chronic Effects 0.000 description 11
- 239000008079 hexane Substances 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000004949 mass spectrometry Methods 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 229910052708 sodium Inorganic materials 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 206010012289 Dementia Diseases 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 10
- 206010038932 Retinopathy Diseases 0.000 description 10
- 206010038923 Retinopathy Diseases 0.000 description 10
- 125000004429 atoms Chemical group 0.000 description 10
- 125000005842 heteroatoms Chemical group 0.000 description 10
- 200000000018 inflammatory disease Diseases 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 229960005181 morphine Drugs 0.000 description 10
- 229930014694 morphine Natural products 0.000 description 10
- 230000002194 synthesizing Effects 0.000 description 10
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 description 9
- 206010057668 Cognitive disease Diseases 0.000 description 9
- 208000004296 Neuralgia Diseases 0.000 description 9
- 208000003251 Pruritus Diseases 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 230000001473 noxious Effects 0.000 description 9
- 230000003364 opioid Effects 0.000 description 9
- 239000000546 pharmaceutic aid Substances 0.000 description 9
- 230000002265 prevention Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- OROGSEYTTFOCAN-DNJOTXNNSA-N Codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 8
- 206010009900 Colitis ulcerative Diseases 0.000 description 8
- 208000001187 Dyskinesias Diseases 0.000 description 8
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapen Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 8
- 231100000601 Intoxication Toxicity 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 210000003932 Urinary Bladder Anatomy 0.000 description 8
- 230000001078 anti-cholinergic Effects 0.000 description 8
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 8
- 229960002870 gabapentin Drugs 0.000 description 8
- 239000000380 hallucinogen Substances 0.000 description 8
- 230000035987 intoxication Effects 0.000 description 8
- 231100000566 intoxication Toxicity 0.000 description 8
- 239000002609 media Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 201000006704 ulcerative colitis Diseases 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 7
- DCRYNQTXGUTACA-UHFFFAOYSA-N 1-ethenylpiperazine Chemical compound C=CN1CCNCC1 DCRYNQTXGUTACA-UHFFFAOYSA-N 0.000 description 7
- 208000004998 Abdominal Pain Diseases 0.000 description 7
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 210000003169 Central Nervous System Anatomy 0.000 description 7
- 206010010774 Constipation Diseases 0.000 description 7
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 7
- 206010019233 Headache Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 206010028334 Muscle spasms Diseases 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 239000012131 assay buffer Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 229960003920 cocaine Drugs 0.000 description 7
- ZPUCINDJVBIVPJ-BARDWOONSA-N cocaine Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 7
- 230000002829 reduced Effects 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000011534 wash buffer Substances 0.000 description 7
- 229940025084 Amphetamine Drugs 0.000 description 6
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 239000007995 HEPES buffer Substances 0.000 description 6
- 208000004547 Hallucinations Diseases 0.000 description 6
- 201000001971 Huntington's disease Diseases 0.000 description 6
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 6
- 206010027175 Memory impairment Diseases 0.000 description 6
- 206010028813 Nausea Diseases 0.000 description 6
- 208000005392 Spasm Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 229960002734 amfetamine Drugs 0.000 description 6
- 150000001412 amines Chemical class 0.000 description 6
- 239000000935 antidepressant agent Substances 0.000 description 6
- 150000001557 benzodiazepines Chemical class 0.000 description 6
- 230000003115 biocidal Effects 0.000 description 6
- 230000003925 brain function Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000002429 large intestine Anatomy 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 231100000486 side effect Toxicity 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 5
- 208000005298 Acute Pain Diseases 0.000 description 5
- YKPUWZUDDOIDPM-SOFGYWHQSA-N Capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 5
- FFGPTBGBLSHEPO-UHFFFAOYSA-N Carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 5
- 206010012239 Delusion Diseases 0.000 description 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N Depacane Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 5
- 206010013654 Drug abuse Diseases 0.000 description 5
- 206010052804 Drug tolerance Diseases 0.000 description 5
- CXOFVDLJLONNDW-UHFFFAOYSA-N Epinat Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 5
- 102100004351 GRM1 Human genes 0.000 description 5
- 206010065390 Inflammatory pain Diseases 0.000 description 5
- PYZRQGJRPPTADH-UHFFFAOYSA-N Lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 5
- 210000003205 Muscles Anatomy 0.000 description 5
- 208000010125 Myocardial Infarction Diseases 0.000 description 5
- DDBREPKUVSBGFI-UHFFFAOYSA-N Phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 5
- 229960002695 Phenobarbital Drugs 0.000 description 5
- 229960002036 Phenytoin Drugs 0.000 description 5
- 210000000278 Spinal Cord Anatomy 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 230000001430 anti-depressive Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000002249 anxiolytic agent Substances 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 235000011148 calcium chloride Nutrition 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 229930003833 capsaicin Natural products 0.000 description 5
- 229960002504 capsaicin Drugs 0.000 description 5
- 235000017663 capsaicin Nutrition 0.000 description 5
- 231100000868 delusion Toxicity 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 230000026781 habituation Effects 0.000 description 5
- 230000003400 hallucinatory Effects 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 229960001848 lamotrigine Drugs 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 230000036961 partial Effects 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 238000002203 pretreatment Methods 0.000 description 5
- 230000002035 prolonged Effects 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 230000001823 pruritic Effects 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 210000001519 tissues Anatomy 0.000 description 5
- 229960000604 valproic acid Drugs 0.000 description 5
- 229940069428 ANTACIDS Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 206010053552 Allodynia Diseases 0.000 description 4
- 229960000836 Amitriptyline Drugs 0.000 description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N Amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 4
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 4
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 4
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 4
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 4
- 210000004556 Brain Anatomy 0.000 description 4
- 241000218236 Cannabis Species 0.000 description 4
- HYPPXZBJBPSRLK-UHFFFAOYSA-N Co-phenotrope Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 4
- 229920002676 Complementary DNA Polymers 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 229960002767 Ethosuximide Drugs 0.000 description 4
- HAPOVYFOVVWLRS-UHFFFAOYSA-N Ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 4
- WKGXYQFOCVYPAC-UHFFFAOYSA-N Felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 4
- 229960002464 Fluoxetine Drugs 0.000 description 4
- 210000002683 Foot Anatomy 0.000 description 4
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 4
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N Haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- BTXNYTINYBABQR-UHFFFAOYSA-N Hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N Imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 4
- 206010022114 Injury Diseases 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 229960001571 Loperamide Drugs 0.000 description 4
- RDOIQAHITMMDAJ-UHFFFAOYSA-N Loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 4
- 210000004379 Membranes Anatomy 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 4
- 229920000272 Oligonucleotide Polymers 0.000 description 4
- DQMZLTXERSFNPB-UHFFFAOYSA-N Primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 210000003497 Sciatic Nerve Anatomy 0.000 description 4
- 229940091252 Sodium supplements Drugs 0.000 description 4
- 210000002784 Stomach Anatomy 0.000 description 4
- MNQYNQBOVCBZIQ-JQOFMKNESA-A Sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 4
- 229960004291 Sucralfate Drugs 0.000 description 4
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 4
- 229960004453 Trimethadione Drugs 0.000 description 4
- IRYJRGCIQBGHIV-UHFFFAOYSA-N Trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000003159 antacid agent Substances 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000001458 anti-acid Effects 0.000 description 4
- 229940019336 antithrombotic Enzymes Drugs 0.000 description 4
- 230000000949 anxiolytic Effects 0.000 description 4
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 4
- 150000001622 bismuth compounds Chemical class 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 229960004126 codeine Drugs 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001143 conditioned Effects 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 201000004624 dermatitis Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229960004192 diphenoxylate Drugs 0.000 description 4
- 235000014632 disordered eating Nutrition 0.000 description 4
- 201000006180 eating disease Diseases 0.000 description 4
- 229960003472 felbamate Drugs 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine group Chemical group NO AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- 229960004801 imipramine Drugs 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 229940079866 intestinal antibiotics Drugs 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108010014719 metabotropic glutamate receptor type 1 Proteins 0.000 description 4
- 210000002569 neurons Anatomy 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 230000003040 nociceptive Effects 0.000 description 4
- 229940121367 non-opioid analgesics Drugs 0.000 description 4
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 4
- 239000003402 opiate agonist Substances 0.000 description 4
- 230000003287 optical Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 230000002085 persistent Effects 0.000 description 4
- 231100000572 poisoning Toxicity 0.000 description 4
- 230000000607 poisoning Effects 0.000 description 4
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229960002393 primidone Drugs 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- 201000000980 schizophrenia Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 201000001880 sexual dysfunction Diseases 0.000 description 4
- 231100000872 sexual dysfunction Toxicity 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000001544 thienyl group Chemical group 0.000 description 4
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3E)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- MAKFMOSBBNKPMS-UHFFFAOYSA-N 2,3-dichloropyridine Chemical compound ClC1=CC=CN=C1Cl MAKFMOSBBNKPMS-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 3
- 206010000269 Abscess Diseases 0.000 description 3
- BZKPWHYZMXOIDC-UHFFFAOYSA-N Acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 3
- 206010003246 Arthritis Diseases 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 3
- 210000004369 Blood Anatomy 0.000 description 3
- OZVBMTJYIDMWIL-AYFBDAFISA-N Bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
- 229960002802 Bromocriptine Drugs 0.000 description 3
- 208000000094 Chronic Pain Diseases 0.000 description 3
- DGBIGWXXNGSACT-UHFFFAOYSA-N Clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 3
- 208000002723 Cocaine-Related Disorders Diseases 0.000 description 3
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 description 3
- 229960001334 Corticosteroids Drugs 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 3
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 3
- 208000002173 Dizziness Diseases 0.000 description 3
- 229960005426 Doxepin Drugs 0.000 description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N Doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 3
- 206010013663 Drug dependence Diseases 0.000 description 3
- 206010013781 Dry mouth Diseases 0.000 description 3
- 229940095399 Enema Drugs 0.000 description 3
- 241000792859 Enema Species 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- 206010016717 Fistula Diseases 0.000 description 3
- WVLOADHCBXTIJK-YNHQPCIGSA-N Hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 3
- 206010061215 Impulse-control disease Diseases 0.000 description 3
- 229960000905 Indomethacin Drugs 0.000 description 3
- 210000000936 Intestines Anatomy 0.000 description 3
- 210000003734 Kidney Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- USSIQXCVUWKGNF-UHFFFAOYSA-N Methadone Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 3
- TTWJBBZEZQICBI-UHFFFAOYSA-N Metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 3
- 208000000060 Migraine with Aura Diseases 0.000 description 3
- 210000003097 Mucus Anatomy 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N Naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 229960002715 Nicotine Drugs 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
- 210000001331 Nose Anatomy 0.000 description 3
- 208000001908 Opioid-Related Disorders Diseases 0.000 description 3
- 239000008896 Opium Substances 0.000 description 3
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycontin Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 3
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 3
- 229960001592 Paclitaxel Drugs 0.000 description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 3
- AQHHHDLHHXJYJD-UHFFFAOYSA-N Proprasylyt Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 3
- 206010037844 Rash Diseases 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 229950006050 Spiromustine Drugs 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229960001940 Sulfasalazine Drugs 0.000 description 3
- 208000001871 Tachycardia Diseases 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 229960000571 acetazolamide Drugs 0.000 description 3
- 229960003692 aminobutyric acid Drugs 0.000 description 3
- 230000000202 analgesic Effects 0.000 description 3
- 239000001961 anticonvulsive agent Substances 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 230000003143 atherosclerotic Effects 0.000 description 3
- 239000003855 balanced salt solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009933 burial Methods 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 229960003120 clonazepam Drugs 0.000 description 3
- 230000003750 conditioning Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 231100000406 dermatitis Toxicity 0.000 description 3
- 229960003914 desipramine Drugs 0.000 description 3
- VPOCYEOOFRNHNL-RQDPQJJXSA-J dexormaplatin Chemical compound Cl[Pt](Cl)(Cl)Cl.N[C@@H]1CCCC[C@H]1N VPOCYEOOFRNHNL-RQDPQJJXSA-J 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000007920 enema Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000003890 fistula Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000002541 furyl group Chemical group 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 239000001963 growth media Substances 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 229960001410 hydromorphone Drugs 0.000 description 3
- 229960001680 ibuprofen Drugs 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000000968 intestinal Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000001786 isothiazolyl group Chemical group 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000000670 limiting Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960001428 mercaptopurine Drugs 0.000 description 3
- 229960001797 methadone Drugs 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 201000008895 mood disease Diseases 0.000 description 3
- 229960002009 naproxen Drugs 0.000 description 3
- 230000002981 neuropathic Effects 0.000 description 3
- 229930015196 nicotine Natural products 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229960001027 opium Drugs 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 229960002085 oxycodone Drugs 0.000 description 3
- 229960005118 oxymorphone Drugs 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N p-acetaminophenol Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229960004618 prednisone Drugs 0.000 description 3
- 229960003712 propranolol Drugs 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000001681 protective Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 125000000168 pyrrolyl group Chemical group 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 150000003457 sulfones Chemical class 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000002522 swelling Effects 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 229930003347 taxol Natural products 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- 230000000699 topical Effects 0.000 description 3
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 description 3
- 125000004306 triazinyl group Chemical group 0.000 description 3
- UIKROCXWUNQSPJ-VIFPVBQESA-N (-)-cotinine Chemical compound C1CC(=O)N(C)[C@@H]1C1=CC=CN=C1 UIKROCXWUNQSPJ-VIFPVBQESA-N 0.000 description 2
- VPAWVRUHMJVRHU-VGDKGRGNSA-N (2R,4R)-N,N-bis(2-chloroethyl)-4-hydroperoxy-2-oxo-1,3,2$l^{5}-oxazaphosphinan-2-amine Chemical compound OO[C@@H]1CCO[P@@](=O)(N(CCCl)CCCl)N1 VPAWVRUHMJVRHU-VGDKGRGNSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 description 2
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8S)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3H-pyrrolo[3,2-e]indole-6-carbonyl]-1H-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 2
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- QNKJFXARIMSDBR-UHFFFAOYSA-N 3-[2-[bis(2-chloroethyl)amino]ethyl]-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound O=C1N(CCN(CCCl)CCCl)C(=O)NC11CCCCC1 QNKJFXARIMSDBR-UHFFFAOYSA-N 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- KDGUIKPOZGYLQJ-UHFFFAOYSA-N 3-phenoxypyridine Chemical compound C=1C=CN=CC=1OC1=CC=CC=C1 KDGUIKPOZGYLQJ-UHFFFAOYSA-N 0.000 description 2
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 2
- NMUSYJAQQFHJEW-ARQDHWQXSA-N 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-ARQDHWQXSA-N 0.000 description 2
- XRZWVSXEDRYQGC-UHFFFAOYSA-N 4-cyclohexylpyrrolidin-1-ium-2-carboxylate Chemical compound C1NC(C(=O)O)CC1C1CCCCC1 XRZWVSXEDRYQGC-UHFFFAOYSA-N 0.000 description 2
- ULGVHUUBIHTFAM-LZYBPNLTSA-N 5-[(2E)-2-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)hydrazinyl]-2-hydroxybenzoic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(O)C(C(O)=O)=C1 ULGVHUUBIHTFAM-LZYBPNLTSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000034451 ATPases Human genes 0.000 description 2
- 108091006096 ATPases Proteins 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 229940022659 Acetaminophen Drugs 0.000 description 2
- 229960004176 Aclarubicin Drugs 0.000 description 2
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 2
- BYRVKDUQDLJUBX-UHFFFAOYSA-N Adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3CC4CC44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-UHFFFAOYSA-N 0.000 description 2
- 206010001605 Alcohol poisoning Diseases 0.000 description 2
- 208000004993 Alcohol-Related Disorders Diseases 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N Alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K Aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229960001280 Amantadine Hydrochloride Drugs 0.000 description 2
- 229960003437 Aminoglutethimide Drugs 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N Aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 206010001954 Amnestic disease Diseases 0.000 description 2
- 229960002519 Amoxapine Drugs 0.000 description 2
- QWGDMFLQWFTERH-UHFFFAOYSA-N Amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 2
- 229960001220 Amsacrine Drugs 0.000 description 2
- XCPGHVQEEXUHNC-UHFFFAOYSA-N Amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 206010059512 Apoptosis Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 210000001130 Astrocytes Anatomy 0.000 description 2
- 229960002170 Azathioprine Drugs 0.000 description 2
- 229950006844 BIZELESIN Drugs 0.000 description 2
- ZREIPSZUJIFJNP-UHFFFAOYSA-K Bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N Bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 229960001058 Bupropion Drugs 0.000 description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N Bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 2
- QWCRAEMEVRGPNT-UHFFFAOYSA-N Buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 2
- BBZDXMBRAFTCAA-AREMUKBSSA-N CARZELESIN Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 2
- FVLVBPDQNARYJU-KYZUINATSA-N CHEMBL1967746 Chemical compound C[C@H]1CC[C@H](NC(=O)N(CCCl)N=O)CC1 FVLVBPDQNARYJU-KYZUINATSA-N 0.000 description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L Calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 2
- OBZHEBDUNPOCJG-WBXJDKIVSA-N Carbenoxolone Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC(O)=O)C1(C)C OBZHEBDUNPOCJG-WBXJDKIVSA-N 0.000 description 2
- 229940052036 Carbidopa / Levodopa Drugs 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N Carbon tetrachloride Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229950007509 Carzelesin Drugs 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N Celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 210000002421 Cell Wall Anatomy 0.000 description 2
- 210000001638 Cerebellum Anatomy 0.000 description 2
- 229960001380 Cimetidine Drugs 0.000 description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N Cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N Citalopram Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- POZRVZJJTULAOH-LHZXLZLDSA-N Danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
- 229960003957 Dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N Diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- RBOXVHNMENFORY-DNJOTXNNSA-N Dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 2
- 208000003164 Diplopia Diseases 0.000 description 2
- 208000001495 Disorganized Schizophrenia Diseases 0.000 description 2
- 208000010309 Disruptive, Impulse Control, and Conduct Disorders Diseases 0.000 description 2
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- FGXWKSZFVQUSTL-UHFFFAOYSA-N Domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 2
- 229950004203 Droloxifene Drugs 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 229960004943 Ergotamine Drugs 0.000 description 2
- OFKDAAIKGIBASY-VFGNJEKYSA-N Ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N Escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N Etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 2
- 229950006566 Etanidazole Drugs 0.000 description 2
- 210000001508 Eye Anatomy 0.000 description 2
- 229950011548 FADROZOLE Drugs 0.000 description 2
- 229950005096 FAZARABINE Drugs 0.000 description 2
- CLPFFLWZZBQMAO-UHFFFAOYSA-N Fadrozole Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N Famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 2
- 229960001596 Famotidine Drugs 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 229960002428 Fentanyl Drugs 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- 229960004038 Fluvoxamine Drugs 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N Gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 208000007565 Gingivitis Diseases 0.000 description 2
- 206010018659 Grand mal convulsion Diseases 0.000 description 2
- 210000002216 Heart Anatomy 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N Hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N Isocarboxazid Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- SIXIIKVOZAGHPV-UHFFFAOYSA-N Lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=C[CH]C2=N1 SIXIIKVOZAGHPV-UHFFFAOYSA-N 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 229960004338 Leuprorelin Drugs 0.000 description 2
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 2
- 229960003406 Levorphanol Drugs 0.000 description 2
- JQSAYKKFZOSZGJ-UHFFFAOYSA-N Lomerizine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 description 2
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 2
- 210000003141 Lower Extremity Anatomy 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- 229950002676 MENOGARIL Drugs 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L Magnesium hydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- WKPWGQKGSOKKOO-RSFHAFMBSA-N Maitansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 2
- QSLMDECMDJKHMQ-GSXCWMCISA-N Maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 2
- 229960003951 Masoprocol Drugs 0.000 description 2
- HCZKYJDFEPMADG-TXEJJXNPSA-N Masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
- HYYBABOKPJLUIN-UHFFFAOYSA-N Mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 2
- LWYJUZBXGAFFLP-OCNCTQISSA-N Menogaril Chemical compound O1[C@@]2(C)[C@H](O)[C@@H](N(C)C)[C@H](O)[C@@H]1OC1=C3C(=O)C(C=C4C[C@@](C)(O)C[C@H](C4=C4O)OC)=C4C(=O)C3=C(O)C=C12 LWYJUZBXGAFFLP-OCNCTQISSA-N 0.000 description 2
- 229940041659 Mephobarbital Drugs 0.000 description 2
- 102000016193 Metabotropic Glutamate Receptors Human genes 0.000 description 2
- 108010010914 Metabotropic Glutamate Receptors Proteins 0.000 description 2
- HRHKSTOGXBBQCB-VFWICMBZSA-N Methylmitomycin Chemical compound O=C1C(N)=C(C)C(=O)C2=C1[C@@H](COC(N)=O)[C@@]1(OC)[C@H]3N(C)[C@H]3CN12 HRHKSTOGXBBQCB-VFWICMBZSA-N 0.000 description 2
- ALARQZQTBTVLJV-UHFFFAOYSA-N Methylphenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)N(C)C1=O ALARQZQTBTVLJV-UHFFFAOYSA-N 0.000 description 2
- KPJZHOPZRAFDTN-ZRGWGRIASA-N Methysergide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 2
- 229960002237 Metoprolol Drugs 0.000 description 2
- IUBSYMUCCVWXPE-UHFFFAOYSA-N Metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 2
- 206010052787 Migraine without aura Diseases 0.000 description 2
- 208000000112 Myalgia Diseases 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N NMDA Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 description 2
- VRBKIVRKKCLPHA-UHFFFAOYSA-N Nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 2
- RGHXWDVNBYKJQH-UHFFFAOYSA-N Nitroacetic acid Chemical compound OC(=O)C[N+]([O-])=O RGHXWDVNBYKJQH-UHFFFAOYSA-N 0.000 description 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N Nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 2
- 229960004872 Nizatidine Drugs 0.000 description 2
- 208000001294 Nociceptive Pain Diseases 0.000 description 2
- 229960001158 Nortriptyline Drugs 0.000 description 2
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 229940005483 OPIOID ANALGESICS Drugs 0.000 description 2
- SBQLYHNEIUGQKH-UHFFFAOYSA-N Omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 2
- 229950008017 Ormaplatin Drugs 0.000 description 2
- 229950009351 Perfosfamide Drugs 0.000 description 2
- 229960004851 Pergolide Drugs 0.000 description 2
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 2
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 2
- 229960000964 Phenelzine Drugs 0.000 description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N Pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N Piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- 210000002381 Plasma Anatomy 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M Potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- VVWYOYDLCMFIEM-UHFFFAOYSA-N Propantheline Chemical compound C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 VVWYOYDLCMFIEM-UHFFFAOYSA-N 0.000 description 2
- BWPIARFWQZKAIA-UHFFFAOYSA-N Protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 2
- VMXUWOKSQNHOCA-LCYFTJDESA-N Ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 2
- 229960000620 Ranitidine Drugs 0.000 description 2
- 229960001534 Risperidone Drugs 0.000 description 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N Risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 2
- QXKJWHWUDVQATH-UHFFFAOYSA-N Rogletimide Chemical compound C=1C=NC=CC=1C1(CC)CCC(=O)NC1=O QXKJWHWUDVQATH-UHFFFAOYSA-N 0.000 description 2
- 229950005230 Rogletimide Drugs 0.000 description 2
- 229950008902 SAFINGOL Drugs 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N Saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 206010039911 Seizure Diseases 0.000 description 2
- 229960002073 Sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N Sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M Sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 210000001032 Spinal Nerves Anatomy 0.000 description 2
- 229960005202 Streptokinase Drugs 0.000 description 2
- 108010023197 Streptokinase Proteins 0.000 description 2
- 229960000894 Sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N Sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 229960003708 Sumatriptan Drugs 0.000 description 2
- GKZARTFJSANTLY-UHFFFAOYSA-N Sumatriptan Chemical compound [CH]1C(CS(=O)(=O)NC)=CC=C2N=CC(CCN(C)C)=C21 GKZARTFJSANTLY-UHFFFAOYSA-N 0.000 description 2
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
- 229960001278 Teniposide Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N Thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- QVMPZNRFXAKISM-UHFFFAOYSA-N Tirapazamine Chemical compound C1=CC=C2[N+]([O-])=NC(=N)N(O)C2=C1 QVMPZNRFXAKISM-UHFFFAOYSA-N 0.000 description 2
- 229950002376 Tirapazamine Drugs 0.000 description 2
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 2
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 2
- UPSPUYADGBWSHF-UHFFFAOYSA-N Tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N Tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- 229960004380 Tramadol Drugs 0.000 description 2
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical compound C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 2
- 229960004479 Trihexyphenidyl Hydrochloride Drugs 0.000 description 2
- 229960004824 Triptorelin Drugs 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- FQCQGOZEWWPOKI-UHFFFAOYSA-K Trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 2
- 206010046736 Urticarias Diseases 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 229960003895 Verteporfin Drugs 0.000 description 2
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N Verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- VBJHPXDIVMXHJU-UHFFFAOYSA-N Zeocin Chemical compound N=1C(C=2SC=C(N=2)C(=O)NCCCCN=C(N)N)CSC=1CCNC(=O)C(C(O)C)NC(=O)C(C)C(O)C(C)NC(=O)C(C(OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1[N]C=NC=1)NC(=O)C1=NC(C(CC(N)=O)NCC(N)C(N)=O)=NC(N)=C1C VBJHPXDIVMXHJU-UHFFFAOYSA-N 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminum Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 230000002429 anti-coagulation Effects 0.000 description 2
- 230000001773 anti-convulsant Effects 0.000 description 2
- 230000001754 anti-pyretic Effects 0.000 description 2
- 239000006067 antibiotic powder Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 239000002282 antimigraine agent Substances 0.000 description 2
- 229940045985 antineoplastic drugs Platinum compounds Drugs 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 239000003420 antiserotonin agent Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000002238 attenuated Effects 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 230000003542 behavioural Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- LKJPYSCBVHEWIU-KRWDZBQOSA-N bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 2
- 229960000997 bicalutamide Drugs 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229960000782 bismuth subsalicylate Drugs 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- RMRJXGBAOAMLHD-CTAPUXPBSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-CTAPUXPBSA-N 0.000 description 2
- 229960002495 buspirone Drugs 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 2
- 229960000530 carbenoxolone Drugs 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 229960004606 clomipramine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000004121 copper complexes of chlorophylls and chlorophyllins Substances 0.000 description 2
- 229960000766 danazol Drugs 0.000 description 2
- 229960003603 decitabine Drugs 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- 229960000920 dihydrocodeine Drugs 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 229960001253 domperidone Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 229950003662 fenretinide Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000002825 functional assay Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 229940005608 hypericin Drugs 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000002757 inflammatory Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 2
- 230000003447 ipsilateral Effects 0.000 description 2
- 229960002672 isocarboxazid Drugs 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 229960003174 lansoprazole Drugs 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 229960004194 lidocaine Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229950007692 lomerizine Drugs 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960004090 maprotiline Drugs 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 229960003803 meclofenamic acid Drugs 0.000 description 2
- 229960003464 mefenamic acid Drugs 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 229960001703 methylphenobarbital Drugs 0.000 description 2
- 229960001186 methysergide Drugs 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L mgso4 Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000003551 muscarinic Effects 0.000 description 2
- 229960005297 nalmefene Drugs 0.000 description 2
- 210000004255 neuroglia Anatomy 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229960004110 olsalazine Drugs 0.000 description 2
- 229960000381 omeprazole Drugs 0.000 description 2
- 230000003204 osmotic Effects 0.000 description 2
- 125000003566 oxetanyl group Chemical group 0.000 description 2
- 229960005434 oxybutynin Drugs 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960003634 pimozide Drugs 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000000770 pro-inflamatory Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002062 proliferating Effects 0.000 description 2
- 229960000697 propantheline Drugs 0.000 description 2
- 229960002601 protriptyline Drugs 0.000 description 2
- 201000004681 psoriasis Diseases 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 230000003134 recirculating Effects 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 229960000953 salsalate Drugs 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- IYETZZCWLLUHIJ-UTONKHPSSA-N selegiline hydrochloride Chemical compound [Cl-].C#CC[NH+](C)[C@H](C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UTONKHPSSA-N 0.000 description 2
- 229960003678 selegiline hydrochloride Drugs 0.000 description 2
- 235000008790 seltzer Nutrition 0.000 description 2
- 229960003440 semustine Drugs 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 231100000197 serious side effect Toxicity 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229960004940 sulpiride Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229960001674 tegafur Drugs 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 229960001017 tolmetin Drugs 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 1
- OPFTUNCRGUEPRZ-QLFBSQMISA-N (-)-β-elemene Chemical compound CC(=C)[C@@H]1CC[C@@](C)(C=C)[C@H](C(C)=C)C1 OPFTUNCRGUEPRZ-QLFBSQMISA-N 0.000 description 1
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- BUSGWUFLNHIBPT-XYBORKQMSA-N (2E,4E,6E)-7-[(1R,5R,6S)-3-[[(2E,4E)-5-cyclohexylpenta-2,4-dienoyl]amino]-5-hydroxy-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-5-yl]hepta-2,4,6-trienoic acid Chemical compound C([C@]([C@H]1O[C@H]1C1=O)(O)/C=C/C=C/C=C/C(=O)O)=C1NC(=O)\C=C\C=C\C1CCCCC1 BUSGWUFLNHIBPT-XYBORKQMSA-N 0.000 description 1
- NOENHWMKHNSHGX-FAZSUBJTSA-N (2R)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-(ca Chemical compound C([C@@H](C(=O)N[C@H](CCCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@H](CCC1)C(=O)NC(C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 NOENHWMKHNSHGX-FAZSUBJTSA-N 0.000 description 1
- FKHUGQZRBPETJR-RXSRXONKSA-N (2R)-2-[[(4R)-4-[[(2S)-2-[[(2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoyl]amino]propanoyl]amino]-5-amino-5-oxopentanoyl]amino]-6-(octadecanoylamino)hexanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCCC[C@H](C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O FKHUGQZRBPETJR-RXSRXONKSA-N 0.000 description 1
- RXWNCPJZOCPEPQ-FNQTVZJVSA-N (2R)-2-amino-N-[(2S,3S,4R,5R)-5-[6-(dimethylamino)purin-9-yl]-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]-3-(4-methoxyphenyl)propanamide Chemical compound C1=CC(OC)=CC=C1C[C@@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-FNQTVZJVSA-N 0.000 description 1
- JOMNTHCQHJPVAZ-RXMQYKEDSA-N (2R)-2-methylpiperazine Chemical compound C[C@@H]1CNCCN1 JOMNTHCQHJPVAZ-RXMQYKEDSA-N 0.000 description 1
- SWTGJCNCBUCXSS-ISUZDFFFSA-N (2R)-3,4-dihydroxy-2-[(4S)-2-phenyl-1,3-dioxolan-4-yl]-2H-furan-5-one Chemical compound OC1=C(O)C(=O)O[C@@H]1[C@H]1OC(C=2C=CC=CC=2)OC1 SWTGJCNCBUCXSS-ISUZDFFFSA-N 0.000 description 1
- RCGXNDQKCXNWLO-YUHQQKLOSA-N (2R)-N-[(2S)-5-amino-1-[[(2R,3S)-1-[[(3S,6Z,9S,12R,15R,18R,19R)-9-benzyl-15-[(2S)-butan-2-yl]-6-ethylidene-19-methyl-2,5,8,11,14,17-hexaoxo-3,12-di(propan-2-yl)-1-oxa-4,7,10,13,16-pentazacyclononadec-18-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopent Chemical compound N([C@@H](CCCN)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]1C(N[C@@H](C(=O)N[C@@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NC(/C(=O)N[C@H](C(=O)O[C@@H]1C)C(C)C)=C\C)C(C)C)[C@@H](C)CC)=O)C(=O)[C@H]1CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CCCC(C)C)C(C)C)[C@@H](C)O)C(C)C)C(C)C RCGXNDQKCXNWLO-YUHQQKLOSA-N 0.000 description 1
- PAYBYKKERMGTSS-MNCSTQPFSA-N (2R,3R,3aS,9aR)-7-fluoro-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydrofuro[1,2][1,3]oxazolo[3,4-a]pyrimidin-3-ol Chemical compound N=C1C(F)=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 PAYBYKKERMGTSS-MNCSTQPFSA-N 0.000 description 1
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2S,3R,4R,5S,6R)-3-amino-4,5-dihydroxy-6-[(1R)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N (2R,3S,4R,5S)-1,6-dibromohexane-2,3,4,5-tetrol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- GJNXBNATEDXMAK-PFLSVRRQSA-N (2S)-1-[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-[bi Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 description 1
- XVOCEQLNJQGCQG-ACRSGXKRSA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl- Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C=CC=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 XVOCEQLNJQGCQG-ACRSGXKRSA-N 0.000 description 1
- CUCSSYAUKKIDJV-FAXBSAIASA-N (2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]-methylamino]-3-phenylpropanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]-4-methylpent Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)N(C)C(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CUCSSYAUKKIDJV-FAXBSAIASA-N 0.000 description 1
- MJINRRBEMOLJAK-DCAQKATOSA-N (2S)-2-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCN=C(N)N MJINRRBEMOLJAK-DCAQKATOSA-N 0.000 description 1
- ZUQBAQVRAURMCL-DOMZBBRYSA-N (2S)-2-[[4-[2-[(6R)-2-amino-4-oxo-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidin-6-yl]ethyl]benzoyl]amino]pentanedioic acid Chemical compound C([C@@H]1CC=2C(=O)N=C(NC=2NC1)N)CC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZUQBAQVRAURMCL-DOMZBBRYSA-N 0.000 description 1
- RUNLLFIZXARADP-FJXQXJEOSA-N (2S)-2-acetamido-4-methylpentanoic acid;2-aminoethanol Chemical compound NCCO.CC(C)C[C@@H](C(O)=O)NC(C)=O RUNLLFIZXARADP-FJXQXJEOSA-N 0.000 description 1
- JRBXPUUAYKCCLQ-QMMMGPOBSA-N (2S)-2-amino-2-[3-hydroxy-4-(hydroxymethyl)phenyl]acetic acid Chemical compound OC(=O)[C@@H](N)C1=CC=C(CO)C(O)=C1 JRBXPUUAYKCCLQ-QMMMGPOBSA-N 0.000 description 1
- RPEPXOHTYVXVMA-CIUDSAMLSA-N (2S)-2-amino-5-[[(2S)-1-[[(1S)-1-carboxy-4-(3H-diazirin-3-yl)-4-oxobutyl]amino]-5-(3H-diazirin-3-yl)-1,5-dioxopentan-2-yl]amino]-5-oxopentanoic acid Chemical compound C([C@H](NC(=O)CC[C@H](N)C(O)=O)C(=O)N[C@@H](CCC(=O)C1N=N1)C(O)=O)CC(=O)C1N=N1 RPEPXOHTYVXVMA-CIUDSAMLSA-N 0.000 description 1
- FVYUQFQCEOZYHZ-CYBMUJFWSA-N (2S)-4-propan-2-yl-2-[3-(trifluoromethyl)phenyl]morpholine Chemical compound C1N(C(C)C)CCO[C@H]1C1=CC=CC(C(F)(F)F)=C1 FVYUQFQCEOZYHZ-CYBMUJFWSA-N 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-( Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- GJKXGJCSJWBJEZ-XRSSZCMZSA-N (2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-5-(diaminomethylideneamino)-1-[(2S)-2-(ethylcarbamoyl)pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CNC2=CC=CC=C12 GJKXGJCSJWBJEZ-XRSSZCMZSA-N 0.000 description 1
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 1
- BEHHCQFBLOARIX-APTPAJQOSA-N (2S,3S)-2-aminooctadecane-1,3-diol;hydrochloride Chemical compound Cl.CCCCCCCCCCCCCCC[C@H](O)[C@@H](N)CO BEHHCQFBLOARIX-APTPAJQOSA-N 0.000 description 1
- HWMMBHOXHRVLCU-QOUANJGESA-N (2S,4S,5S)-4-[(1E,3E,5E)-7-[(2R,6R)-6-[(2R,3S,4aR,12bS)-2,3,4a,8,12b-pentahydroxy-3-methyl-1,7,12-trioxo-2,4-dihydrobenzo[a]anthracen-9-yl]-2-methyloxan-3-yl]oxy-7-oxohepta-1,3,5-trienyl]-2,5-dimethyl-1,3-dioxolane-2-carboxylic acid Chemical compound C[C@@H]1O[C@](C)(C(O)=O)O[C@H]1\C=C\C=C\C=C\C(=O)OC1[C@@H](C)O[C@@H](C=2C(=C3C(=O)C4=C([C@]5(C(=O)[C@H](O)[C@@](C)(O)C[C@@]5(O)C=C4)O)C(=O)C3=CC=2)O)CC1 HWMMBHOXHRVLCU-QOUANJGESA-N 0.000 description 1
- JSUANXYBLFQZGI-HDFWGNLJSA-N (2Z,4S,5R)-N-[4-[(2,3-dihydroxybenzoyl)amino]butyl]-N-[3-[(2,3-dihydroxybenzoyl)amino]propyl]-5-methyl-2-(6-oxocyclohexa-2,4-dien-1-ylidene)-1,3-oxazolidine-4-carboxamide Chemical compound O=C([C@H]1NC(/O[C@@H]1C)=C\1C(C=CC=C/1)=O)N(CCCNC(=O)C=1C(=C(O)C=CC=1)O)CCCCNC(=O)C1=CC=CC(O)=C1O JSUANXYBLFQZGI-HDFWGNLJSA-N 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N (3S)-3-(aminomethyl)-5-methylhexanoic acid Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- VZVRZTZPHOHSCK-YVLHZVERSA-N (3Z)-3-(12H-[1]benzofuro[3,2-c][1]benzoxepin-6-ylidene)-N,N-dimethylpropan-1-amine Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=C1C1=CC=CC=C1O2 VZVRZTZPHOHSCK-YVLHZVERSA-N 0.000 description 1
- UYRMXZIBPZVBNO-QPJJXVBHSA-N (4E)-4-[amino-(hydroxyamino)methylidene]-2-hydroxycyclohexa-2,5-dien-1-one Chemical compound ONC(/N)=C1\C=CC(=O)C(O)=C1 UYRMXZIBPZVBNO-QPJJXVBHSA-N 0.000 description 1
- SWXOGPJRIDTIRL-HFQRKYADSA-N (4R,7S,10S,13S,16S,19R)-10-(4-aminobutyl)-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-19-[[(2R)-2-amino-3-phenylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-pent Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 SWXOGPJRIDTIRL-HFQRKYADSA-N 0.000 description 1
- DRCNRVYVCHHIJP-AQBORDMYSA-N (4S)-4-[[(2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-5-[[(2S)-1-[[(1S)-1-carboxy-2-(4-hydroxyphenyl)ethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DRCNRVYVCHHIJP-AQBORDMYSA-N 0.000 description 1
- JOGKWALAFPNFPR-VURMDHGXSA-N (4Z)-cycloocta-1,4-diene Chemical group [CH]1CC\C=C/CC=C1 JOGKWALAFPNFPR-VURMDHGXSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- WTSKMKRYHATLLL-UHFFFAOYSA-N (6-benzoyloxy-3-cyanopyridin-2-yl) 3-[3-(ethoxymethyl)-5-fluoro-2,6-dioxopyrimidine-1-carbonyl]benzoate Chemical compound O=C1N(COCC)C=C(F)C(=O)N1C(=O)C1=CC=CC(C(=O)OC=2C(=CC=C(OC(=O)C=3C=CC=CC=3)N=2)C#N)=C1 WTSKMKRYHATLLL-UHFFFAOYSA-N 0.000 description 1
- LKBBOPGQDRPCDS-YAOXHJNESA-N (7S,9R,10R)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O([C@H]1C[C@]([C@@H](C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)O)(O)CC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 LKBBOPGQDRPCDS-YAOXHJNESA-N 0.000 description 1
- MWWSFMDVAYGXBV-FGBSZODSSA-N (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydron;chloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-FGBSZODSSA-N 0.000 description 1
- JVHPTYWUBOQMBP-RVFAQHLVSA-N (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride Chemical compound Cl.C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 JVHPTYWUBOQMBP-RVFAQHLVSA-N 0.000 description 1
- VHZXNQKVFDBFIK-NBBHSKLNSA-N (8R,9S,10R,13S,14S,16R)-16-fluoro-10,13-dimethyl-1,2,3,4,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-one Chemical compound C1CCC[C@]2(C)[C@H]3CC[C@](C)(C([C@H](F)C4)=O)[C@@H]4[C@@H]3CC=C21 VHZXNQKVFDBFIK-NBBHSKLNSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8S,11R,13R,14S,17S)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- LDCXGZCEMNMWIL-VOTSOKGWSA-N (E)-3-(3-bromophenyl)-N-ethylprop-2-enamide Chemical compound CCNC(=O)\C=C\C1=CC=CC(Br)=C1 LDCXGZCEMNMWIL-VOTSOKGWSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- OYPPVKRFBIWMSX-SXGWCWSVSA-N (Z)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-3-ylprop-2-en-1-amine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 1
- OJRZEKJECRTBPJ-NGAMADIESA-N (Z,5S)-5-acetamido-1-diazonio-6-hydroxy-6-oxohex-1-en-2-olate Chemical compound CC(=O)N[C@H](C(O)=O)CC\C([O-])=C\[N+]#N OJRZEKJECRTBPJ-NGAMADIESA-N 0.000 description 1
- NXGHEDHQXXXTTP-UHFFFAOYSA-N 1,1-bis(methylsulfanyl)-2-nitroethene Chemical group CSC(SC)=C[N+]([O-])=O NXGHEDHQXXXTTP-UHFFFAOYSA-N 0.000 description 1
- NBEALWAVEGMZQY-UHFFFAOYSA-N 1,1-diphenylprop-2-ynyl N-cyclohexylcarbamate Chemical compound C=1C=CC=CC=1C(C#C)(C=1C=CC=CC=1)OC(=O)NC1CCCCC1 NBEALWAVEGMZQY-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OUPZKGBUJRBPGC-HLTSFMKQSA-N 1,5-bis[[(2R)-oxiran-2-yl]methyl]-3-[[(2S)-oxiran-2-yl]methyl]-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(C[C@H]2OC2)C(=O)N(C[C@H]2OC2)C(=O)N1C[C@H]1CO1 OUPZKGBUJRBPGC-HLTSFMKQSA-N 0.000 description 1
- UOAFGUOASVSLPK-UHFFFAOYSA-N 1-(2-chloroethyl)-3-(2,2-dimethylpropyl)-1-nitrosourea Chemical compound CC(C)(C)CNC(=O)N(N=O)CCCl UOAFGUOASVSLPK-UHFFFAOYSA-N 0.000 description 1
- YQYBWJPESSJLTK-HXFLIBJXSA-N 1-(2-chloroethyl)-3-[(2R,3S,4R,6S)-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]-1-nitrosourea Chemical compound CO[C@@H]1C[C@@H](NC(=O)N(CCCl)N=O)[C@H](O)[C@@H](CO)O1 YQYBWJPESSJLTK-HXFLIBJXSA-N 0.000 description 1
- RCLLNBVPCJDIPX-UHFFFAOYSA-N 1-(2-chloroethyl)-3-[2-(dimethylsulfamoyl)ethyl]-1-nitrosourea Chemical compound CN(C)S(=O)(=O)CCNC(=O)N(N=O)CCCl RCLLNBVPCJDIPX-UHFFFAOYSA-N 0.000 description 1
- BQXQGZPYHWWCEB-UHFFFAOYSA-N 1-(9H-carbazol-4-yloxy)-3-(propan-2-ylamino)propan-2-ol Chemical compound N1C2=CC=CC=C2C2=C1C=CC=C2OCC(O)CNC(C)C BQXQGZPYHWWCEB-UHFFFAOYSA-N 0.000 description 1
- SNYUHPPZINRDSG-UHFFFAOYSA-N 1-(oxiran-2-ylmethyl)-4-[1-(oxiran-2-ylmethyl)piperidin-4-yl]piperidine Chemical compound C1CC(C2CCN(CC3OC3)CC2)CCN1CC1CO1 SNYUHPPZINRDSG-UHFFFAOYSA-N 0.000 description 1
- OZOMQRBLCMDCEG-VIZOYTHASA-N 1-[(E)-[5-(4-nitrophenyl)furan-2-yl]methylideneamino]imidazolidine-2,4-dione Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(O1)=CC=C1\C=N\N1C(=O)NC(=O)C1 OZOMQRBLCMDCEG-VIZOYTHASA-N 0.000 description 1
- OEGDFSLNGABBKJ-UHFFFAOYSA-N 1-[2-[2-(diethylamino)ethoxy]phenyl]-3-phenylpropan-1-one Chemical compound CCN(CC)CCOC1=CC=CC=C1C(=O)CCC1=CC=CC=C1 OEGDFSLNGABBKJ-UHFFFAOYSA-N 0.000 description 1
- PPJVXZVTPWQOQS-UHFFFAOYSA-N 1-ethoxy-1-(1-ethoxyethoxy)ethane Chemical compound CCOC(C)OC(C)OCC PPJVXZVTPWQOQS-UHFFFAOYSA-N 0.000 description 1
- PRNNIHPVNFPWAH-UHFFFAOYSA-N 1-ethylsulfonyl-4-fluorobenzene Chemical compound CCS(=O)(=O)C1=CC=C(F)C=C1 PRNNIHPVNFPWAH-UHFFFAOYSA-N 0.000 description 1
- GPAAEZIXSQCCES-UHFFFAOYSA-N 1-methoxy-2-(2-methoxyethoxymethoxymethoxy)ethane Chemical compound COCCOCOCOCCOC GPAAEZIXSQCCES-UHFFFAOYSA-N 0.000 description 1
- ARARQWKFKMWCDL-UHFFFAOYSA-N 1-nitro-2-[(2-nitrophenyl)methoxymethyl]benzene Chemical compound [O-][N+](=O)C1=CC=CC=C1COCC1=CC=CC=C1[N+]([O-])=O ARARQWKFKMWCDL-UHFFFAOYSA-N 0.000 description 1
- CTRLABGOLIVAIY-UHFFFAOYSA-N 10-oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N 103890-78-4 Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- JCBQCKFFSPGEDY-UHFFFAOYSA-N 11-(1-azabicyclo[2.2.2]octan-3-yl)-5,6-dihydrobenzo[b][1]benzazepine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1C(C1)C2CCN1CC2 JCBQCKFFSPGEDY-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1H-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- PJYYBCXMCWDUAZ-JJJZTNILSA-N 2,3,14,20,22-pentahydroxy-(2β,3β,5β,22R)-Cholest-7-en-6-one Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 PJYYBCXMCWDUAZ-JJJZTNILSA-N 0.000 description 1
- ATPQHBQUXWELOE-UHFFFAOYSA-M 2,4-dinitro-1-sulfenatobenzene Chemical compound [O-]SC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O ATPQHBQUXWELOE-UHFFFAOYSA-M 0.000 description 1
- KLIVRBFRQSOGQI-UHFFFAOYSA-N 2-(11-oxo-6H-benzo[c][1]benzothiepin-3-yl)acetic acid Chemical compound S1CC2=CC=CC=C2C(=O)C2=CC=C(CC(=O)O)C=C12 KLIVRBFRQSOGQI-UHFFFAOYSA-N 0.000 description 1
- 125000006475 2-(3-bromopyridyl) group Chemical group [H]C1=C([H])C([H])=C(Br)C(*)=N1 0.000 description 1
- 125000006397 2-(3-chloropyrazinyl) group Chemical group [H]C1=C([H])N=C(*)C(Cl)=N1 0.000 description 1
- 125000006382 2-(3-chloropyridyl) group Chemical group [H]C1=C([H])C([H])=C(Cl)C(*)=N1 0.000 description 1
- 125000006476 2-(3-fluoropyridyl) group Chemical group [H]C1=C([H])C([H])=C(F)C(*)=N1 0.000 description 1
- 125000006385 2-(3-methylpyridyl) group Chemical group [H]C1=C([H])C([H])=C(C(*)=N1)C([H])([H])[H] 0.000 description 1
- 125000006388 2-(3-trifluoromethyl-pyridyl) group Chemical group [H]C1=C([H])C([H])=C(C(*)=N1)C(F)(F)F 0.000 description 1
- SNJDSTGQYRTZJT-UHFFFAOYSA-N 2-(4-chlorophenyl)-4-methylpentane-2,4-diol Chemical compound CC(C)(O)CC(C)(O)C1=CC=C(Cl)C=C1 SNJDSTGQYRTZJT-UHFFFAOYSA-N 0.000 description 1
- HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical compound O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
- ARUGKOZUKWAXDS-SEWALLKFSA-N 2-[(2E)-2-[(3aS,4S,5R,6aS)-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]ethoxy]acetic acid Chemical compound C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 description 1
- JUNILAWHCDMYAE-HGJPKUQDSA-N 2-[(3E,7E,9E,17E)-14,19-dihydroxy-3,5,9,11,13,15,17-heptamethyl-12-oxononadeca-3,7,9,17-tetraenyl]-2,3-dihydropyran-6-one Chemical compound OC/C=C(C)/CC(C)C(O)C(C)C(=O)C(C)/C=C(\C)/C=C/CC(C)\C=C(/C)CCC1CC=CC(=O)O1 JUNILAWHCDMYAE-HGJPKUQDSA-N 0.000 description 1
- DCXHLPGLBYHNMU-UHFFFAOYSA-N 2-[1-(4-azidobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(N=[N+]=[N-])C=C1 DCXHLPGLBYHNMU-UHFFFAOYSA-N 0.000 description 1
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 description 1
- ZTHJULTYCAQOIJ-KSBRXOFISA-N 2-[2-(4-benzo[b][1,4]benzothiazepin-6-ylpiperazin-1-yl)ethoxy]ethanol;(Z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-KSBRXOFISA-N 0.000 description 1
- XXVLKDRPHSFIIB-UHFFFAOYSA-N 2-[2-(dimethylamino)ethyl]-5-nitrobenzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N(CCN(C)C)C2=O)=O)=C3C2=CC=CC3=C1 XXVLKDRPHSFIIB-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- JIEKMACRVQTPRC-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid Chemical compound OC(=O)CC=1SC(C=2C=CC=CC=2)=NC=1C1=CC=C(Cl)C=C1 JIEKMACRVQTPRC-UHFFFAOYSA-N 0.000 description 1
- PXJJOGITBQXZEQ-JTHROIFXSA-M 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]ethyl-trimethylazanium;iodide Chemical compound [I-].C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCC[N+](C)(C)C)=CC=1)/C1=CC=CC=C1 PXJJOGITBQXZEQ-JTHROIFXSA-M 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N 2-[[2-[bis(2-hydroxyethyl)amino]-4-piperidin-1-ylpyrimido[5,4-d]pyrimidin-6-yl]-(2-hydroxyethyl)amino]ethanol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- XKSAJZSJKURQRX-UHFFFAOYSA-N 2-acetyloxy-5-(4-fluorophenyl)benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1C1=CC=C(F)C=C1 XKSAJZSJKURQRX-UHFFFAOYSA-N 0.000 description 1
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-N-[(3S,6S,7R,10S,16S)-3-[(2S)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-N-[(3S,6S,7R,10S,16S)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 1
- VDCRFBBZFHHYGT-IOSLPCCCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-enyl-3H-purine-6,8-dione Chemical compound O=C1N(CC=C)C=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VDCRFBBZFHHYGT-IOSLPCCCSA-N 0.000 description 1
- NIXVOFULDIFBLB-QVRNUERCSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purine-6-sulfinamide Chemical compound C12=NC(N)=NC(S(N)=O)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NIXVOFULDIFBLB-QVRNUERCSA-N 0.000 description 1
- GEQZTCMVWVDEDF-UHFFFAOYSA-N 2-cyanoacetyl chloride Chemical group ClC(=O)CC#N GEQZTCMVWVDEDF-UHFFFAOYSA-N 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- SGUAFYQXFOLMHL-ACJLOTCBSA-N 2-hydroxy-5-[(1R)-1-hydroxy-2-[[(2R)-4-phenylbutan-2-yl]amino]ethyl]benzamide Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(C(O)=CC=1)C(N)=O)CC1=CC=CC=C1 SGUAFYQXFOLMHL-ACJLOTCBSA-N 0.000 description 1
- YFLRYAVDPKONNX-UHFFFAOYSA-N 2-hydroxyethyl N-benzylcarbamate Chemical compound OCCOC(=O)NCC1=CC=CC=C1 YFLRYAVDPKONNX-UHFFFAOYSA-N 0.000 description 1
- MGOLNIXAPIAKFM-UHFFFAOYSA-N 2-isocyanato-2-methylpropane Chemical compound CC(C)(C)N=C=O MGOLNIXAPIAKFM-UHFFFAOYSA-N 0.000 description 1
- DTCYSRAEJHGSNY-UHFFFAOYSA-N 2-methoxy-2-(2-methoxypropan-2-yloxy)propane Chemical compound COC(C)(C)OC(C)(C)OC DTCYSRAEJHGSNY-UHFFFAOYSA-N 0.000 description 1
- BGNUMADLMZQLCF-UHFFFAOYSA-N 2-methoxy-2-(2-methoxythian-2-yl)oxythiane Chemical compound C1CCCSC1(OC)OC1(OC)CCCCS1 BGNUMADLMZQLCF-UHFFFAOYSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N 2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenol Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- YNZQOVYRCBAMEU-UHFFFAOYSA-N 3,4-dichloro-1,2,5-thiadiazole Chemical compound ClC1=NSN=C1Cl YNZQOVYRCBAMEU-UHFFFAOYSA-N 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical group O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- SADQVAVFGNTEOD-UHFFFAOYSA-N 3-(2-piperidin-4-ylethyl)-1H-indole Chemical compound C=1NC2=CC=CC=C2C=1CCC1CCNCC1 SADQVAVFGNTEOD-UHFFFAOYSA-N 0.000 description 1
- 125000006403 3-(4-chloropyridazinyl) group Chemical group [H]C1=C([H])C(Cl)=C(*)N=N1 0.000 description 1
- QZIQORUGXBPDSU-UHFFFAOYSA-N 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine oxide Chemical compound C1CC2=CC=CC=C2N(CCC[N+](C)([O-])C)C2=CC=CC=C21 QZIQORUGXBPDSU-UHFFFAOYSA-N 0.000 description 1
- GRLUHXSUZYFZCW-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-N,N-dimethylpropan-1-amine;dihydrochloride Chemical compound Cl.Cl.C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 GRLUHXSUZYFZCW-UHFFFAOYSA-N 0.000 description 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-M 3-[[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]propanoate Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GHOKWGTUZJEAQD-ZETCQYMHSA-M 0.000 description 1
- WUIABRMSWOKTOF-PATWWPTKSA-N 3-[[2-[2-[2-[[(2R,3R)-2-[[(2R,3R,4S)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2R)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2S,3R,4R,5R,6R)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan- Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@@H](C)[C@H](O)[C@@H](C)C(=O)N[C@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)C(O[C@@H]1[C@@H]([C@H](O)[C@@H](O)[C@@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-PATWWPTKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- JUIHCCIFJCSFON-UHFFFAOYSA-N 3-chloro-4-(2,5-dioxo-3-phenylpyrrolidin-1-yl)benzenesulfonamide Chemical compound ClC1=CC(S(=O)(=O)N)=CC=C1N1C(=O)C(C=2C=CC=CC=2)CC1=O JUIHCCIFJCSFON-UHFFFAOYSA-N 0.000 description 1
- XSCKKKKCZBNKQZ-UHFFFAOYSA-N 3-chloroquinoxaline-2-sulfonamide Chemical compound C1=CC=C2N=C(Cl)C(S(=O)(=O)N)=NC2=C1 XSCKKKKCZBNKQZ-UHFFFAOYSA-N 0.000 description 1
- GQWNECFJGBQMBO-UHFFFAOYSA-N 3-ethyl-2-methyl-5-(morpholin-4-ium-4-ylmethyl)-1,5,6,7-tetrahydroindol-4-one;chloride Chemical compound Cl.O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 GQWNECFJGBQMBO-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- FAIIFDPAEUKBEP-UHFFFAOYSA-N 3-methyl 5-propan-2-yl 2-cyano-6-methyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C#N)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 FAIIFDPAEUKBEP-UHFFFAOYSA-N 0.000 description 1
- FAYMRSZJXWFWRS-UHFFFAOYSA-N 3-methyl-5-phenylimidazolidine-2,4-dione Chemical compound O=C1N(C)C(=O)NC1C1=CC=CC=C1 FAYMRSZJXWFWRS-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ATVJXMYDOSMEPO-UHFFFAOYSA-N 3-prop-2-enoxyprop-1-ene Chemical compound C=CCOCC=C ATVJXMYDOSMEPO-UHFFFAOYSA-N 0.000 description 1
- PDQGEKGUTOTUNV-TZSSRYMLSA-N 4'-deoxy-4'-iododoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](I)[C@H](C)O1 PDQGEKGUTOTUNV-TZSSRYMLSA-N 0.000 description 1
- LIETVYHJBSLSSW-UHFFFAOYSA-N 4,6,9-trihydroxy-8-methyl-3,4-dihydro-2H-anthracen-1-one Chemical compound OC1CCC(=O)C2=C1C=C1C=C(O)C=C(C)C1=C2O LIETVYHJBSLSSW-UHFFFAOYSA-N 0.000 description 1
- 125000006391 4-(5-chloropyrimidinyl) group Chemical group ClC1=CN=CN=C1* 0.000 description 1
- 125000006394 4-(5-methylpyrimidinyl) group Chemical group [H]C([H])([H])C1=CN=CN=C1* 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-Aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- RJYQLMILDVERHH-UHFFFAOYSA-N 4-Ipomeanol Chemical compound CC(O)CCC(=O)C=1C=COC=1 RJYQLMILDVERHH-UHFFFAOYSA-N 0.000 description 1
- HQFSNUYUXXPVKL-UHFFFAOYSA-N 4-[(4-fluorophenyl)methyl]-2-[1-(2-phenylethyl)azepan-4-yl]phthalazin-1-one Chemical compound C1=CC(F)=CC=C1CC(C1=CC=CC=C1C1=O)=NN1C1CCN(CCC=2C=CC=CC=2)CCC1 HQFSNUYUXXPVKL-UHFFFAOYSA-N 0.000 description 1
- OUQPTBCOEKUHBH-LSDHQDQOSA-N 4-[2-[4-[(E)-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)prop-1-enyl]phenoxy]ethyl]morpholine Chemical compound C=1C=C(C(CCC2(C)C)(C)C)C2=CC=1C(/C)=C/C(C=C1)=CC=C1OCCN1CCOCC1 OUQPTBCOEKUHBH-LSDHQDQOSA-N 0.000 description 1
- VAZAPHZUAVEOMC-UHFFFAOYSA-N 4-acetamido-N-(2-aminophenyl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 description 1
- QRQMZZNDJGHPHZ-UHFFFAOYSA-N 4-amino-2-methoxy-5-(methylsulfamoyl)-N-[(1-prop-2-enylpyrrolidin-2-yl)methyl]benzamide Chemical compound C1=C(N)C(S(=O)(=O)NC)=CC(C(=O)NCC2N(CCC2)CC=C)=C1OC QRQMZZNDJGHPHZ-UHFFFAOYSA-N 0.000 description 1
- REYUZOLYIOQRIG-UHFFFAOYSA-N 4-decoxy-3,5-dimethoxybenzamide Chemical compound CCCCCCCCCCOC1=C(OC)C=C(C(N)=O)C=C1OC REYUZOLYIOQRIG-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-N-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- WRDWWAVNELMWAM-UHFFFAOYSA-N 4-tert-butylaniline Chemical compound CC(C)(C)C1=CC=C(N)C=C1 WRDWWAVNELMWAM-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- NSUDGNLOXMLAEB-UHFFFAOYSA-N 5-(2-formyl-3-hydroxyphenoxy)pentanoic acid Chemical compound OC(=O)CCCCOC1=CC=CC(O)=C1C=O NSUDGNLOXMLAEB-UHFFFAOYSA-N 0.000 description 1
- RATGSRSDPNECNO-UHFFFAOYSA-N 5-(2-methylpropyl)-3-prop-2-enyl-2-sulfanylideneimidazolidin-4-one Chemical compound CC(C)CC1NC(=S)N(CC=C)C1=O RATGSRSDPNECNO-UHFFFAOYSA-N 0.000 description 1
- PXLPCZJACKUXGP-UHFFFAOYSA-N 5-(3,4-dichlorophenyl)-6-ethylpyrimidine-2,4-diamine Chemical compound CCC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 PXLPCZJACKUXGP-UHFFFAOYSA-N 0.000 description 1
- 229940000681 5-Hydroxytryptophan Drugs 0.000 description 1
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2R)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
- KQPKPCNLIDLUMF-MRVPVSSYSA-N 5-[(2R)-pentan-2-yl]-5-prop-2-enyl-1,3-diazinane-2,4,6-trione Chemical compound CCC[C@@H](C)C1(CC=C)C(=O)NC(=O)NC1=O KQPKPCNLIDLUMF-MRVPVSSYSA-N 0.000 description 1
- APNRZHLOPQFNMR-WEIUTZTHSA-N 5-[(E)-5-[(1S)-2,2-dimethyl-6-methylidenecyclohexyl]-3-methylpent-2-enyl]phenazin-1-one Chemical compound C12=CC=CC=C2N=C(C(C=CC=2)=O)C=2N1C\C=C(/C)CC[C@@H]1C(=C)CCCC1(C)C APNRZHLOPQFNMR-WEIUTZTHSA-N 0.000 description 1
- NEGMMKYAVYNLCG-UHFFFAOYSA-N 5-ethyl-1-methyl-5-phenylimidazolidine-2,4-dione Chemical compound C=1C=CC=CC=1C1(CC)N(C)C(=O)NC1=O NEGMMKYAVYNLCG-UHFFFAOYSA-N 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N 5-ethynyl-1H-pyrimidine-2,4-dione Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- ANERHPOLUMFRDC-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-bismabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Bi+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ANERHPOLUMFRDC-UHFFFAOYSA-K 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan zwitterion Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- ZCJXQWYMBJYJNB-LRDBBFHQSA-N 5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline-2,4-diamine;(2S,3S,4S,5R)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O.COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 ZCJXQWYMBJYJNB-LRDBBFHQSA-N 0.000 description 1
- PXBZKHOQHTVCSQ-QZTJIDSGSA-N 5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound [O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 PXBZKHOQHTVCSQ-QZTJIDSGSA-N 0.000 description 1
- UGSLDMJXBQKDCT-UHFFFAOYSA-N 5-oxo-N-(2-phenylcyclopropyl)pyrrolidine-2-carboxamide Chemical compound C1CC(=O)NC1C(=O)NC1CC1C1=CC=CC=C1 UGSLDMJXBQKDCT-UHFFFAOYSA-N 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N 52468-60-7 Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- ATCGGEJZONJOCL-UHFFFAOYSA-N 6-(2,5-dichlorophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC(N)=NC(C=2C(=CC=C(Cl)C=2)Cl)=N1 ATCGGEJZONJOCL-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N 6-(3-methyl-5-nitroimidazol-4-yl)sulfanyl-7H-purin-2-amine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- QIRAYNIFEOXSPW-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-ol Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(O)CC)C1=CC=CC=C1 QIRAYNIFEOXSPW-UHFFFAOYSA-N 0.000 description 1
- OTSZCHORPMQCBZ-UHFFFAOYSA-N 6-[(3-chlorophenyl)-imidazol-1-ylmethyl]-1H-benzimidazole;hydron;chloride Chemical compound Cl.ClC1=CC=CC(C(C=2C=C3NC=NC3=CC=2)N2C=NC=C2)=C1 OTSZCHORPMQCBZ-UHFFFAOYSA-N 0.000 description 1
- LRHPCRBOMKRVOA-UHFFFAOYSA-N 6-[2-(2-hydroxyethylamino)ethyl]indeno[1,2-c]isoquinoline-5,11-dione Chemical compound C12=CC=CC=C2C(=O)N(CCNCCO)C2=C1C(=O)C1=CC=CC=C12 LRHPCRBOMKRVOA-UHFFFAOYSA-N 0.000 description 1
- YFLBETLXDPBWTD-UHFFFAOYSA-N 6-[2-(dimethylamino)propyl]-11H-pyrido[3,2-c][1,5]benzodiazepin-5-one Chemical compound O=C1N(CC(C)N(C)C)C2=CC=CC=C2NC2=NC=CC=C21 YFLBETLXDPBWTD-UHFFFAOYSA-N 0.000 description 1
- KXBCLNRMQPRVTP-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one Chemical compound O=C1NC(N)=CC2=C1N=CN2 KXBCLNRMQPRVTP-UHFFFAOYSA-N 0.000 description 1
- ZNTIXVYOBQDFFV-UHFFFAOYSA-N 6-amino-1,5-dihydroimidazo[4,5-c]pyridin-4-one;methanesulfonic acid Chemical compound CS(O)(=O)=O.O=C1NC(N)=CC2=C1N=CN2 ZNTIXVYOBQDFFV-UHFFFAOYSA-N 0.000 description 1
- LJIRBXZDQGQUOO-KVTDHHQDSA-N 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,4-dihydro-1,3,5-triazin-2-one Chemical compound C1NC(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LJIRBXZDQGQUOO-KVTDHHQDSA-N 0.000 description 1
- OIRAEJWYWSAQNG-UHFFFAOYSA-N 6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid Chemical compound ClC=1C=C2C(C(=O)O)CCC2=CC=1C1CCCCC1 OIRAEJWYWSAQNG-UHFFFAOYSA-N 0.000 description 1
- GFYRZTLCYQQVHZ-UHFFFAOYSA-N 6-hydroxy-4-oxo-N-phenyl-2-sulfanylidene-1H-pyrimidine-5-carboxamide Chemical compound N1C(=S)NC(=O)C(C(=O)NC=2C=CC=CC=2)=C1O GFYRZTLCYQQVHZ-UHFFFAOYSA-N 0.000 description 1
- GOYNNCPGHOBFCK-UHFFFAOYSA-N 7-[4-(dimethylamino)-5-[(2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl)oxy]-6-methyloxan-2-yl]oxy-9-ethyl-4,6,9,10,11-pentahydroxy-8,10-dihydro-7H-tetracene-5,12-dione Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1C(O)=C1C(OC3OC(C)C(OC4OC(C)C5OC6OC(C)C(=O)CC6OC5C4)C(C3)N(C)C)CC(CC)(O)C(O)C1=C2O GOYNNCPGHOBFCK-UHFFFAOYSA-N 0.000 description 1
- GOJJWDOZNKBUSR-UHFFFAOYSA-N 7-sulfamoyloxyheptyl sulfamate Chemical compound NS(=O)(=O)OCCCCCCCOS(N)(=O)=O GOJJWDOZNKBUSR-UHFFFAOYSA-N 0.000 description 1
- RIYRAFARMCGSSW-UWNPAEFKSA-N 9-Dihydrotaxol Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@H](O)[C@@]2(C)[C@@H](O)[C@@H](C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)OC(=O)C)C(=O)C1=CC=CC=C1 RIYRAFARMCGSSW-UWNPAEFKSA-N 0.000 description 1
- TWHSQQYCDVSBRK-UHFFFAOYSA-N 9-[4-(methanesulfonamido)-2-methoxyanilino]-N,5-dimethylacridine-4-carboxamide Chemical compound C12=CC=CC(C)=C2N=C2C(C(=O)NC)=CC=CC2=C1NC1=CC=C(NS(C)(=O)=O)C=C1OC TWHSQQYCDVSBRK-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9H-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- QAWIHIJWNYOLBE-OKKQSCSOSA-N ACIVICIN Chemical compound OC(=O)[C@@H](N)[C@@H]1CC(Cl)=NO1 QAWIHIJWNYOLBE-OKKQSCSOSA-N 0.000 description 1
- 229950008427 ACIVICIN Drugs 0.000 description 1
- 229950004955 ADOZELESIN Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N AMRUBICIN Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229940035676 ANALGESICS Drugs 0.000 description 1
- 229960003965 ANTIEPILEPTICS Drugs 0.000 description 1
- 229940116904 ANTIINFLAMMATORY THERAPEUTIC RADIOPHARMACEUTICALS Drugs 0.000 description 1
- 229940005530 ANXIOLYTICS Drugs 0.000 description 1
- 101700033480 ARL3 Proteins 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- 229950004810 ATAMESTANE Drugs 0.000 description 1
- 101700084127 AVP Proteins 0.000 description 1
- 102100017238 AVP Human genes 0.000 description 1
- 210000001015 Abdomen Anatomy 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N Abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960002122 Acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N Acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960004892 Acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N Acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- 229960004373 Acetylcholine Drugs 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- SMPZPKRDRQOOHT-UHFFFAOYSA-N Acronine Chemical compound CN1C2=CC=CC=C2C(=O)C2=C1C(C=CC(C)(C)O1)=C1C=C2OC SMPZPKRDRQOOHT-UHFFFAOYSA-N 0.000 description 1
- 229950000616 Acronine Drugs 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Adhd patch Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 1
- GJSLOMWRLALDCT-UHFFFAOYSA-N Adinazolam Chemical compound C12=CC(Cl)=CC=C2N2C(CN(C)C)=NN=C2CN=C1C1=CC=CC=C1 GJSLOMWRLALDCT-UHFFFAOYSA-N 0.000 description 1
- CGNMLOKEMNBUAI-UHFFFAOYSA-N Adrafinil Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)NO)C1=CC=CC=C1 CGNMLOKEMNBUAI-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010001584 Alcohol abuse Diseases 0.000 description 1
- 208000004797 Alcohol-Induced Disorders Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229960001391 Alfentanil Drugs 0.000 description 1
- KSEYRUGYKHXGFW-UHFFFAOYSA-N Alizapride Chemical compound COC1=CC2=NNN=C2C=C1C(=O)NCC1CCCN1CC=C KSEYRUGYKHXGFW-UHFFFAOYSA-N 0.000 description 1
- 208000005223 Alkalosis Diseases 0.000 description 1
- 229950002006 Alpiropride Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N Alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N Alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N Amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 Amantadine Drugs 0.000 description 1
- 229950010949 Ambamustine Drugs 0.000 description 1
- 229950004821 Ambomycin Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N Amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 229960001301 Amobarbital Drugs 0.000 description 1
- VIROVYVQCGLCII-UHFFFAOYSA-N Amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 1
- 208000009028 Amphetamine-Related Disorders Diseases 0.000 description 1
- 206010002023 Amyloidosis Diseases 0.000 description 1
- 206010002022 Amyloidosis Diseases 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N Anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000003455 Anaphylaxis Diseases 0.000 description 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 description 1
- 229940006211 Anticholinergic mydriatics and cycloplegics Drugs 0.000 description 1
- 229940065524 Anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 241001282138 Antigonia capros Species 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Antorphin Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- 206010002965 Aplasia pure red cell Diseases 0.000 description 1
- 206010002967 Aplastic anaemia Diseases 0.000 description 1
- UORJNBVJVRLXMQ-UHFFFAOYSA-N Aprobarbital Chemical compound C=CCC1(C(C)C)C(=O)NC(=O)NC1=O UORJNBVJVRLXMQ-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 240000005781 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- NCUCGYYHUFIYNU-UHFFFAOYSA-N Aranidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1C1=CC=CC=C1[N+]([O-])=O NCUCGYYHUFIYNU-UHFFFAOYSA-N 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 229950010731 Arotinolol Drugs 0.000 description 1
- BHIAIPWSVYSKJS-UHFFFAOYSA-N Arotinolol Chemical compound S1C(SCC(O)CNC(C)(C)C)=NC(C=2SC(=CC=2)C(N)=O)=C1 BHIAIPWSVYSKJS-UHFFFAOYSA-N 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N Aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 Aspartame Drugs 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- PEPMWUSGRKINHX-TXTPUJOMSA-N Atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 229960002274 Atenolol Drugs 0.000 description 1
- 229950006933 Atrimustine Drugs 0.000 description 1
- 241001263178 Auriparus Species 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- PICZCWCKOLHDOJ-GHTSNYPWSA-N Axinastatin 1 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)=O)C(C)C)C(C)C)C(C)C)C1=CC=CC=C1 PICZCWCKOLHDOJ-GHTSNYPWSA-N 0.000 description 1
- OXNAATCTZCSVKR-AVGVIDKOSA-N Axinastatin 2 Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@H](C(N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)CC(C)C)C(C)C)C1=CC=CC=C1 OXNAATCTZCSVKR-AVGVIDKOSA-N 0.000 description 1
- ANLDPEXRVVIABH-WUUSPZRJSA-N Axinastatin 3 Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)N2CCC[C@H]2C(=O)N1)C(C)C)=O)[C@@H](C)CC)C1=CC=CC=C1 ANLDPEXRVVIABH-WUUSPZRJSA-N 0.000 description 1
- 229960002756 Azacitidine Drugs 0.000 description 1
- WUKZPHOXUVCQOR-UHFFFAOYSA-N Azasetron Chemical compound C1N(CC2)CCC2C1NC(=O)C1=CC(Cl)=CC2=C1OCC(=O)N2C WUKZPHOXUVCQOR-UHFFFAOYSA-N 0.000 description 1
- 229950005951 Azasetron Drugs 0.000 description 1
- MIXLRUYCYZPSOQ-HXPMCKFVSA-N Azatoxin Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@@H]3N2C(OC3)=O)=C1 MIXLRUYCYZPSOQ-HXPMCKFVSA-N 0.000 description 1
- 229950004295 Azotomycin Drugs 0.000 description 1
- 229950005567 BENZODEPA Drugs 0.000 description 1
- 229950002370 BISNAFIDE Drugs 0.000 description 1
- 229960001035 BOPINDOLOL Drugs 0.000 description 1
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
- 229960000794 Baclofen Drugs 0.000 description 1
- XYUFCXJZFZPEJD-PGRDOPGGSA-N Balanol Chemical compound OC(=O)C1=CC=CC(O)=C1C(=O)C1=C(O)C=C(C(=O)O[C@H]2[C@H](CNCCC2)NC(=O)C=2C=CC(O)=CC=2)C=C1O XYUFCXJZFZPEJD-PGRDOPGGSA-N 0.000 description 1
- VXMOONUMYLCFJD-DHLKQENFSA-N Barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 description 1
- 206010050258 Basilar migraine Diseases 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 Batimastat Drugs 0.000 description 1
- JPYQFYIEOUVJDU-UHFFFAOYSA-N Beclamide Chemical compound ClCCC(=O)NCC1=CC=CC=C1 JPYQFYIEOUVJDU-UHFFFAOYSA-N 0.000 description 1
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N Befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N Benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- BEWNZPMDJIGBED-UHFFFAOYSA-N Benmoxin Chemical compound C=1C=CC=CC=1C(C)NNC(=O)C1=CC=CC=C1 BEWNZPMDJIGBED-UHFFFAOYSA-N 0.000 description 1
- JSZILQVIPPROJI-UHFFFAOYSA-N Benzquinamide Chemical compound C1CC2=CC(OC)=C(OC)C=C2C2N1CC(C(=O)N(CC)CC)C(OC(C)=O)C2 JSZILQVIPPROJI-UHFFFAOYSA-N 0.000 description 1
- RDJGWRFTDZZXSM-RNWLQCGYSA-N Benzylmorphine Chemical compound O([C@@H]1[C@]23CCN([C@H](C4)[C@@H]3C=C[C@@H]1O)C)C1=C2C4=CC=C1OCC1=CC=CC=C1 RDJGWRFTDZZXSM-RNWLQCGYSA-N 0.000 description 1
- 229960003665 Bepridil Drugs 0.000 description 1
- UIEATEWHFDRYRU-UHFFFAOYSA-N Bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- UVAZQQHAVMNMHE-UHFFFAOYSA-N Betaprodine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCN(C)CC1C UVAZQQHAVMNMHE-UHFFFAOYSA-N 0.000 description 1
- NWIUTZDMDHAVTP-UHFFFAOYSA-N Betaxolol Chemical compound C1=CC(OCC(O)CNC(C)C)=CC=C1CCOCC1CC1 NWIUTZDMDHAVTP-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N Betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- QGJZLNKBHJESQX-CASBDLHJSA-N Betulinic acid Natural products O=C(O)[C@@]12[C@@H]([C@@H](C(=C)C)CC1)[C@@H]1[C@](C)([C@@]3(C)[C@@H]([C@]4(C)[C@H](C(C)(C)[C@@H](O)CC4)CC3)CC1)CC2 QGJZLNKBHJESQX-CASBDLHJSA-N 0.000 description 1
- 229960003588 Bevantolol Drugs 0.000 description 1
- HXLAFSUPPDYFEO-UHFFFAOYSA-N Bevantolol Chemical compound C1=C(OC)C(OC)=CC=C1CCNCC(O)COC1=CC=CC(C)=C1 HXLAFSUPPDYFEO-UHFFFAOYSA-N 0.000 description 1
- FLKWNFFCSSJANB-UHFFFAOYSA-N Bezitramide Chemical compound O=C1N(C(=O)CC)C2=CC=CC=C2N1C(CC1)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 FLKWNFFCSSJANB-UHFFFAOYSA-N 0.000 description 1
- 208000003770 Biliary Dyskinesia Diseases 0.000 description 1
- 229950004874 Binedaline Drugs 0.000 description 1
- SXYFFMXPDDGOEK-UHFFFAOYSA-N Binedaline Chemical compound C12=CC=CC=C2N(N(C)CCN(C)C)C=C1C1=CC=CC=C1 SXYFFMXPDDGOEK-UHFFFAOYSA-N 0.000 description 1
- 230000036912 Bioavailability Effects 0.000 description 1
- 229960002781 Bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N Bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- 229960004395 Bleomycin Sulfate Drugs 0.000 description 1
- 230000035639 Blood Levels Effects 0.000 description 1
- 208000003432 Bone Disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- UUOJIACWOAYWEZ-UHFFFAOYSA-N Bopindolol Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 102000004219 Brain-Derived Neurotrophic Factor Human genes 0.000 description 1
- 108090000715 Brain-Derived Neurotrophic Factor Proteins 0.000 description 1
- 240000000772 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 206010006242 Breast enlargement Diseases 0.000 description 1
- GIYAQDDTCWHPPL-UHFFFAOYSA-N Bromopride Chemical compound CCN(CC)CCNC(=O)C1=CC(Br)=C(N)C=C1OC GIYAQDDTCWHPPL-UHFFFAOYSA-N 0.000 description 1
- UMSGKTJDUHERQW-UHFFFAOYSA-N Brotizolam Chemical compound C1=2C=C(Br)SC=2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl UMSGKTJDUHERQW-UHFFFAOYSA-N 0.000 description 1
- MOYGZHXDRJNJEP-UHFFFAOYSA-N Buclizine Chemical compound C1=CC(C(C)(C)C)=CC=C1CN1CCN(C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1 MOYGZHXDRJNJEP-UHFFFAOYSA-N 0.000 description 1
- CIJVBYRUFLGDHY-UHFFFAOYSA-N Bucumolol Chemical compound O1C(=O)C=CC2=C1C(OCC(O)CNC(C)(C)C)=CC=C2C CIJVBYRUFLGDHY-UHFFFAOYSA-N 0.000 description 1
- 229950009385 Bufetolol Drugs 0.000 description 1
- AKLNLVOZXMQGSI-UHFFFAOYSA-N Bufetolol Chemical compound CC(C)(C)NCC(O)COC1=CC=CC=C1OCC1OCCC1 AKLNLVOZXMQGSI-UHFFFAOYSA-N 0.000 description 1
- 208000000594 Bullous Pemphigoid Diseases 0.000 description 1
- HQIRNZOQPUAHHV-UHFFFAOYSA-N Bupranolol Chemical compound CC1=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1 HQIRNZOQPUAHHV-UHFFFAOYSA-N 0.000 description 1
- 229950009824 Buramate Drugs 0.000 description 1
- ZRIHAIZYIMGOAB-UHFFFAOYSA-N Butabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=O)NC1=O ZRIHAIZYIMGOAB-UHFFFAOYSA-N 0.000 description 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N Butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 description 1
- KJQFBVYMGADDTQ-UHFFFAOYSA-N Buthionine sulfoximine Chemical compound CCCCS(=N)(=O)CCC(N)C(O)=O KJQFBVYMGADDTQ-UHFFFAOYSA-N 0.000 description 1
- NMBNQRJDEPOXCP-UHFFFAOYSA-N Butofilolol Chemical compound CCCC(=O)C1=CC(F)=CC=C1OCC(O)CNC(C)(C)C NMBNQRJDEPOXCP-UHFFFAOYSA-N 0.000 description 1
- 229960001113 Butorphanol Drugs 0.000 description 1
- IFKLAQQSCNILHL-QHAWAJNXSA-N Butorphanol Chemical compound N1([C@@H]2CC3=CC=C(C=C3[C@@]3([C@]2(CCCC3)O)CC1)O)CC1CCC1 IFKLAQQSCNILHL-QHAWAJNXSA-N 0.000 description 1
- 229960004301 Butriptyline Drugs 0.000 description 1
- ALELTFCQZDXAMQ-UHFFFAOYSA-N Butriptyline Chemical compound C1CC2=CC=CC=C2C(CC(C)CN(C)C)C2=CC=CC=C21 ALELTFCQZDXAMQ-UHFFFAOYSA-N 0.000 description 1
- KEHXXUBQJIUIJD-UHFFFAOYSA-N C(#N)C=CN1CCNCC1 Chemical compound C(#N)C=CN1CCNCC1 KEHXXUBQJIUIJD-UHFFFAOYSA-N 0.000 description 1
- ZIWXKGQDQBLUMV-JUDXGUMMSA-N C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O Chemical compound C(C)(=O)[C@@]1([C@]([C@@](O[C@@H]1CO)(N1C(=O)NC(=O)C=C1)C(C)=O)(O)C(C)=O)O ZIWXKGQDQBLUMV-JUDXGUMMSA-N 0.000 description 1
- PSIDLHYGESPOMK-UHFFFAOYSA-L C(C1=CC=CC=C1)S=C([O-])[O-] Chemical compound C(C1=CC=CC=C1)S=C([O-])[O-] PSIDLHYGESPOMK-UHFFFAOYSA-L 0.000 description 1
- 229960005084 CALCITRIOL Drugs 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N CARUBICIN Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229950001725 CARUBICIN Drugs 0.000 description 1
- PUDHBTGHUJUUFI-PURAGXGVSA-N CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 Chemical compound CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC2=CNC3=C2C=CC=C3)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)NC(=O)[C@@H](N)CC1=CC=C2C=CC=CC2=C1 PUDHBTGHUJUUFI-PURAGXGVSA-N 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical compound CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 229950003205 CETAMOLOL Drugs 0.000 description 1
- HZCWPKGYTCJSEB-UHFFFAOYSA-N CHEMBL118841 Chemical compound C12=CC(OC)=CC=C2NC2=C([N+]([O-])=O)C=CC3=C2C1=NN3CCCN(C)C HZCWPKGYTCJSEB-UHFFFAOYSA-N 0.000 description 1
- 101710026546 CLEC10A Proteins 0.000 description 1
- 229950000308 CLENTIAZEM Drugs 0.000 description 1
- 229950007258 CRISNATOL Drugs 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 229950009908 Cactinomycin Drugs 0.000 description 1
- LWQQLNNNIPYSNX-UROSTWAQSA-N Calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L Calcium bromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N Calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 Calusterone Drugs 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 229960000846 Camphor Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229960004117 Capecitabine Drugs 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- 229950009338 Caracemide Drugs 0.000 description 1
- 229950005155 Carbetimer Drugs 0.000 description 1
- 229960004562 Carboplatin Drugs 0.000 description 1
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 1
- WNRZHQBJSXRYJK-UHFFFAOYSA-N Carboxyamidotriazole Chemical compound NC1=C(C(=O)N)N=NN1CC(C=C1Cl)=CC(Cl)=C1C(=O)C1=CC=C(Cl)C=C1 WNRZHQBJSXRYJK-UHFFFAOYSA-N 0.000 description 1
- 206010007515 Cardiac arrest Diseases 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 208000005846 Cardiomyopathy Diseases 0.000 description 1
- KYCBWEZLKCTALM-UHFFFAOYSA-N Caroxazone Chemical compound C1=CC=C2OC(=O)N(CC(=O)N)CC2=C1 KYCBWEZLKCTALM-UHFFFAOYSA-N 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N Carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960001222 Carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N Carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N Carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 102000005403 Casein Kinases Human genes 0.000 description 1
- 108010031425 Casein Kinases Proteins 0.000 description 1
- JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 description 1
- JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 206010007749 Cataract diabetic Diseases 0.000 description 1
- 208000009810 Catatonic Schizophrenia Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108050004290 Cecropins Proteins 0.000 description 1
- 229950010667 Cedefingol Drugs 0.000 description 1
- 229940047495 Celebrex Drugs 0.000 description 1
- 229960002320 Celiprolol Drugs 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 210000003710 Cerebral Cortex Anatomy 0.000 description 1
- UWCBNAVPISMFJZ-UHFFFAOYSA-N Cetamolol Chemical compound CNC(=O)COC1=CC=CC=C1OCC(O)CNC(C)(C)C UWCBNAVPISMFJZ-UHFFFAOYSA-N 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 229960004630 Chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- WSPOMRSOLSGNFJ-AUWJEWJLSA-N Chlorprothixene Chemical compound C1=C(Cl)C=C2C(=C/CCN(C)C)\C3=CC=CC=C3SC2=C1 WSPOMRSOLSGNFJ-AUWJEWJLSA-N 0.000 description 1
- 208000003167 Cholangitis Diseases 0.000 description 1
- 229950000634 Cicaprost Drugs 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N Cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 Cinnarizine Drugs 0.000 description 1
- 229950011359 Cirolemycin Drugs 0.000 description 1
- 229940001468 Citrate Drugs 0.000 description 1
- 241000221751 Claviceps purpurea Species 0.000 description 1
- BVPWJMCABCPUQY-UHFFFAOYSA-N Clebopride Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)NC1CCN(CC=2C=CC=CC=2)CC1 BVPWJMCABCPUQY-UHFFFAOYSA-N 0.000 description 1
- 229950010886 Clidanac Drugs 0.000 description 1
- CXOXHMZGEKVPMT-UHFFFAOYSA-N Clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Clometiazol Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N Clomifene Chemical class C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- GPZLDQAEBHTMPG-UHFFFAOYSA-N Clonitazene Chemical compound N=1C2=CC([N+]([O-])=O)=CC=C2N(CCN(CC)CC)C=1CC1=CC=C(Cl)C=C1 GPZLDQAEBHTMPG-UHFFFAOYSA-N 0.000 description 1
- 229950001604 Clonitazene Drugs 0.000 description 1
- XYCMOTOFHFTUIU-UHFFFAOYSA-N Cloranolol Chemical compound CC(C)(C)NCC(O)COC1=CC(Cl)=CC=C1Cl XYCMOTOFHFTUIU-UHFFFAOYSA-N 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N Clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229920001405 Coding region Polymers 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010010145 Complex partial seizure Diseases 0.000 description 1
- 210000002808 Connective Tissue Anatomy 0.000 description 1
- 208000010247 Contact Dermatitis Diseases 0.000 description 1
- 206010011005 Corneal dystrophy Diseases 0.000 description 1
- 208000004981 Coronary Disease Diseases 0.000 description 1
- 229950006073 Cotinine Drugs 0.000 description 1
- SBRXTSOCZITGQG-UHFFFAOYSA-N Crisnatol Chemical compound C1=CC=C2C(CNC(CO)(CO)C)=CC3=C(C=CC=C4)C4=CC=C3C2=C1 SBRXTSOCZITGQG-UHFFFAOYSA-N 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N Cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- MLIREBYILWEBDM-UHFFFAOYSA-N Cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- VMKJWLXVLHBJNK-UHFFFAOYSA-N Cyanuric fluoride Chemical compound FC1=NC(F)=NC(F)=N1 VMKJWLXVLHBJNK-UHFFFAOYSA-N 0.000 description 1
- UVKZSORBKUEBAZ-UHFFFAOYSA-N Cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 description 1
- KDUIUFJBNGTBMD-VXMYFEMYSA-N Cyclooctatetraene Chemical group C1=C\C=C/C=C\C=C1 KDUIUFJBNGTBMD-VXMYFEMYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960000684 Cytarabine Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-L D-glucarate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O DSLZVSRJTYRBFB-LLEIAEIESA-L 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229950002134 DIMETHAZAN Drugs 0.000 description 1
- 229960002500 DIPIPANONE Drugs 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010084740 Daclizumab Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 229960000640 Dactinomycin Drugs 0.000 description 1
- 229960001987 Dantrolene Drugs 0.000 description 1
- 229960003109 Daunorubicin Hydrochloride Drugs 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 229950010189 Demexiptiline Drugs 0.000 description 1
- SEDQWOMFMIJKCU-UHFFFAOYSA-N Demexiptiline Chemical compound C1=CC2=CC=CC=C2C(=NOCCNC)C2=CC=CC=C21 SEDQWOMFMIJKCU-UHFFFAOYSA-N 0.000 description 1
- 229950010734 Demoxepam Drugs 0.000 description 1
- GGRWZBVSUZZMKS-UHFFFAOYSA-N Demoxepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C[N+]([O-])=C1C1=CC=CC=C1 GGRWZBVSUZZMKS-UHFFFAOYSA-N 0.000 description 1
- 208000004275 Demyelinating Disease Diseases 0.000 description 1
- 210000004268 Dentin Anatomy 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N Desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 description 1
- HGKAMARNFGKMLC-RBUKOAKNSA-N Dexoxadrol Chemical compound C([C@H]1[C@@H]2OC(OC2)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCN1 HGKAMARNFGKMLC-RBUKOAKNSA-N 0.000 description 1
- 229960000605 Dexrazoxane Drugs 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N Dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- 229940119750 Dextroamphetamine Drugs 0.000 description 1
- 229960001985 Dextromethorphan Drugs 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N Dextromethorphan Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 229950005878 Dexverapamil Drugs 0.000 description 1
- 229950010621 Dezaguanine Drugs 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N Di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012601 Diabetes mellitus Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010061835 Diabetic nephropathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- RXTHKWVSXOIHJS-UHFFFAOYSA-N Diampromide Chemical compound C=1C=CC=CC=1N(C(=O)CC)CC(C)N(C)CCC1=CC=CC=C1 RXTHKWVSXOIHJS-UHFFFAOYSA-N 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N Diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- QPGGEKPRGVJKQB-UHFFFAOYSA-N Dibenzepin Chemical compound O=C1N(CCN(C)C)C2=CC=CC=C2N(C)C2=CC=CC=C21 QPGGEKPRGVJKQB-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 229940120131 Dicyclomine Drugs 0.000 description 1
- CURUTKGFNZGFSE-UHFFFAOYSA-N Dicycloverine Chemical compound C1CCCCC1C1(C(=O)OCCN(CC)CC)CCCCC1 CURUTKGFNZGFSE-UHFFFAOYSA-N 0.000 description 1
- 229960002777 Dicycloverine Drugs 0.000 description 1
- KYHUYMLIVQFXRI-SJPGYWQQSA-N Didemnin B Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)[C@H](C)O KYHUYMLIVQFXRI-SJPGYWQQSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N Dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 description 1
- 229950007942 Dilevalol Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N Diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- RHUWRJWFHUKVED-UHFFFAOYSA-N Dimenoxadol Chemical compound C=1C=CC=CC=1C(C(=O)OCCN(C)C)(OCC)C1=CC=CC=C1 RHUWRJWFHUKVED-UHFFFAOYSA-N 0.000 description 1
- RYQOGSFEJBUZBX-UHFFFAOYSA-N Dimetacrine Chemical compound C1=CC=C2N(CCCN(C)C)C3=CC=CC=C3C(C)(C)C2=C1 RYQOGSFEJBUZBX-UHFFFAOYSA-N 0.000 description 1
- 229950004446 Dimethadione Drugs 0.000 description 1
- CMKUGKVVUUGBHJ-UHFFFAOYSA-N Dimethazan Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCN(C)C CMKUGKVVUUGBHJ-UHFFFAOYSA-N 0.000 description 1
- VWNWVCJGUMZDIU-UHFFFAOYSA-N Dimetotiazine Chemical compound C1=C(S(=O)(=O)N(C)C)C=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 VWNWVCJGUMZDIU-UHFFFAOYSA-N 0.000 description 1
- OGAKLTJNUQRZJU-UHFFFAOYSA-N Diphenidol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)CCCN1CCCCC1 OGAKLTJNUQRZJU-UHFFFAOYSA-N 0.000 description 1
- SVDHSZFEQYXRDC-UHFFFAOYSA-N Dipipanone Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)CC)CC(C)N1CCCCC1 SVDHSZFEQYXRDC-UHFFFAOYSA-N 0.000 description 1
- NOPFSRXAKWQILS-UHFFFAOYSA-N Docosanol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 1
- CGHRJBLSXVCYQF-YXSUXZIUSA-N Dolasetron Chemical compound C1=CC=C[C]2C(C(O[C@@H]3C[C@@H]4C[C@@H]5C[C@@H](N4CC5=O)C3)=O)=CN=C21 CGHRJBLSXVCYQF-YXSUXZIUSA-N 0.000 description 1
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 1
- 229940000011 Dothiepin Drugs 0.000 description 1
- 229960004679 Doxorubicin Drugs 0.000 description 1
- 229960002918 Doxorubicin Hydrochloride Drugs 0.000 description 1
- CYQFCXCEBYINGO-DLBZAZTESA-N Dronabinol Natural products C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@H]21 CYQFCXCEBYINGO-DLBZAZTESA-N 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N Drostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229950005133 Duazomycin Drugs 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N Duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- 208000000718 Duodenal Ulcer Diseases 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 108010092799 EC 2.7.7.49 Proteins 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 210000003027 Ear, Inner Anatomy 0.000 description 1
- 229950010033 Ebselen Drugs 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselenum Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 229950005678 Ecomustine Drugs 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 108010070635 Edrecolomab Proteins 0.000 description 1
- NSVFSAJIGAJDMR-UHFFFAOYSA-N Efonidipine Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- 229950003102 Efonidipine Drugs 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 229950005450 Emitefur Drugs 0.000 description 1
- 206010014599 Encephalitis Diseases 0.000 description 1
- 206010014801 Endophthalmitis Diseases 0.000 description 1
- JPGQOUSTVILISH-UHFFFAOYSA-N Enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N Entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 1
- YARKMNAWFIMDKV-UHFFFAOYSA-N Epanolol Chemical compound C=1C=CC=C(C#N)C=1OCC(O)CNCCNC(=O)CC1=CC=C(O)C=C1 YARKMNAWFIMDKV-UHFFFAOYSA-N 0.000 description 1
- 229960003265 Epirubicin Hydrochloride Drugs 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- ZOWQTJXNFTWSCS-IAQYHMDHSA-N Eptazocine Chemical compound C1N(C)CC[C@@]2(C)C3=CC(O)=CC=C3C[C@@H]1C2 ZOWQTJXNFTWSCS-IAQYHMDHSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- KLEPCGBEXOCIGS-QPPBQGQZSA-N Erbulozole Chemical compound C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C=CC(OC)=CC=2)OC1 KLEPCGBEXOCIGS-QPPBQGQZSA-N 0.000 description 1
- 229950001426 Erbulozole Drugs 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- UJYGDMFEEDNVBF-UHFFFAOYSA-N Ergocornin Chemical compound C1=CC(C=2C(N(C)CC(C=2)C(=O)NC2(C(=O)N3C(C(N4CCCC4C3(O)O2)=O)C(C)C)C(C)C)C2)=C3C2=CNC3=C1 UJYGDMFEEDNVBF-UHFFFAOYSA-N 0.000 description 1
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
- 229940011336 Ergonovine Drugs 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 210000003743 Erythrocytes Anatomy 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 229960002336 Estazolam Drugs 0.000 description 1
- CDCHDCWJMGXXRH-UHFFFAOYSA-N Estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960004351 Etafenone Drugs 0.000 description 1
- DACOQFZGGLCXMA-UHFFFAOYSA-N Eterobarb Chemical compound C=1C=CC=CC=1C1(CC)C(=O)N(COC)C(=O)N(COC)C1=O DACOQFZGGLCXMA-UHFFFAOYSA-N 0.000 description 1
- WGJHHMKQBWSQIY-UHFFFAOYSA-N Ethoheptazine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCCN(C)CC1 WGJHHMKQBWSQIY-UHFFFAOYSA-N 0.000 description 1
- 229960003533 Ethotoin Drugs 0.000 description 1
- SZQIFWWUIBRPBZ-UHFFFAOYSA-N Ethotoin Chemical compound O=C1N(CC)C(=O)NC1C1=CC=CC=C1 SZQIFWWUIBRPBZ-UHFFFAOYSA-N 0.000 description 1
- OGDVEMNWJVYAJL-LEPYJNQMSA-N Ethyl morphine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OCC OGDVEMNWJVYAJL-LEPYJNQMSA-N 0.000 description 1
- LIWAQLJGPBVORC-UHFFFAOYSA-N Ethylmethylamine Chemical compound CCNC LIWAQLJGPBVORC-UHFFFAOYSA-N 0.000 description 1
- MORSAEFGQPDBKM-UHFFFAOYSA-N Ethylmethylthiambutene Chemical compound C=1C=CSC=1C(=CC(C)N(C)CC)C1=CC=CS1 MORSAEFGQPDBKM-UHFFFAOYSA-N 0.000 description 1
- 229960004578 Ethylmorphine Drugs 0.000 description 1
- XEHVFKKSDRMODV-UHFFFAOYSA-N Ethynyl radical Chemical group C#[C] XEHVFKKSDRMODV-UHFFFAOYSA-N 0.000 description 1
- 229960005293 Etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N Etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- PXDBZSCGSQSKST-UHFFFAOYSA-N Etonitazene Chemical compound C1=CC(OCC)=CC=C1CC1=NC2=CC([N+]([O-])=O)=CC=C2N1CCN(CC)CC PXDBZSCGSQSKST-UHFFFAOYSA-N 0.000 description 1
- 229950004538 Etonitazene Drugs 0.000 description 1
- IZBNNCFOBMGTQX-UHFFFAOYSA-N Etoperidone Chemical compound O=C1N(CC)C(CC)=NN1CCCN1CCN(C=2C=C(Cl)C=CC=2)CC1 IZBNNCFOBMGTQX-UHFFFAOYSA-N 0.000 description 1
- 229960005420 Etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 102100008634 FGF2 Human genes 0.000 description 1
- 101700082364 FGF2 Proteins 0.000 description 1
- 229950007979 FLUFENISAL Drugs 0.000 description 1
- YMDXZJFXQJVXBF-STHAYSLISA-N FOSFOMYCIN Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 1
- 229950010404 FOSTRIECIN Drugs 0.000 description 1
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Farmotal Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- QHZQILHUJDRDAI-UHFFFAOYSA-N Febarbamate Chemical compound O=C1N(CC(COCCCC)OC(N)=O)C(=O)NC(=O)C1(CC)C1=CC=CC=C1 QHZQILHUJDRDAI-UHFFFAOYSA-N 0.000 description 1
- 208000002091 Febrile Seizure Diseases 0.000 description 1
- 229960003580 Felodipine Drugs 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N Felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- OJSFTALXCYKKFQ-YLJYHZDGSA-N Femoxetine Chemical compound C1=CC(OC)=CC=C1OC[C@@H]1[C@@H](C=2C=CC=CC=2)CCN(C)C1 OJSFTALXCYKKFQ-YLJYHZDGSA-N 0.000 description 1
- PDTADBTVZXKSJM-UHFFFAOYSA-N Fencamine Chemical compound N=1C=2N(C)C(=O)N(C)C(=O)C=2N(C)C=1NCCN(C)C(C)CC1=CC=CC=C1 PDTADBTVZXKSJM-UHFFFAOYSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N Fendiline Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-UHFFFAOYSA-N Fenoprofen Chemical compound OC(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-UHFFFAOYSA-N 0.000 description 1
- 229960001419 Fenoprofen Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N Finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- 206010016754 Flashback Diseases 0.000 description 1
- 229950006000 Flezelastine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000961 Floxuridine Drugs 0.000 description 1
- 229950002413 Fluacizine Drugs 0.000 description 1
- VHEOUJNDDFHPGJ-UHFFFAOYSA-N Fluacizine Chemical compound C1=C(C(F)(F)F)C=C2N(C(=O)CCN(CC)CC)C3=CC=CC=C3SC2=C1 VHEOUJNDDFHPGJ-UHFFFAOYSA-N 0.000 description 1
- 229960004369 Flufenamic Acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N Flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- OFBIFZUFASYYRE-UHFFFAOYSA-N Flumazenil Chemical compound C1N(C)C(=O)C2=CC(F)=CC=C2N2C=NC(C(=O)OCC)=C21 OFBIFZUFASYYRE-UHFFFAOYSA-N 0.000 description 1
- 229960004381 Flumazenil Drugs 0.000 description 1
- 229960000326 Flunarizine Drugs 0.000 description 1
- 229950011300 Fluoresone Drugs 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N Fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 229960002949 Fluorouracil Drugs 0.000 description 1
- 229950001284 Fluprofen Drugs 0.000 description 1
- 229960003528 Flurazepam Drugs 0.000 description 1
- SAADBVWGJQAEFS-UHFFFAOYSA-N Flurazepam Chemical compound N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F SAADBVWGJQAEFS-UHFFFAOYSA-N 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N Flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229950005682 Flurocitabine Drugs 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 229950004217 Forfenimex Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N Formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- UXTSQCOOUJTIAC-UHFFFAOYSA-N Fosquidone Chemical compound C=1N2CC3=CC=CC=C3C(C)C2=C(C(C2=CC=C3)=O)C=1C(=O)C2=C3OP(O)(=O)OCC1=CC=CC=C1 UXTSQCOOUJTIAC-UHFFFAOYSA-N 0.000 description 1
- 229950005611 Fosquidone Drugs 0.000 description 1
- 229960002737 Fructose Drugs 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N Gadolinium Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- 229960000457 Gallopamil Drugs 0.000 description 1
- 208000001130 Gallstone Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229950004410 Galocitabine Drugs 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 210000004211 Gastric Acid Anatomy 0.000 description 1
- 208000008665 Gastrointestinal Disease Diseases 0.000 description 1
- 229960005144 Gemcitabine hydrochloride Drugs 0.000 description 1
- 206010018075 Generalised anxiety disease Diseases 0.000 description 1
- 208000003078 Generalized Epilepsy Diseases 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N Gentisic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N Gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 208000009693 Gingival Hyperplasia Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229960003180 Glutathione Drugs 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229940015042 Glycopyrrolate Drugs 0.000 description 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 210000003128 Head Anatomy 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019375 Helicobacter infection Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 229940037467 Helicobacter pylori Drugs 0.000 description 1
- 229960003569 Hematoporphyrin Drugs 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019692 Hepatic necrosis Diseases 0.000 description 1
- LSAOZCAKUIANSQ-UHFFFAOYSA-N Heptobarbital Chemical compound C=1C=CC=CC=1C1(C)C(=O)NC(=O)NC1=O LSAOZCAKUIANSQ-UHFFFAOYSA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 229940120060 Heroin Drugs 0.000 description 1
- UQEAIHBTYFGYIE-UHFFFAOYSA-N Hexamethyldisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)C UQEAIHBTYFGYIE-UHFFFAOYSA-N 0.000 description 1
- BNQSTAOJRULKNX-UHFFFAOYSA-N Hexamethylene bisacetamide Chemical compound CC(=O)NCCCCCCNC(C)=O BNQSTAOJRULKNX-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N Hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N Hyoscyamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- 208000009576 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020993 Hypoglycaemia Diseases 0.000 description 1
- 206010021015 Hypokalaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229960000908 Idarubicin Drugs 0.000 description 1
- 229960001176 Idarubicin Hydrochloride Drugs 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 229950002248 Idoxifene Drugs 0.000 description 1
- 229950009926 Idramantone Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- 208000009326 Ileitis Diseases 0.000 description 1
- 210000003405 Ileum Anatomy 0.000 description 1
- NITYDPDXAAFEIT-DYVFJYSZSA-N Ilomastat Chemical compound C1=CC=C2C(C[C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)CC(=O)NO)=CNC2=C1 NITYDPDXAAFEIT-DYVFJYSZSA-N 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N Imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 210000000987 Immune System Anatomy 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 229950008838 Indenolol Drugs 0.000 description 1
- MPGBPFMOOXKQRX-UHFFFAOYSA-N Indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 description 1
- RJMIEHBSYVWVIN-UHFFFAOYSA-N Indoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-UHFFFAOYSA-N 0.000 description 1
- 206010021750 Infantile spasms Diseases 0.000 description 1
- 208000001271 Inhalant Abuse Diseases 0.000 description 1
- 102000020344 Insulin-Like Growth Factor Binding Proteins Human genes 0.000 description 1
- 108091022066 Insulin-Like Growth Factor Binding Proteins Proteins 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 229960003507 Interferon Alfa-2b Drugs 0.000 description 1
- 108010054698 Interferon Alfa-n3 Proteins 0.000 description 1
- 229940109242 Interferon Alfa-n3 Drugs 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940047122 Interleukins Drugs 0.000 description 1
- 206010022568 Intermittent explosive disease Diseases 0.000 description 1
- 210000004347 Intestinal Mucosa Anatomy 0.000 description 1
- 208000003243 Intestinal Obstruction Diseases 0.000 description 1
- PDWUPXJEEYOOTR-UHFFFAOYSA-N Iobenguane Chemical compound NC(=N)NCC1=CC=CC(I)=C1 PDWUPXJEEYOOTR-UHFFFAOYSA-N 0.000 description 1
- PLIGPBGDXASWPX-UHFFFAOYSA-N Iprindole Chemical compound C1CCCCCC2=C1N(CCCN(C)C)C1=CC=CC=C12 PLIGPBGDXASWPX-UHFFFAOYSA-N 0.000 description 1
- GGECDTUJZOXAAR-UHFFFAOYSA-N Iproclozide Chemical compound CC(C)NNC(=O)COC1=CC=C(Cl)C=C1 GGECDTUJZOXAAR-UHFFFAOYSA-N 0.000 description 1
- NYMGNSNKLVNMIA-UHFFFAOYSA-N Iproniazid Chemical compound CC(C)NNC(=O)C1=CC=NC=C1 NYMGNSNKLVNMIA-UHFFFAOYSA-N 0.000 description 1
- 229950010897 Iproplatin Drugs 0.000 description 1
- GURKHSYORGJETM-WAQYZQTGSA-N Irinotecan hydrochloride Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
- 229960000779 Irinotecan hydrochloride Drugs 0.000 description 1
- 229950000855 Iroplact Drugs 0.000 description 1
- 229950010984 Irsogladine Drugs 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- IFKPLJWIEQBPGG-UHFFFAOYSA-N Isomethadone Chemical compound C=1C=CC=CC=1C(C(C)CN(C)C)(C(=O)CC)C1=CC=CC=C1 IFKPLJWIEQBPGG-UHFFFAOYSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- FPCCSQOGAWCVBH-UHFFFAOYSA-N Ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 1
- ALFGKMXHOUSVAD-UHFFFAOYSA-N Ketobemidone Chemical compound C=1C=CC(O)=CC=1C1(C(=O)CC)CCN(C)CC1 ALFGKMXHOUSVAD-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N Ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N Ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- 206010023461 Kleptomania Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- GSDBGCKBBJVPNC-BYPYZUCNSA-N L-lombricine dizwitterion Chemical compound NC(=[NH2+])NCCOP([O-])(=O)OC[C@H]([NH3+])C([O-])=O GSDBGCKBBJVPNC-BYPYZUCNSA-N 0.000 description 1
- 108010043135 L-methionine gamma-lyase Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 229960004873 LEVOMENTHOL Drugs 0.000 description 1
- 229950005634 LOXORIBINE Drugs 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N Labetalol Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 206010059204 Labour pain Diseases 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N Laracor Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 229960004294 Lercanidipine Drugs 0.000 description 1
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N Lercanidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- XBMIVRRWGCYBTQ-AVRDEDQJSA-N Levacetylmethadol Chemical compound C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 1
- 229960000831 Levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N Levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229940018399 Levomethadyl Acetate Hydrochloride Drugs 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levotetramisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 208000009874 Lice Infestations Diseases 0.000 description 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N Lidoflazine Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
- 229960001941 Lidoflazine Drugs 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- RBBBWKUBQVARPL-SWQMWMPHSA-N Lissoclinamide 7 Chemical compound C([C@H]1C(=O)N2CCC[C@H]2C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H](C=2SC[C@H](N=2)C(=O)N[C@H](CC=2C=CC=CC=2)C=2SC[C@H](N=2)C(=O)N1)C(C)C)C1=CC=CC=C1 RBBBWKUBQVARPL-SWQMWMPHSA-N 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 208000007903 Liver Failure Diseases 0.000 description 1
- 229950008991 Lobaplatin Drugs 0.000 description 1
- IMYHGORQCPYVBZ-NLFFAJNJSA-N Lofentanil Chemical compound CCC(=O)N([C@@]1([C@@H](CN(CCC=2C=CC=CC=2)CC1)C)C(=O)OC)C1=CC=CC=C1 IMYHGORQCPYVBZ-NLFFAJNJSA-N 0.000 description 1
- 229950010274 Lofentanil Drugs 0.000 description 1
- SAPNXPWPAUFAJU-UHFFFAOYSA-N Lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
- 229950000909 Lometrexol Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N Lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N Losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 Losoxantrone Drugs 0.000 description 1
- XDMHALQMTPSGEA-UHFFFAOYSA-N Losoxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO XDMHALQMTPSGEA-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960000589 Loxapine Succinate Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N Lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 Lurtotecan Drugs 0.000 description 1
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229950009131 METAZOCINE Drugs 0.000 description 1
- VQJHOPSWBGJHQS-UHFFFAOYSA-N METOPRINE, METHODICHLOROPHEN Chemical compound CC1=NC(N)=NC(N)=C1C1=CC=C(Cl)C(Cl)=C1 VQJHOPSWBGJHQS-UHFFFAOYSA-N 0.000 description 1
- 102100012644 MIF Human genes 0.000 description 1
- 108090000028 MMP12 Proteins 0.000 description 1
- 229950010718 MOPIDAMOL Drugs 0.000 description 1
- 102100006003 MT3 Human genes 0.000 description 1
- 229940035363 MUSCLE RELAXANTS Drugs 0.000 description 1
- 229950001846 Mabuprofen Drugs 0.000 description 1
- OTCKOJUMXQWKQG-UHFFFAOYSA-L Magnesium bromide Chemical compound [Mg+2].[Br-].[Br-] OTCKOJUMXQWKQG-UHFFFAOYSA-L 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L Magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- ANEBWFXPVPTEET-UHFFFAOYSA-N Manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 Marimastat Drugs 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 102000004318 Matrilysin Human genes 0.000 description 1
- 229960004961 Mechlorethamine Drugs 0.000 description 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 1
- 229940041321 Meclizine Drugs 0.000 description 1
- QNMGHBMGNRQPNL-UHFFFAOYSA-N Medifoxamine Chemical compound C=1C=CC=CC=1OC(CN(C)C)OC1=CC=CC=C1 QNMGHBMGNRQPNL-UHFFFAOYSA-N 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229960003846 Melengestrol Acetate Drugs 0.000 description 1
- UDKABVSQKJNZBH-DWNQPYOZSA-N Melengestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC(=C)[C@](OC(=O)C)(C(C)=O)[C@@]1(C)CC2 UDKABVSQKJNZBH-DWNQPYOZSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 240000006217 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 229940041616 Menthol Drugs 0.000 description 1
- 229940041655 Meperidine Drugs 0.000 description 1
- GMHKMTDVRCWUDX-UHFFFAOYSA-N Mephenytoin Chemical compound C=1C=CC=CC=1C1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-UHFFFAOYSA-N 0.000 description 1
- 229960000906 Mephenytoin Drugs 0.000 description 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004815 Meprobamate Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N Mesalazine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- AJXPJJZHWIXJCJ-UHFFFAOYSA-N Mesuximide Chemical compound O=C1N(C)C(=O)CC1(C)C1=CC=CC=C1 AJXPJJZHWIXJCJ-UHFFFAOYSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- YXVZOBVWVRFPTE-UHFFFAOYSA-N Metapramine Chemical compound CNC1CC2=CC=CC=C2N(C)C2=CC=CC=C12 YXVZOBVWVRFPTE-UHFFFAOYSA-N 0.000 description 1
- YGSVZRIZCHZUHB-COLVAYQJSA-N Metazocine Chemical compound C1C2=CC=C(O)C=C2[C@]2(C)CCN(C)[C@@]1([H])[C@@H]2C YGSVZRIZCHZUHB-COLVAYQJSA-N 0.000 description 1
- 229950007330 Metetoin Drugs 0.000 description 1
- FWJKNZONDWOGMI-UHFFFAOYSA-N Metharbital Chemical compound CCC1(CC)C(=O)NC(=O)N(C)C1=O FWJKNZONDWOGMI-UHFFFAOYSA-N 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N Methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229960003058 Methotrexate Sodium Drugs 0.000 description 1
- UNBRKDKAWYKMIV-QWQRMKEZSA-N Methylergometrine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CNC3=C1 UNBRKDKAWYKMIV-QWQRMKEZSA-N 0.000 description 1
- 229940042112 Methylergonovine Drugs 0.000 description 1
- 229960001344 Methylphenidate Drugs 0.000 description 1
- 229960002704 Metipranolol Drugs 0.000 description 1
- BQIPXWYNLPYNHW-UHFFFAOYSA-N Metipranolol Chemical compound CC(C)NCC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BQIPXWYNLPYNHW-UHFFFAOYSA-N 0.000 description 1
- NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
- BQDBKDMTIJBJLA-UHFFFAOYSA-N Metopimazine Chemical compound C12=CC(S(=O)(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCC(C(N)=O)CC1 BQDBKDMTIJBJLA-UHFFFAOYSA-N 0.000 description 1
- GVXBHSBKKJRBMS-UHFFFAOYSA-N Metralindole Chemical compound C1CN(C)C2=NCCC3=C2N1C1=CC=C(OC)C=C13 GVXBHSBKKJRBMS-UHFFFAOYSA-N 0.000 description 1
- 229960003955 Mianserin Drugs 0.000 description 1
- HBNPJJILLOYFJU-VMPREFPWSA-N Mibefradil Chemical compound C1CC2=CC(F)=CC=C2[C@H](C(C)C)[C@@]1(OC(=O)COC)CCN(C)CCCC1=NC2=CC=CC=C2N1 HBNPJJILLOYFJU-VMPREFPWSA-N 0.000 description 1
- 229960004438 Mibefradil Drugs 0.000 description 1
- 210000000274 Microglia Anatomy 0.000 description 1
- 229960003793 Midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N Midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N Mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 description 1
- 229960000600 Milnacipran Drugs 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N Milnacipran Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- PQLXHQMOHUQAKB-UHFFFAOYSA-N Miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 1
- 229960004758 Minaprine Drugs 0.000 description 1
- LDMWSLGGVTVJPG-UHFFFAOYSA-N Minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 1
- 229950008541 Mirimostim Drugs 0.000 description 1
- 229960001785 Mirtazapine Drugs 0.000 description 1
- RONZAEMNMFQXRA-UHFFFAOYSA-N Mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
- DRCJGCOYHLTVNR-ZUIZSQJWSA-N Mitindomide Chemical compound C1=C[C@@H]2[C@@H]3[C@H]4C(=O)NC(=O)[C@H]4[C@@H]3[C@H]1[C@@H]1C(=O)NC(=O)[C@H]21 DRCJGCOYHLTVNR-ZUIZSQJWSA-N 0.000 description 1
- 229950001314 Mitindomide Drugs 0.000 description 1
- 229950002137 Mitocarcin Drugs 0.000 description 1
- 229960003539 Mitoguazone Drugs 0.000 description 1
- 229950007612 Mitomalcin Drugs 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- 229950001745 Mitonafide Drugs 0.000 description 1
- 229950005715 Mitosper Drugs 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- 229950008012 Mofarotene Drugs 0.000 description 1
- 229960004684 Molindone Hydrochloride Drugs 0.000 description 1
- 208000010076 Mononeuropathy Diseases 0.000 description 1
- 229950002481 Moprolol Drugs 0.000 description 1
- LFTFGCDECFPSQD-UHFFFAOYSA-N Moprolol Chemical compound COC1=CC=CC=C1OCC(O)CNC(C)C LFTFGCDECFPSQD-UHFFFAOYSA-N 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor family Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor family Proteins 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 206010028323 Muscle pain Diseases 0.000 description 1
- 229940083876 Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 231100000678 Mycotoxin Toxicity 0.000 description 1
- 208000003067 Myocardial Ischemia Diseases 0.000 description 1
- PAVKBQLPQCDVNI-UHFFFAOYSA-N N',N'-diethyl-N-(9-methoxy-5,11-dimethyl-6H-pyrido[4,3-b]carbazol-1-yl)propane-1,3-diamine Chemical class N1C2=CC=C(OC)C=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2C PAVKBQLPQCDVNI-UHFFFAOYSA-N 0.000 description 1
- USVMJSALORZVDV-SDBHATRESA-N N(6)-(Delta(2)-isopentenyl)adenosine Chemical compound C1=NC=2C(NCC=C(C)C)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O USVMJSALORZVDV-SDBHATRESA-N 0.000 description 1
- QJMCKEPOKRERLN-UHFFFAOYSA-N N,3,4-trihydroxybenzamide Chemical compound ONC(=O)C1=CC=C(O)C(O)=C1 QJMCKEPOKRERLN-UHFFFAOYSA-N 0.000 description 1
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 1
- JVGUNCHERKJFCM-UHFFFAOYSA-N N-(2-hydroxyethyl)-2-[4-(2-methylpropyl)phenyl]propanamide Chemical compound CC(C)CC1=CC=C(C(C)C(=O)NCCO)C=C1 JVGUNCHERKJFCM-UHFFFAOYSA-N 0.000 description 1
- GBPZSCQLDXUGNO-UHFFFAOYSA-N N-(acetylcarbamoyl)-2-phenylbutanamide Chemical compound CC(=O)NC(=O)NC(=O)C(CC)C1=CC=CC=C1 GBPZSCQLDXUGNO-UHFFFAOYSA-N 0.000 description 1
- CRJGESKKUOMBCT-PMACEKPBSA-N N-[(2S,3S)-1,3-dihydroxyoctadecan-2-yl]acetamide Chemical compound CCCCCCCCCCCCCCC[C@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-PMACEKPBSA-N 0.000 description 1
- NKFHKYQGZDAKMX-PPRKPIOESA-N N-[(E)-1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethylideneamino]benzamide;hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 NKFHKYQGZDAKMX-PPRKPIOESA-N 0.000 description 1
- TVYPSLDUBVTDIS-FUOMVGGVSA-N N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]-3,4,5-trimethoxybenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NC=2C(=CN(C(=O)N=2)[C@H]2[C@@H]([C@H](O)[C@@H](C)O2)O)F)=C1 TVYPSLDUBVTDIS-FUOMVGGVSA-N 0.000 description 1
- QTNZYVAMNRDUAD-UHFFFAOYSA-N N-[4-[(2-methylpropan-2-yl)oxy]phenyl]acetamide Chemical compound CC(=O)NC1=CC=C(OC(C)(C)C)C=C1 QTNZYVAMNRDUAD-UHFFFAOYSA-N 0.000 description 1
- DURULFYMVIFBIR-ZDUSSCGKSA-N N-[4-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide Chemical compound CC(C)NC[C@H](O)COC1=CC=C(NC(C)=O)C=C1 DURULFYMVIFBIR-ZDUSSCGKSA-N 0.000 description 1
- HRXVDDOKERXBEY-UHFFFAOYSA-N N-[bis(aziridin-1-yl)phosphoryl]-N-ethyl-1,3,4-thiadiazol-2-amine Chemical compound C1CN1P(=O)(N1CC1)N(CC)C1=NN=CS1 HRXVDDOKERXBEY-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- PWXJULSLLONQHY-UHFFFAOYSA-M N-phenylcarbamate Chemical compound [O-]C(=O)NC1=CC=CC=C1 PWXJULSLLONQHY-UHFFFAOYSA-M 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M N-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- JPASRFGVACYSJG-UHFFFAOYSA-N N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 Chemical class N1=C2C=CC3=NC=NC3=C2C=C2C1=CCC(=O)C2 JPASRFGVACYSJG-UHFFFAOYSA-N 0.000 description 1
- GECBBEABIDMGGL-RTBURBONSA-N Nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 description 1
- 229960004255 Nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N Nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- UPZVYDSBLFNMLK-UHFFFAOYSA-N Nadoxolol Chemical compound C1=CC=C2C(OCC(O)CC(/N)=N/O)=CC=CC2=C1 UPZVYDSBLFNMLK-UHFFFAOYSA-N 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 229960002333 Nafarelin Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N Nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 Nalbuphine Drugs 0.000 description 1
- 229960004127 Naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N Naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 Naltrexone Drugs 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N Naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- DEXMFYZAHXMZNM-UHFFFAOYSA-N Narceine Chemical compound OC(=O)C1=C(OC)C(OC)=CC=C1C(=O)CC1=C(CCN(C)C)C=C(OCO2)C2=C1OC DEXMFYZAHXMZNM-UHFFFAOYSA-N 0.000 description 1
- 229950010676 Nartograstim Drugs 0.000 description 1
- 229950007221 Nedaplatin Drugs 0.000 description 1
- QZGIWPZCWHMVQL-UIYAJPBUSA-N Neocarzinostatin Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029149 Nephropathy Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 208000009928 Nephrosis Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 description 1
- NOIIUHRQUVNIDD-UHFFFAOYSA-N Nialamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 1
- 229960003057 Nialamide Drugs 0.000 description 1
- 229960001783 Nicardipine Drugs 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- HNDXBGYRMHRUFN-CIVUWBIHSA-N Nicomorphine Chemical compound O([C@H]1C=C[C@H]2[C@H]3CC=4C5=C(C(=CC=4)OC(=O)C=4C=NC=CC=4)O[C@@H]1[C@]52CCN3C)C(=O)C1=CC=CN=C1 HNDXBGYRMHRUFN-CIVUWBIHSA-N 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- 229960001597 Nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N Nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- UAORFCGRZIGNCI-UHFFFAOYSA-N Nifenalol Chemical compound CC(C)NCC(O)C1=CC=C([N+]([O-])=O)C=C1 UAORFCGRZIGNCI-UHFFFAOYSA-N 0.000 description 1
- 229960000916 Niflumic Acid Drugs 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N Nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N Nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 229960000715 Nimodipine Drugs 0.000 description 1
- UIAGMCDKSXEBJQ-UHFFFAOYSA-N Nimodipine Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-UHFFFAOYSA-N 0.000 description 1
- 229950000754 Nipradilol Drugs 0.000 description 1
- OMCPLEZZPVJJIS-UHFFFAOYSA-N Nipradilol Chemical compound C1C(O[N+]([O-])=O)COC2=C1C=CC=C2OCC(O)CNC(C)C OMCPLEZZPVJJIS-UHFFFAOYSA-N 0.000 description 1
- 229960000227 Nisoldipine Drugs 0.000 description 1
- 229960001454 Nitrazepam Drugs 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N Nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 229950006344 Nocodazole Drugs 0.000 description 1
- 229960002640 Nordazepam Drugs 0.000 description 1
- AKPLHCDWDRPJGD-UHFFFAOYSA-N Nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
- 229950011519 Norlevorphanol Drugs 0.000 description 1
- WCJFBSYALHQBSK-UHFFFAOYSA-N Normethadone Chemical compound C=1C=CC=CC=1C(CCN(C)C)(C(=O)CC)C1=CC=CC=C1 WCJFBSYALHQBSK-UHFFFAOYSA-N 0.000 description 1
- ONBWJWYUHXVEJS-ZTYRTETDSA-N Normorphine Chemical compound C([C@@H](NCC1)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 ONBWJWYUHXVEJS-ZTYRTETDSA-N 0.000 description 1
- 229950006134 Normorphine Drugs 0.000 description 1
- GPTURHKXTUDRPC-UHFFFAOYSA-N Noxiptiline Chemical compound C1CC2=CC=CC=C2C(=NOCCN(C)C)C2=CC=CC=C21 GPTURHKXTUDRPC-UHFFFAOYSA-N 0.000 description 1
- 210000001009 Nucleus accumbens Anatomy 0.000 description 1
- 206010029864 Nystagmus Diseases 0.000 description 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O(6)-benzylguanine; Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 description 1
- 229940074726 OPHTHALMOLOGIC ANTIINFLAMMATORY AGENTS Drugs 0.000 description 1
- 101710003000 ORF1/ORF2 Proteins 0.000 description 1
- FODQIVGFADUBKE-UHFFFAOYSA-N Octamoxin Chemical compound CCCCCCC(C)NN FODQIVGFADUBKE-UHFFFAOYSA-N 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229940049964 Oleate Drugs 0.000 description 1
- 210000000956 Olfactory Bulb Anatomy 0.000 description 1
- 210000004248 Oligodendroglia Anatomy 0.000 description 1
- 229950011093 Onapristone Drugs 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 208000002042 Onchocerciasis Diseases 0.000 description 1
- YNZFUWZUGRBMHL-UHFFFAOYSA-N Opipramol Chemical compound C1CN(CCO)CCN1CCCN1C2=CC=CC=C2C=CC2=CC=CC=C21 YNZFUWZUGRBMHL-UHFFFAOYSA-N 0.000 description 1
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- ZLLOIFNEEWYATC-XMUHMHRVSA-N Osaterone Chemical compound C1=C(Cl)C2=CC(=O)OC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 ZLLOIFNEEWYATC-XMUHMHRVSA-N 0.000 description 1
- 229950006466 Osaterone Drugs 0.000 description 1
- 208000005368 Osteomalacia Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N Oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N Oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- XCWPUUGSGHNIDZ-UHFFFAOYSA-N Oxypertine Chemical compound C1=2C=C(OC)C(OC)=CC=2NC(C)=C1CCN(CC1)CCN1C1=CC=CC=C1 XCWPUUGSGHNIDZ-UHFFFAOYSA-N 0.000 description 1
- 229950003180 PEPLOMYCIN Drugs 0.000 description 1
- 102100012884 PF4 Human genes 0.000 description 1
- 101710014074 PF4 Proteins 0.000 description 1
- 229950006445 PIMINODINE Drugs 0.000 description 1
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N PUROMYCIN Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 1
- 229950010131 PUROMYCIN Drugs 0.000 description 1
- VYOQBYCIIJYKJA-VORKOXQSSA-N Palau'amine Chemical compound N([C@@]12[C@@H](Cl)[C@@H]([C@@H]3[C@@H]2[C@]24N=C(N)N[C@H]2N2C=CC=C2C(=O)N4C3)CN)C(N)=N[C@H]1O VYOQBYCIIJYKJA-VORKOXQSSA-N 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N Pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033666 Panic disease Diseases 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- VQASKUSHBVDKGU-UHFFFAOYSA-N Paramethadione Chemical compound CCC1(C)OC(=O)N(C)C1=O VQASKUSHBVDKGU-UHFFFAOYSA-N 0.000 description 1
- 229960003274 Paramethadione Drugs 0.000 description 1
- 208000002851 Paranoid Schizophrenia Diseases 0.000 description 1
- 206010034005 Parkinson's disease and parkinsonism Diseases 0.000 description 1
- 208000007697 Partial Epilepsy Diseases 0.000 description 1
- 206010061334 Partial seizure Diseases 0.000 description 1
- LPHSYQSMAGVYNT-UHFFFAOYSA-N Pazelliptine Chemical compound N1C2=CC=NC=C2C2=C1C(C)=C1C=CN=C(NCCCN(CC)CC)C1=C2 LPHSYQSMAGVYNT-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N Penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- FCCNSUIJIOOXEZ-SJYYZXOBSA-N Pentosan Polysulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@@H](OS(O)(=O)=O)[C@H](O)CO[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](O)OC1 FCCNSUIJIOOXEZ-SJYYZXOBSA-N 0.000 description 1
- 229940043138 Pentosan Polysulfate Drugs 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- WTWWXOGTJWMJHI-UHFFFAOYSA-N Perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000001293 Peripheral Nervous System Disease Diseases 0.000 description 1
- 206010062585 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 206010034606 Peripheral neuropathy Diseases 0.000 description 1
- 206010034721 Personality disease Diseases 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Petidina Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 240000005158 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- XPFRXWCVYUEORT-UHFFFAOYSA-N Phenacemide Chemical compound NC(=O)NC(=O)CC1=CC=CC=C1 XPFRXWCVYUEORT-UHFFFAOYSA-N 0.000 description 1
- 229960003893 Phenacetin Drugs 0.000 description 1
- CPJSUEIXXCENMM-UHFFFAOYSA-N Phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 1
- 229960000897 Phenazocine Drugs 0.000 description 1
- ZQHYKVKNPWDQSL-KNXBSLHKSA-N Phenazocine Chemical compound C([C@@]1(C)C2=CC(O)=CC=C2C[C@@H]2[C@@H]1C)CN2CCC1=CC=CC=C1 ZQHYKVKNPWDQSL-KNXBSLHKSA-N 0.000 description 1
- AJOQSQHYDOFIOX-UHFFFAOYSA-N Pheneturide Chemical compound NC(=O)NC(=O)C(CC)C1=CC=CC=C1 AJOQSQHYDOFIOX-UHFFFAOYSA-N 0.000 description 1
- 229960004315 Phenoperidine Drugs 0.000 description 1
- WLWFNJKHKGIJNW-UHFFFAOYSA-N Phensuximide Chemical compound O=C1N(C)C(=O)CC1C1=CC=CC=C1 WLWFNJKHKGIJNW-UHFFFAOYSA-N 0.000 description 1
- 229960002895 Phenylbutazone Drugs 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N Phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N Phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- TZFUBYYADABEAV-UHFFFAOYSA-N Piberaline Chemical compound C=1C=CC=NC=1C(=O)N(CC1)CCN1CC1=CC=CC=C1 TZFUBYYADABEAV-UHFFFAOYSA-N 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- PXXKIYPSXYFATG-UHFFFAOYSA-N Piminodine Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCCNC1=CC=CC=C1 PXXKIYPSXYFATG-UHFFFAOYSA-N 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N Pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- IHEHEFLXQFOQJO-UHFFFAOYSA-N Piritramide Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 IHEHEFLXQFOQJO-UHFFFAOYSA-N 0.000 description 1
- FIADGNVRKBPQEU-UHFFFAOYSA-N Pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 description 1
- 229940068199 Pizotyline Drugs 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229960003171 Plicamycin Drugs 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004358 Polyneuropathy Diseases 0.000 description 1
- PJYYBCXMCWDUAZ-YKDQUOQBSA-N Ponasterone A Natural products O=C1[C@H]2[C@@](C)([C@@H]3C([C@@]4(O)[C@@](C)([C@H]([C@@](O)([C@@H](O)CCC(C)C)C)CC4)CC3)=C1)C[C@H](O)[C@H](O)C2 PJYYBCXMCWDUAZ-YKDQUOQBSA-N 0.000 description 1
- 229960004293 Porfimer Sodium Drugs 0.000 description 1
- 229950004406 Porfiromycin Drugs 0.000 description 1
- 206010036376 Post herpetic neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 229960001749 Practolol Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N Pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 229960004856 Prazepam Drugs 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- IFFPICMESYHZPQ-UHFFFAOYSA-N Prenylamine Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)CCNC(C)CC1=CC=CC=C1 IFFPICMESYHZPQ-UHFFFAOYSA-N 0.000 description 1
- 229960001989 Prenylamine Drugs 0.000 description 1
- 229960001586 Procarbazine Hydrochloride Drugs 0.000 description 1
- 208000000399 Procedural Pain Diseases 0.000 description 1
- IBALRBWGSVJPAP-HEHNFIMWSA-N Progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- ZXWAUWBYASJEOE-UHFFFAOYSA-N Proheptazine Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)CCCN(C)CC1C ZXWAUWBYASJEOE-UHFFFAOYSA-N 0.000 description 1
- 229950010387 Proheptazine Drugs 0.000 description 1
- OJCPSBCUMRIPFL-UHFFFAOYSA-N Prolintane Chemical group C1CCCN1C(CCC)CC1=CC=CC=C1 OJCPSBCUMRIPFL-UHFFFAOYSA-N 0.000 description 1
- HRSANNODOVBCST-UHFFFAOYSA-N Pronethalol Chemical compound C1=CC=CC2=CC(C(O)CNC(C)C)=CC=C21 HRSANNODOVBCST-UHFFFAOYSA-N 0.000 description 1
- 229960005439 Propantheline Bromide Drugs 0.000 description 1
- XLBIBBZXLMYSFF-UHFFFAOYSA-M Propantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=CC=CC=C3OC2=C1 XLBIBBZXLMYSFF-UHFFFAOYSA-M 0.000 description 1
- ZBAFFZBKCMWUHM-UHFFFAOYSA-N Propiram Chemical compound C=1C=CC=NC=1N(C(=O)CC)C(C)CN1CCCCC1 ZBAFFZBKCMWUHM-UHFFFAOYSA-N 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 240000002799 Prunus avium Species 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 208000009954 Pyoderma Gangrenosum Diseases 0.000 description 1
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N Quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960005197 Quetiapine fumarate Drugs 0.000 description 1
- 229960000279 Quinupramine Drugs 0.000 description 1
- 229960004356 RIBOPRINE Drugs 0.000 description 1
- NTHPAPBPFQJABD-LLVKDONJSA-N Ramosetron Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)[C@H]1CC(NC=N2)=C2CC1 NTHPAPBPFQJABD-LLVKDONJSA-N 0.000 description 1
- 108090000231 Ras GTPase-activating proteins Proteins 0.000 description 1
- 102000003901 Ras GTPase-activating proteins Human genes 0.000 description 1
- 206010037870 Rash morbilliform Diseases 0.000 description 1
- 210000000664 Rectum Anatomy 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010038776 Retching Diseases 0.000 description 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- WUAPFZMCVAUBPE-UHFFFAOYSA-N Rhenium Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N Rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- JUQLTPCYUFPYKE-UHFFFAOYSA-N Ritanserin Chemical compound CC=1N=C2SC=CN2C(=O)C=1CCN(CC1)CCC1=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 JUQLTPCYUFPYKE-UHFFFAOYSA-N 0.000 description 1
- TXHZXHICDBAVJW-UHFFFAOYSA-N Rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N Rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229950004252 Rolicyprine Drugs 0.000 description 1
- SGOOQMRIPALTEL-UHFFFAOYSA-N Roquinimex Chemical compound OC=1C2=CC=CC=C2N(C)C(=O)C=1C(=O)N(C)C1=CC=CC=C1 SGOOQMRIPALTEL-UHFFFAOYSA-N 0.000 description 1
- BKTTWZADZNUOBW-UHFFFAOYSA-N Roxindole Chemical compound C=12[CH]C(O)=CC=C2N=CC=1CCCCN(CC=1)CCC=1C1=CC=CC=C1 BKTTWZADZNUOBW-UHFFFAOYSA-N 0.000 description 1
- 229950000366 Roxindole Drugs 0.000 description 1
- 229950005175 SUDOXICAM Drugs 0.000 description 1
- 229950005165 SULFINALOL Drugs 0.000 description 1
- 229940081974 Saccharin Drugs 0.000 description 1
- 206010039361 Sacroiliitis Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010039637 Schizophrenia, catatonic type Diseases 0.000 description 1
- 206010039638 Schizophrenia, disorganised type Diseases 0.000 description 1
- 206010039639 Schizophrenia, paranoid type Diseases 0.000 description 1
- 229950008243 Secbutabarbital Drugs 0.000 description 1
- 229940076279 Serotonin Drugs 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 206010040943 Skin ulcer Diseases 0.000 description 1
- 206010040984 Sleep disease Diseases 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N Sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M Sodium stearate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 229950004225 Sonermin Drugs 0.000 description 1
- 229960002370 Sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N Sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- XKLZIVIOZDNKEQ-CLQLPEFOSA-N Sparsomycin Chemical compound CSC[S@](=O)C[C@H](CO)NC(=O)\C=C\C1=C(C)NC(=O)NC1=O XKLZIVIOZDNKEQ-CLQLPEFOSA-N 0.000 description 1
- 229950009641 Sparsomycin Drugs 0.000 description 1
- YBZRLMLGUBIIDN-UHFFFAOYSA-N Spicamycin Chemical compound O1C(C(O)CO)C(NC(=O)CNC(=O)CCCCCCCCCCCCC(C)C)C(O)C(O)C1NC1=NC=NC2=C1NC=N2 YBZRLMLGUBIIDN-UHFFFAOYSA-N 0.000 description 1
- 208000008513 Spinal Cord Injury Diseases 0.000 description 1
- HAOCRCFHEPRQOY-JKTUOYIXSA-N Spongistatin-1 Chemical compound C([C@@H]1C[C@@H](C[C@@]2(C[C@@H](O)C[C@@H](C2)\C=C/CCC[C@@H]2[C@H](C)[C@@H](O)C[C@](O2)(O)[C@H]2O)O1)OC)C(=O)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)C(=C)C[C@H](O1)C[C@](C)(O)C[C@@]1(O1)C[C@@H](OC(C)=O)C[C@@H]1CC(=O)O[C@H]1[C@H](O)[C@@H](CC(=C)C(C)[C@H](O)\C=C\C(Cl)=C)O[C@@H]2[C@@H]1C HAOCRCFHEPRQOY-JKTUOYIXSA-N 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- 229950001248 Squalamine Drugs 0.000 description 1
- 208000005809 Status Epilepticus Diseases 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 208000003265 Stomatitis Diseases 0.000 description 1
- 206010066218 Stress urinary incontinence Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- YJPVTCSBVRMESK-UHFFFAOYSA-L Strontium bromide Chemical compound [Br-].[Br-].[Sr+2] YJPVTCSBVRMESK-UHFFFAOYSA-L 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229960004739 Sufentanil Drugs 0.000 description 1
- PAQZZCOZHPGCFW-UHFFFAOYSA-N Sulfinalol Chemical compound C1=CC(OC)=CC=C1CCC(C)NCC(O)C1=CC=C(O)C(S(C)=O)=C1 PAQZZCOZHPGCFW-UHFFFAOYSA-N 0.000 description 1
- HMHVCUVYZFYAJI-UHFFFAOYSA-N Sultiame Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1S(=O)(=O)CCCC1 HMHVCUVYZFYAJI-UHFFFAOYSA-N 0.000 description 1
- 229960004492 Suprofen Drugs 0.000 description 1
- MDKGKXOCJGEUJW-UHFFFAOYSA-N Suprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-UHFFFAOYSA-N 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N Suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 Suramin Drugs 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 206010042772 Syncope Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 1
- 229950002345 TIOPINAC Drugs 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 102100009263 TRPV1 Human genes 0.000 description 1
- 229960001685 Tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N Tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- MXFWWQICDIZSOA-UHFFFAOYSA-N Talinolol Chemical compound C1=CC(OCC(O)CNC(C)(C)C)=CC=C1NC(=O)NC1CCCCC1 MXFWWQICDIZSOA-UHFFFAOYSA-N 0.000 description 1
- 229950002687 Talisomycin Drugs 0.000 description 1
- VOKSWYLNZZRQPF-UHFFFAOYSA-N Talwin Chemical compound C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-UHFFFAOYSA-N 0.000 description 1
- CEIJFEGBUDEYSX-FZDBZEDMSA-N Tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 206010043118 Tardive dyskinesia Diseases 0.000 description 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N Tasmar Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 1
- 229950010168 Tauromustine Drugs 0.000 description 1
- RNVNXVVEDMSRJE-UHFFFAOYSA-N Teloxantrone hydrochloride Chemical compound Cl.Cl.OCCNCCN1NC2=C3C(=O)C=CC(=O)C3=C(O)C3=C2C1=CC=C3NCCNC RNVNXVVEDMSRJE-UHFFFAOYSA-N 0.000 description 1
- 229960003188 Temazepam Drugs 0.000 description 1
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temodal Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- UISARWKNNNHPGI-UHFFFAOYSA-N Terodiline Chemical compound C=1C=CC=CC=1C(CC(C)NC(C)(C)C)C1=CC=CC=C1 UISARWKNNNHPGI-UHFFFAOYSA-N 0.000 description 1
- 229950008703 Teroxirone Drugs 0.000 description 1
- 229960005353 Testolactone Drugs 0.000 description 1
- 229940033529 Tetrahydrocannabinol Drugs 0.000 description 1
- XCTYLCDETUVOIP-UHFFFAOYSA-N Thiethylperazine Chemical compound C12=CC(SCC)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 XCTYLCDETUVOIP-UHFFFAOYSA-N 0.000 description 1
- 229960004869 Thiethylperazine Drugs 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N ThioTEPA Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- UPGGKUQISSWRJJ-XLTUSUNSSA-N Thiocoraline Chemical compound O=C([C@H]1CSSC[C@@H](N(C(=O)CNC2=O)C)C(=O)N(C)[C@@H](C(SC[C@@H](C(=O)NCC(=O)N1C)NC(=O)C=1C(=CC3=CC=CC=C3N=1)O)=O)CSC)N(C)[C@H](CSC)C(=O)SC[C@@H]2NC(=O)C1=NC2=CC=CC=C2C=C1O UPGGKUQISSWRJJ-XLTUSUNSSA-N 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- HFRXJVQOXRXOPP-UHFFFAOYSA-N Thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 1
- RKIDPTUGNXTOMU-UHFFFAOYSA-N Thionyl iodide Chemical compound IS(I)=O RKIDPTUGNXTOMU-UHFFFAOYSA-N 0.000 description 1
- 229960003279 Thiopental Drugs 0.000 description 1
- VZYCZNZBPPHOFY-UHFFFAOYSA-N Thioproperazine Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(C)CC1 VZYCZNZBPPHOFY-UHFFFAOYSA-N 0.000 description 1
- 229960001196 Thiotepa Drugs 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 229960000882 Thiothixene hydrochloride Drugs 0.000 description 1
- JJSHYECKYLDYAR-UHFFFAOYSA-N Thozalinone Chemical compound O1C(N(C)C)=NC(=O)C1C1=CC=CC=C1 JJSHYECKYLDYAR-UHFFFAOYSA-N 0.000 description 1
- 206010043554 Thrombocytopenia Diseases 0.000 description 1
- 102000036902 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 229950010183 Thymotrinan Drugs 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N Tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 229950011457 Tiamiprine Drugs 0.000 description 1
- JICJBGPOMZQUBB-UHFFFAOYSA-N Tianeptine Chemical compound O=S1(=O)N(C)C2=CC=CC=C2C(NCCCCCCC(O)=O)C2=CC=C(Cl)C=C21 JICJBGPOMZQUBB-UHFFFAOYSA-N 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N Tilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- TWVUMMQUXMYOOH-UHFFFAOYSA-N Tilisolol Chemical compound C1=CC=C2C(=O)N(C)C=C(OCC(O)CNC(C)(C)C)C2=C1 TWVUMMQUXMYOOH-UHFFFAOYSA-N 0.000 description 1
- XFYDIVBRZNQMJC-UHFFFAOYSA-N Tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
- 229960000488 Tizanidine Drugs 0.000 description 1
- PNYKGCPSFKLFKA-UHFFFAOYSA-N Tofenacin Chemical compound C=1C=CC=C(C)C=1C(OCCNC)C1=CC=CC=C1 PNYKGCPSFKLFKA-UHFFFAOYSA-N 0.000 description 1
- YEZNLOUZAIOMLT-UHFFFAOYSA-N Tolfenamic acid Chemical compound CC1=C(Cl)C=CC=C1NC1=CC=CC=C1C(O)=O YEZNLOUZAIOMLT-UHFFFAOYSA-N 0.000 description 1
- 229950000245 Toliprolol Drugs 0.000 description 1
- NXQMNKUGGYNLBY-UHFFFAOYSA-N Toliprolol Chemical compound CC(C)NCC(O)COC1=CC=CC(C)=C1 NXQMNKUGGYNLBY-UHFFFAOYSA-N 0.000 description 1
- MXUNKHLAEDCYJL-UHFFFAOYSA-N Toloxatone Chemical compound CC1=CC=CC(N2C(OC(CO)C2)=O)=C1 MXUNKHLAEDCYJL-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Tolvon Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- TVPNFKRGOFJQOO-UHFFFAOYSA-N Topsentin B1 Chemical compound C1=CC=C2C(C3=CN=C(N3)C(=O)C=3C4=CC=C(C=C4NC=3)O)=CNC2=C1 TVPNFKRGOFJQOO-UHFFFAOYSA-N 0.000 description 1
- 229960004167 Toremifene Citrate Drugs 0.000 description 1
- 229950007145 Tozalinone Drugs 0.000 description 1
- 206010044325 Trachoma Diseases 0.000 description 1
- 241000390203 Trachoma Species 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000005765 Traumatic Brain Injury Diseases 0.000 description 1
- JOFWLTCLBGQGBO-UHFFFAOYSA-N Triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 1
- 208000002271 Trichotillomania Diseases 0.000 description 1
- 229950003873 Triciribine Drugs 0.000 description 1
- FEZBIKUBAYAZIU-UHFFFAOYSA-N Trimethobenzamide Chemical compound COC1=C(OC)C(OC)=CC(C(=O)NCC=2C=CC(OCCN(C)C)=CC=2)=C1 FEZBIKUBAYAZIU-UHFFFAOYSA-N 0.000 description 1
- 229960001099 Trimetrexate Drugs 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N Trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N Trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 229960004799 Tryptophan Drugs 0.000 description 1
- WMPQMBUXZHMEFZ-YJPJVVPASA-N Turosteride Chemical compound CN([C@@H]1CC2)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)N(C(C)C)C(=O)NC(C)C)[C@@]2(C)CC1 WMPQMBUXZHMEFZ-YJPJVVPASA-N 0.000 description 1
- 229950007816 Turosteride Drugs 0.000 description 1
- PRBORDFJHHAISJ-UHFFFAOYSA-N Tybamate Chemical compound CCCCNC(=O)OCC(C)(CCC)COC(N)=O PRBORDFJHHAISJ-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 1
- 108009000112 Type II diabetes mellitus Proteins 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 229950009811 UBENIMEX Drugs 0.000 description 1
- 210000001364 Upper Extremity Anatomy 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N Uramustine Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 229950008261 Velaresol Drugs 0.000 description 1
- 206010052769 Vertigos Diseases 0.000 description 1
- PJDFLNIOAUIZSL-UHFFFAOYSA-N Vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 1
- 229960001255 Viloxazine Drugs 0.000 description 1
- YWPHCCPCQOJSGZ-UHFFFAOYSA-N Viloxazine Chemical compound CCOC1=CC=CC=C1OCC1OCCNC1 YWPHCCPCQOJSGZ-UHFFFAOYSA-N 0.000 description 1
- 229960004982 Vinblastine Sulfate Drugs 0.000 description 1
- 229960002110 Vincristine Sulfate Drugs 0.000 description 1
- AQTQHPDCURKLKT-PNYVAJAMSA-N Vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-PNYVAJAMSA-N 0.000 description 1
- 229960004355 Vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N Vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960005212 Vindesine Sulfate Drugs 0.000 description 1
- BCXOZISMDZTYHW-IFQBWSDRSA-N Vinepidine sulfate Chemical compound OS(O)(=O)=O.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@H](C2)CC)N2CCC2=C1NC1=CC=CC=C21 BCXOZISMDZTYHW-IFQBWSDRSA-N 0.000 description 1
- YNSIUGHLISOIRQ-XGNYHKEJSA-N Vinglycinate Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(=O)CN(C)C)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 YNSIUGHLISOIRQ-XGNYHKEJSA-N 0.000 description 1
- JXLYSJRDGCGARV-JOSRYNDLSA-N Vinrosidine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-JOSRYNDLSA-N 0.000 description 1
- MMRCWWRFYLZGAE-UHFFFAOYSA-N Vinzolidine Chemical compound C1C(CC)(O)CC(C2)CN1CCC(C1=CC=CC=C1N1)=C1C2(C(=O)OC)C(C(=C1)OC)=CC2=C1N(C)C1C2(C23)CCN3CC=CC2(CC)C(OC(C)=O)C11OC(=O)N(CCCl)C1=O MMRCWWRFYLZGAE-UHFFFAOYSA-N 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 229950005561 ZANOTERONE Drugs 0.000 description 1
- MHDDZDPNIDVLNK-ZGIWMXSJSA-N Zanoterone Chemical compound C1C2=NN(S(C)(=O)=O)C=C2C[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CC[C@H]21 MHDDZDPNIDVLNK-ZGIWMXSJSA-N 0.000 description 1
- 229950007802 Zidometacin Drugs 0.000 description 1
- 235000005042 Zier Kohl Nutrition 0.000 description 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N Ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N Zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 1
- ZAFYATHCZYHLPB-UHFFFAOYSA-N Zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 1
- ZXVNMYWKKDOREA-UHFFFAOYSA-N Zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 description 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N Zonegran Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- ZMQRJWIYMXZORG-GZIFKOAOSA-N [(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2S)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] dihydrogen phosphate Chemical compound OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)(O)=O)[C@@](O)(C)\C=C\[C@@H]1CC=CC(=O)O1 ZMQRJWIYMXZORG-GZIFKOAOSA-N 0.000 description 1
- ZZWKZQDOSJAGGF-BVTJJHQYSA-N [(1S,2Z,7S,10Z,12R,13R,15S)-12-hydroxy-7-methyl-9-oxo-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-15-yl] 2-(dimethylamino)acetate Chemical compound O[C@@H]1\C=C/C(=O)O[C@@H](C)CCC\C=C/[C@@H]2C[C@H](OC(=O)CN(C)C)C[C@H]21 ZZWKZQDOSJAGGF-BVTJJHQYSA-N 0.000 description 1
- SPKNARKFCOPTSY-XWPZMVOTSA-N [(2R,3S)-2-[(2S,3R)-3-methyloxiran-2-yl]-6-oxo-2,3-dihydropyran-3-yl] acetate Chemical compound C[C@H]1O[C@@H]1[C@H]1[C@@H](OC(C)=O)C=CC(=O)O1 SPKNARKFCOPTSY-XWPZMVOTSA-N 0.000 description 1
- VUPBDWQPEOWRQP-YDYCAPBPSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R)-3-[[5-[[1-[[2-[4-[4-[[4-amino-6-[3-(4-aminobutylamino)propylamino]-6-oxohexyl]carbamoyl]-1,3-thiazol-2-yl]-1,3-thiazol-2-yl]-1-[(2S,3R,4R,5S,6S)-5-amino-3,4-dihydroxy-6-methyloxan-2-yl]oxy-2-hydroxyethyl]amino Chemical compound O([C@H]1[C@@H]([C@H](O)[C@H](N)[C@H](C)O1)O)C(C(O)C=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCC(N)CC(=O)NCCCNCCCCN)NC(=O)C(C(O)C)NC(=O)CC(O)C(C)NC(=O)C([C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)NC(=O)C1=NC(C(CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C VUPBDWQPEOWRQP-YDYCAPBPSA-N 0.000 description 1
- ZHHIHQFAUZZMTG-BSVJBJGJSA-N [(2R,3S,4S,5R,6R)-2-[(2R,3S,4S,5S,6S)-2-[(1R,2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[[(2R,3S,4S)-3-hydroxy-5-[[(2S,3R)-3-hydroxy-1-oxo-1-[2-[4-[4-[3-[[(1S)-1-phenylethyl] Chemical compound OS(O)(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C ZHHIHQFAUZZMTG-BSVJBJGJSA-N 0.000 description 1
- GYKFWCDBQAFCLJ-RTWAWAEBSA-N [(2S,3S)-8-chloro-5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3-dihydro-1,5-benzothiazepin-3-yl] acetate Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=C(Cl)C=C2S1 GYKFWCDBQAFCLJ-RTWAWAEBSA-N 0.000 description 1
- UVITTYOJFDLOGI-LICQEQMYSA-N [(2S,5R)-1,2,5-trimethyl-4-phenylpiperidin-4-yl] propanoate Chemical compound C=1C=CC=CC=1C1(OC(=O)CC)C[C@H](C)N(C)C[C@H]1C UVITTYOJFDLOGI-LICQEQMYSA-N 0.000 description 1
- MXZYUFNILISKBC-WXLIAARGSA-N [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-6-(trifluoromethyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1([C@H](C2)C(F)(F)F)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(C)=O)(OC(=O)C)[C@@]2(C)CC1 MXZYUFNILISKBC-WXLIAARGSA-N 0.000 description 1
- PQNNIEWMPIULRS-SUTYWZMXSA-N [(8E,10E,12E)-7-hydroxy-6-methyl-2-(3-methyl-6-oxo-2,3-dihydropyran-2-yl)tetradeca-8,10,12-trien-5-yl] dihydrogen phosphate Chemical compound C\C=C\C=C\C=C\C(O)C(C)C(OP(O)(O)=O)CCC(C)C1OC(=O)C=CC1C PQNNIEWMPIULRS-SUTYWZMXSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8R,9S,13S,14S,17S)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- JJULHOZRTCDZOH-JGJFOBQESA-N [1-[[[(2R,3S,4S,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-3-octadecylsulfanylpropan-2-yl] hexadecanoate Chemical compound O[C@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(CSCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 JJULHOZRTCDZOH-JGJFOBQESA-N 0.000 description 1
- XSMVECZRZBFTIZ-UHFFFAOYSA-M [2-(aminomethyl)cyclobutyl]methanamine;2-oxidopropanoate;platinum(4+) Chemical compound [Pt+4].CC([O-])C([O-])=O.NCC1CCC1CN XSMVECZRZBFTIZ-UHFFFAOYSA-M 0.000 description 1
- OCOKWVBYZHBHLU-UHFFFAOYSA-N [4-[2-[4-(2-methylpropoxycarbonyloxymethyl)-3,5-dioxopiperazin-1-yl]ethyl]-2,6-dioxopiperazin-1-yl]methyl 2-methylpropyl carbonate Chemical compound C1C(=O)N(COC(=O)OCC(C)C)C(=O)CN1CCN1CC(=O)N(COC(=O)OCC(C)C)C(=O)C1 OCOKWVBYZHBHLU-UHFFFAOYSA-N 0.000 description 1
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N [N-]=C=S Chemical compound [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 description 1
- JURAJLFHWXNPHG-UHFFFAOYSA-N [acetyl(methylcarbamoyl)amino] N-methylcarbamate Chemical compound CNC(=O)ON(C(C)=O)C(=O)NC JURAJLFHWXNPHG-UHFFFAOYSA-N 0.000 description 1
- XXFXTBNFFMQVKJ-UHFFFAOYSA-N [diphenyl(trityloxy)methyl]benzene Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)OC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 XXFXTBNFFMQVKJ-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DEXPIBGCLCPUHE-UISHROKMSA-N acetic acid;(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5, Chemical compound CC(O)=O.C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 DEXPIBGCLCPUHE-UISHROKMSA-N 0.000 description 1
- IAGMBSXKAGFBJT-UHFFFAOYSA-N acetic acid;1,4-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione Chemical compound CC(O)=O.O=C1C2=CC=CC=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO IAGMBSXKAGFBJT-UHFFFAOYSA-N 0.000 description 1
- PDODBKYPSUYQGT-UHFFFAOYSA-N acetic acid;1H-indene Chemical class CC(O)=O.C1=CC=C2CC=CC2=C1 PDODBKYPSUYQGT-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229950009984 acetylpheneturide Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000003044 adaptive Effects 0.000 description 1
- 229960003148 adinazolam Drugs 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960002820 adrafinil Drugs 0.000 description 1
- 230000001919 adrenal Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 201000010000 agranulocytosis Diseases 0.000 description 1
- 229950000351 albutoin Drugs 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 201000003082 alcohol use disease Diseases 0.000 description 1
- 229960003687 alizapride Drugs 0.000 description 1
- 230000002340 alkalosis Effects 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N aminolevulinic acid Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- 201000002472 amphetamine abuse Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitors Drugs 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 108010070670 antarelix Proteins 0.000 description 1
- 230000002280 anti-androgenic Effects 0.000 description 1
- 230000000844 anti-bacterial Effects 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000003556 anti-epileptic Effects 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003070 anti-hyperalgesia Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003502 anti-nociceptive Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000000573 anti-seizure Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940082988 antihypertensives Serotonin antagonists Drugs 0.000 description 1
- 229940111136 antiinflammatory and antirheumatic drugs Fenamates Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drugs Oxicams Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229960003153 aprobarbital Drugs 0.000 description 1
- 229950007556 aranidipine Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000002917 arthritic Effects 0.000 description 1
- 125000002908 as-indacenyl group Chemical group C1(=CC=C2C=CC3=CC=CC3=C12)* 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 229950011088 asulacrine Drugs 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002567 autonomic Effects 0.000 description 1
- 108010093161 axinastatin 1 Proteins 0.000 description 1
- 108010093000 axinastatin 2 Proteins 0.000 description 1
- 108010092978 axinastatin 3 Proteins 0.000 description 1
- OPWOOOGFNULJAQ-UHFFFAOYSA-L azane;cyclopentanamine;2-hydroxybutanedioate;platinum(2+) Chemical compound N.[Pt+2].NC1CCCC1.[O-]C(=O)C(O)CC([O-])=O OPWOOOGFNULJAQ-UHFFFAOYSA-L 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 229960002992 barnidipine Drugs 0.000 description 1
- 229960005200 beclamide Drugs 0.000 description 1
- 229960004374 befunolol Drugs 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- 229950011271 benmoxin Drugs 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 229960004564 benzquinamide Drugs 0.000 description 1
- VFIUCBTYGKMLCM-UHFFFAOYSA-N benzyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C=1C=CC=CC=1COC(=O)NP(=O)(N1CC1)N1CC1 VFIUCBTYGKMLCM-UHFFFAOYSA-N 0.000 description 1
- NJAPCAIWQRPQPY-UHFFFAOYSA-M benzyl carbonate Chemical compound [O-]C(=O)OCC1=CC=CC=C1 NJAPCAIWQRPQPY-UHFFFAOYSA-M 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 125000003460 beta-lactamyl group Chemical class 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- 229960004611 bezitramide Drugs 0.000 description 1
- 230000035514 bioavailability Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000003008 brain-resident macrophage Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- DNPRVXJGNANVCZ-UHFFFAOYSA-N bromo(nitro)methane Chemical compound [O-][N+](=O)CBr DNPRVXJGNANVCZ-UHFFFAOYSA-N 0.000 description 1
- 229960001034 bromopride Drugs 0.000 description 1
- 229960003051 brotizolam Drugs 0.000 description 1
- 229960001705 buclizine Drugs 0.000 description 1
- 229950002568 bucumolol Drugs 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960000330 bupranolol Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229940015694 butabarbital Drugs 0.000 description 1
- 229950011189 butacetin Drugs 0.000 description 1
- 229960002546 butalbital Drugs 0.000 description 1
- KHBXORBAOCQNMC-UHFFFAOYSA-N butan-2-yl-[2-hydroxy-2-(5,6,7,8-tetrahydronaphthalen-2-yl)ethyl]azanium;chloride Chemical compound [Cl-].C1CCCC2=CC(C(O)C[NH2+]C(C)CC)=CC=C21 KHBXORBAOCQNMC-UHFFFAOYSA-N 0.000 description 1
- 229950003097 butidrine Drugs 0.000 description 1
- 229950009191 butofilolol Drugs 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 229960004649 calcipotriene Drugs 0.000 description 1
- 229960002882 calcipotriol Drugs 0.000 description 1
- 229940059251 calcium bromide Drugs 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- 229930007890 camphor Natural products 0.000 description 1
- 201000009322 cannabis abuse Diseases 0.000 description 1
- 201000001843 cannabis dependence Diseases 0.000 description 1
- 229960004634 carazolol Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 201000008031 cardiomyopathy Diseases 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 229950006044 caroxazone Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 229930016259 castanospermine Natural products 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960003020 cilnidipine Drugs 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229950008460 cinromide Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- 229960001791 clebopride Drugs 0.000 description 1
- 229960001403 clobazam Drugs 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229960004893 cloranolol Drugs 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 201000001272 cocaine abuse Diseases 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002860 competitive Effects 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 201000008739 coronary artery disease Diseases 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- 108010090203 cryptophycin 8 Proteins 0.000 description 1
- 238000010192 crystallographic characterization Methods 0.000 description 1
- 229960003564 cyclizine Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001945 cyclooctatrienyl group Chemical group C1(=CC=CC=CCC1)* 0.000 description 1
- 125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 229950011023 decimemide Drugs 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 231100000080 dermatitis contact Toxicity 0.000 description 1
- 229960005408 deslorelin Drugs 0.000 description 1
- 229950003851 desomorphine Drugs 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229950001640 dexormaplatin Drugs 0.000 description 1
- SGTNSNPWRIOYBX-HHHXNRCGSA-N dexverapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCC[C@@](C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-HHHXNRCGSA-N 0.000 description 1
- 201000007025 diabetic cataract Diseases 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- 229950001059 diampromide Drugs 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 229960003075 dibenzepin Drugs 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M diethyl-methyl-[2-(9H-xanthene-9-carbonyloxy)ethyl]azanium;bromide Chemical group [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive Effects 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229950011187 dimenoxadol Drugs 0.000 description 1
- 229960003524 dimetacrine Drugs 0.000 description 1
- JYJFNDQBESEHJQ-UHFFFAOYSA-N dimethadione Chemical compound CC1(C)OC(=O)NC1=O JYJFNDQBESEHJQ-UHFFFAOYSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- SRXOCFMDUSFFAK-UHFFFAOYSA-N dimethyl peroxide Chemical compound COOC SRXOCFMDUSFFAK-UHFFFAOYSA-N 0.000 description 1
- 229960001640 dimetotiazine Drugs 0.000 description 1
- 229950006161 dioxadrol Drugs 0.000 description 1
- 229960003520 diphenidol Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- HTWFXPCUFWKXOP-UHFFFAOYSA-N dl-Tertatalol Chemical compound C1CCSC2=C1C=CC=C2OCC(O)CNC(C)(C)C HTWFXPCUFWKXOP-UHFFFAOYSA-N 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N dl-Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 229940017743 dromostanolone propionate Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 108010057988 ecdysone receptor Proteins 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960000305 enflurane Drugs 0.000 description 1
- 229960003337 entacapone Drugs 0.000 description 1
- 229960002711 epanolol Drugs 0.000 description 1
- 210000002919 epithelial cells Anatomy 0.000 description 1
- 229950010920 eptazocine Drugs 0.000 description 1
- 229960001405 ergometrine Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229950009327 eterobarb Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960000569 ethoheptazine Drugs 0.000 description 1
- XPGDODOEEWLHOI-GSDHBNRESA-N ethyl (2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-fluorophenyl)propanoyl]amino]-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)OCC)NC(=O)[C@@H](N)CC=1C=CC(F)=CC=1)C1=CC=CC(N(CCCl)CCCl)=C1 XPGDODOEEWLHOI-GSDHBNRESA-N 0.000 description 1
- IPOPQVVNCFQFRK-UHFFFAOYSA-N ethyl 1-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(O)C1=CC=CC=C1 IPOPQVVNCFQFRK-UHFFFAOYSA-N 0.000 description 1
- HZQPPNNARUQMJA-IMIWJGOWSA-N ethyl N-[4-[[(2R,4R)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methylsulfanyl]phenyl]carbamate;hydrochloride Chemical compound Cl.C1=CC(NC(=O)OCC)=CC=C1SC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 HZQPPNNARUQMJA-IMIWJGOWSA-N 0.000 description 1
- SPDZFJLQFWSJGA-UHFFFAOYSA-N ethyl N-[bis(aziridin-1-yl)phosphoryl]carbamate Chemical compound C1CN1P(=O)(NC(=O)OCC)N1CC1 SPDZFJLQFWSJGA-UHFFFAOYSA-N 0.000 description 1
- QTFKTBRIGWJQQL-UHFFFAOYSA-N ethyl N-bis(2,2-dimethylaziridin-1-yl)phosphorylcarbamate Chemical compound C1C(C)(C)N1P(=O)(NC(=O)OCC)N1CC1(C)C QTFKTBRIGWJQQL-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229950006111 ethylmethylthiambutene Drugs 0.000 description 1
- 229960005437 etoperidone Drugs 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960005182 febarbamate Drugs 0.000 description 1
- 229950003930 femoxetine Drugs 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- 229950011196 fenpentadiol Drugs 0.000 description 1
- 229960002679 fentiazac Drugs 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- 229960005304 fludarabine phosphate Drugs 0.000 description 1
- 229950010868 flumedroxone acetate Drugs 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229940042966 fonazine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- PGTKVMVZBBZCKQ-UHFFFAOYSA-N fulvene Chemical compound C=C1C=CC=C1 PGTKVMVZBBZCKQ-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229960003794 ganirelix Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000002406 gelatinase inhibitor Substances 0.000 description 1
- OKKDEIYWILRZIA-OSZBKLCCSA-N gemcitabine hydrochloride Chemical compound [H+].[Cl-].O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 OKKDEIYWILRZIA-OSZBKLCCSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 201000006529 generalized anxiety disease Diseases 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229960002462 glycopyrronium bromide Drugs 0.000 description 1
- 201000005569 gout Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 108010075381 growth inhibitory factor Proteins 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229960005007 haloperidol decanoate Drugs 0.000 description 1
- 230000002489 hematologic Effects 0.000 description 1
- 230000002008 hemorrhagic Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229950010282 heptobarbital Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- SOCGJDYHNGLZEC-UHFFFAOYSA-N hydron;N-methyl-N-[4-[(7-methyl-3H-imidazo[4,5-f]quinolin-9-yl)amino]phenyl]acetamide;chloride Chemical compound Cl.C1=CC(N(C(C)=O)C)=CC=C1NC1=CC(C)=NC2=CC=C(NC=N3)C3=C12 SOCGJDYHNGLZEC-UHFFFAOYSA-N 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 230000003345 hyperglycaemic Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 201000001948 hypertensive retinopathy Diseases 0.000 description 1
- 230000002218 hypoglycaemic Effects 0.000 description 1
- 230000000396 hypokalemic Effects 0.000 description 1
- 230000001146 hypoxic Effects 0.000 description 1
- 229960005236 ibandronic acid Drugs 0.000 description 1
- TZBDEVBNMSLVKT-UHFFFAOYSA-N idramantone Chemical compound C1C(C2)CC3CC1(O)CC2C3=O TZBDEVBNMSLVKT-UHFFFAOYSA-N 0.000 description 1
- 229960003696 ilomastat Drugs 0.000 description 1
- 229960003441 imipramine oxide Drugs 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- 230000003308 immunostimulating Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001976 improved Effects 0.000 description 1
- 229950002473 indalpine Drugs 0.000 description 1
- 229960004333 indeloxazine Drugs 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000000266 injurious Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 229960003795 iobenguane (123I) Drugs 0.000 description 1
- 229960002844 iprindole Drugs 0.000 description 1
- 229960002589 iproclozide Drugs 0.000 description 1
- 229960003049 iproniazid Drugs 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229950009272 isomethadone Drugs 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 229950002252 isoxicam Drugs 0.000 description 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 description 1
- 229960004427 isradipine Drugs 0.000 description 1
- GQWYWHOHRVVHAP-DHKPLNAMSA-N jaspamide Chemical compound C1([C@@H]2NC(=O)[C@@H](CC=3C4=CC=CC=C4NC=3Br)N(C)C(=O)[C@H](C)NC(=O)[C@@H](C)C/C(C)=C/[C@H](C)C[C@@H](OC(=O)C2)C)=CC=C(O)C=C1 GQWYWHOHRVVHAP-DHKPLNAMSA-N 0.000 description 1
- 108010052440 jasplakinolide Proteins 0.000 description 1
- 108010091711 kahalalide F Proteins 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229960005417 ketanserin Drugs 0.000 description 1
- 229960003029 ketobemidone Drugs 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960001739 lanreotide acetate Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229950006661 levomethadyl acetate Drugs 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 108010020270 lissoclinamide 7 Proteins 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000010807 litter Substances 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960002813 lofepramine Drugs 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- YQZBAXDVDZTKEQ-UHFFFAOYSA-N loxapine succinate Chemical compound [H+].[H+].[O-]C(=O)CCC([O-])=O.C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 YQZBAXDVDZTKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- 230000002101 lytic Effects 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001623 magnesium bromide Inorganic materials 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 239000011776 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 229960003390 magnesium sulfate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 229960003963 manidipine Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960001474 meclozine Drugs 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 201000009906 meningitis Diseases 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 description 1
- 229960000365 meptazinol Drugs 0.000 description 1
- 229940072739 mesalamine Drugs 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229950006180 metapramine Drugs 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- KPQJSSLKKBKWEW-RKDOVGOJSA-N methanesulfonic acid;5-nitro-2-[(2R)-1-[2-[[(2R)-2-(5-nitro-1,3-dioxobenzo[de]isoquinolin-2-yl)propyl]amino]ethylamino]propan-2-yl]benzo[de]isoquinoline-1,3-dione Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.[O-][N+](=O)C1=CC(C(N([C@@H](CNCCNC[C@@H](C)N2C(C=3C=C(C=C4C=CC=C(C=34)C2=O)[N+]([O-])=O)=O)C)C2=O)=O)=C3C2=CC=CC3=C1 KPQJSSLKKBKWEW-RKDOVGOJSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M methanoate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 229960002683 methohexital Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- DASQOOZCTWOQPA-GXKRWWSZSA-L methotrexate disodium Chemical compound [Na+].[Na+].C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 DASQOOZCTWOQPA-GXKRWWSZSA-L 0.000 description 1
- OJGGXQRRIZICIT-UHFFFAOYSA-N methoxysulfanyl(methoxysulfanylmethoxy)methane Chemical compound COSCOCSOC OJGGXQRRIZICIT-UHFFFAOYSA-N 0.000 description 1
- 229960003477 methsuximide Drugs 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- ALBSWLMUHHZLLR-UHFFFAOYSA-N methyl 2-nitroacetate Chemical compound COC(=O)C[N+]([O-])=O ALBSWLMUHHZLLR-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 description 1
- 229960000328 methylergometrine Drugs 0.000 description 1
- 229960000767 metopimazine Drugs 0.000 description 1
- 229950006787 metralindole Drugs 0.000 description 1
- 229950009847 meturedepa Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960003248 mifepristone Drugs 0.000 description 1
- 229960003775 miltefosine Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 108010026677 mitomalcin Proteins 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 230000003020 moisturizing Effects 0.000 description 1
- 229960003063 molgramostim Drugs 0.000 description 1
- 108010032806 molgramostim Proteins 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000001002 morphogenetic Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004690 mucosal barrier Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229960002967 nabilone Drugs 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N nabumeton Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960004501 nadoxolol Drugs 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- 108010032539 nartograstim Proteins 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229950010733 neridronic acid Drugs 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 201000009053 neurodermatitis Diseases 0.000 description 1
- 230000001272 neurogenic Effects 0.000 description 1
- 230000000926 neurological Effects 0.000 description 1
- 229960004300 nicomorphine Drugs 0.000 description 1
- 229950000096 nifenalol Drugs 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- 229960005366 nilvadipine Drugs 0.000 description 1
- 229950001981 nimetazepam Drugs 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MAZYQGHSTXUZJF-ZBRHGPMOSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](O)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@]5(C)C[C@H](C[C@@H](O5)CC4=C3C3=O)N(C)C)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 MAZYQGHSTXUZJF-ZBRHGPMOSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229950004461 noxiptiline Drugs 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 229950006863 octamoxin Drugs 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 239000003401 opiate antagonist Substances 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229960005290 opipramol Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960002019 oxaflozane Drugs 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-L oxalate Chemical compound [O-]C(=O)C([O-])=O MUBZPKHOEPUJKR-UHFFFAOYSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 229960003544 oxetorone Drugs 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229960002841 oxypertine Drugs 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229960003978 pamidronic acid Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229960003294 papaveretum Drugs 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 235000006678 peppermint Nutrition 0.000 description 1
- 235000015132 peppermint Nutrition 0.000 description 1
- 235000007735 peppermint Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000001175 peptic Effects 0.000 description 1
- 229960001217 perflubron Drugs 0.000 description 1
- 201000008838 periodontal disease Diseases 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000275 pharmacokinetic Effects 0.000 description 1
- 229960003396 phenacemide Drugs 0.000 description 1
- 229960003877 pheneturide Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 229960004227 phensuximide Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-M phenylacetate Chemical compound [O-]C(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-M 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- 229960003424 phenylacetic acid Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- 229960001286 piritramide Drugs 0.000 description 1
- 229960004572 pizotifen Drugs 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- FXSKHQLAUMGYJK-UHFFFAOYSA-J platinum(4+);propan-2-amine;dichloride;dihydroxide Chemical compound [OH-].[OH-].[Cl-].[Cl-].[Pt+4].CC(C)N.CC(C)N FXSKHQLAUMGYJK-UHFFFAOYSA-J 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 230000001144 postural Effects 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229940094035 potassium bromide Drugs 0.000 description 1
- OFPTZWGZSRJCOT-MSPNRCMCSA-M potassium;2-[(1S,2S,3R,4S,5S,6R)-3-(diaminomethylideneamino)-4-[(2R,3R,4R,5S)-3-[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;(2S,5R,6R)-3,3-d Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@H]1[C@H](N=C(N)N)[C@@H](O)[C@H](N=C(N)N)[C@@H](O)[C@@H]1O OFPTZWGZSRJCOT-MSPNRCMCSA-M 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 description 1
- 229960002752 progabide Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229950000992 pronetalol Drugs 0.000 description 1
- 229950003779 propiram Drugs 0.000 description 1
- 229950003857 propizepine Drugs 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- UQOQENZZLBSFKO-POPPZSFYSA-N prostaglandin J2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)C=CC1=O UQOQENZZLBSFKO-POPPZSFYSA-N 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 230000036678 protein binding Effects 0.000 description 1
- 230000003236 psychic Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- 230000001543 purgative Effects 0.000 description 1
- CYMJPJKHCSDSRG-UHFFFAOYSA-N pyrazolidine-3,4-dione Chemical class O=C1CNNC1=O CYMJPJKHCSDSRG-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M pyridine-4-carboxylate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 201000004645 pyromania Diseases 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229960001964 quazepam Drugs 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N rac-1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 229950001588 ramosetron Drugs 0.000 description 1
- 108091006066 receptor inhibitors Proteins 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 239000003638 reducing agent Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000024437 response to mechanical stimulus Effects 0.000 description 1
- 229940100552 retinamide Drugs 0.000 description 1
- 230000002441 reversible Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 229920002033 ribozyme Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229960000425 rizatriptan Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- 229960003522 roquinimex Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000003870 salicylic acids Chemical class 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000002393 scratching Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 229960002060 secobarbital Drugs 0.000 description 1
- 230000001624 sedative Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003369 serotonin 5-HT3 receptor antagonist Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 229950010372 sobuzoxane Drugs 0.000 description 1
- 229940075581 sodium bromide Drugs 0.000 description 1
- 229940006198 sodium phenylacetate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- HZOREEUASZHZBI-UHFFFAOYSA-M sodium;2-phenylacetate Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1 HZOREEUASZHZBI-UHFFFAOYSA-M 0.000 description 1
- PZOHOALJQOFNTB-UHFFFAOYSA-M sodium;6-fluoro-2-[4-(2-fluorophenyl)phenyl]-3-methylquinoline-4-carboxylate Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 description 1
- XBUIKNRVGYFSHL-IAVQPKKASA-M sodium;[(1E,3R,4R,6R,7Z,9Z,11E)-3,6,13-trihydroxy-3-methyl-1-[(2R)-6-oxo-2,3-dihydropyran-2-yl]trideca-1,7,9,11-tetraen-4-yl] hydrogen phosphate Chemical compound [Na+].OC/C=C/C=C\C=C/[C@H](O)C[C@@H](OP(O)([O-])=O)[C@@](O)(C)\C=C\[C@H]1CC=CC(=O)O1 XBUIKNRVGYFSHL-IAVQPKKASA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 230000000392 somatic Effects 0.000 description 1
- 230000003238 somatosensory Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 201000001716 specific phobia Diseases 0.000 description 1
- 108010032486 splenopentin Proteins 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229940074155 strontium bromide Drugs 0.000 description 1
- 229910001625 strontium bromide Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229950011251 suclofenide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960002573 sultiame Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003658 talinolol Drugs 0.000 description 1
- 229950000505 tandospirone Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960005383 terodiline Drugs 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- KJTULOVPMGUBJS-UHFFFAOYSA-N tert-butyl-[tert-butyl(diphenyl)silyl]oxy-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](C=1C=CC=CC=1)(C(C)(C)C)O[Si](C(C)(C)C)(C=1C=CC=CC=1)C1=CC=CC=C1 KJTULOVPMGUBJS-UHFFFAOYSA-N 0.000 description 1
- 229960003352 tertatolol Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 230000000542 thalamic Effects 0.000 description 1
- ZCTJIMXXSXQXRI-KYJUHHDHSA-N thalicarpine Chemical compound CN1CCC2=CC(OC)=C(OC)C3=C2[C@@H]1CC1=C3C=C(OC)C(OC2=C(C[C@H]3C4=CC(OC)=C(OC)C=C4CCN3C)C=C(C(=C2)OC)OC)=C1 ZCTJIMXXSXQXRI-KYJUHHDHSA-N 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 108010062880 thiocoraline Proteins 0.000 description 1
- 229960003397 thioproperazine Drugs 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 150000005075 thioxanthenes Chemical class 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- 229960005138 tianeptine Drugs 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
- 229950008411 tilisolol Drugs 0.000 description 1
- 239000003106 tissue adhesive Substances 0.000 description 1
- FQYFLFUZRJOLBC-UHFFFAOYSA-N titanocene Chemical compound C12C3C4C5C1[Ti]16782345C2C7C6C1C82 FQYFLFUZRJOLBC-UHFFFAOYSA-N 0.000 description 1
- 229950010076 tofenacin Drugs 0.000 description 1
- 229960004603 tolcapone Drugs 0.000 description 1
- 229960002905 tolfenamic acid Drugs 0.000 description 1
- 229960002309 toloxatone Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002936 tranquilizing Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 230000001052 transient Effects 0.000 description 1
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 229960003386 triazolam Drugs 0.000 description 1
- HOGVTUZUJGHKPL-HTVVRFAVSA-N triciribine Chemical compound C=12C3=NC=NC=1N(C)N=C(N)C2=CN3[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O HOGVTUZUJGHKPL-HTVVRFAVSA-N 0.000 description 1
- 230000001960 triggered Effects 0.000 description 1
- 229960004161 trimethobenzamide Drugs 0.000 description 1
- 229960000538 trimetrexate glucuronate Drugs 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZNRGQMMCGHDTEI-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CNC2=C1 ZNRGQMMCGHDTEI-ITGUQSILSA-N 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 229960002560 tybamate Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 229950006929 uredepa Drugs 0.000 description 1
- 230000002568 urticarial Effects 0.000 description 1
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 1
- 229960001930 valpromide Drugs 0.000 description 1
- 229960002730 vapreotide Drugs 0.000 description 1
- 230000002227 vasoactive Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229960005318 vigabatrin Drugs 0.000 description 1
- KDQAABAKXDWYSZ-JKDPCDLQSA-N vincaleukoblastine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 KDQAABAKXDWYSZ-JKDPCDLQSA-N 0.000 description 1
- COFJBSXICYYSKG-FJFFLIEUSA-N vindesine sulfate Chemical compound OS(O)(=O)=O.C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 COFJBSXICYYSKG-FJFFLIEUSA-N 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 229960002791 zimeldine Drugs 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229950009268 zinostatin Drugs 0.000 description 1
- 229960000607 ziprasidone Drugs 0.000 description 1
- 229960001360 zolmitriptan Drugs 0.000 description 1
- 229960001475 zolpidem Drugs 0.000 description 1
- 229960003414 zomepirac Drugs 0.000 description 1
- 229960002911 zonisamide Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
Abstract
Compounds of formulae (I) and (II) where Ar1, Ar2, R3, R4, and m, are disclosed herein, or a pharmaceutically acceptable salt thereof (a"Nitro(cyano)vinylpiperazine Compound");compositions comprising an effective amount of a Nitro(cyano)vinylpiperazine Compound;and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Nitro(cyano)vinylpiperazine Compound are disclosed.
Description
USEFUL PGPERAZINES FOR THE TREATMENT OF PAIN
1. FIELD OF THE INVENTION
The present invention relates to Nitro (cyano) vinylpiperazine Compounds, compositions comprising an effective amount of a Compound
Nitro (cyano) vinylpiperazine and methods for treating or preventing a Condition such as pain comprising administering to an animal in need thereof an effective amount Q of a Nitro (cyano) vinyl piperazine Compound.
2. BACKGROUND OF THE INVENTION
Pain is the most common symptom for which patients seek medical advice and
treatment. The pain can be acute or chronic. While acute pain is usually self-limited, chronic pain persists for 3 months or longer and can produce significant changes in the patient's personality, lifestyle, functioning ability, and overall lifestyle (KM Foley, Pain, in Cecil Textbook of Q Medicine 100-107 (JC Bennett and F. Plu eds., 20th ed., 1996)).
In addition, chronic pain can be classified as either nociceptive or neuropathic. Nociceptive pain includes pain from tissue damage and inflammatory pain such as that associated with arthritis. Neuropathic pain is caused by damage to the peripheral or central nervous system and is maintained by injurious somato sensory processes. There is a wide range of evidence related to activity in both Group I mGluRs (mGluRl and mGluR5) (ME Fundytus, CNSD gs 15: 29-58 (2001)) and vanilloid receptors (VRl) (V. Di Marzo et al, Current Opinion in Neurobiology 12: 372-379 (2002)) for the pain process. Inhibiting mGluRl or mGluR5 reduces pain, as demonstrated by in vivo treatment with selective anticuefos for either mGluRl or mGluR5, where the neuropathic pain in rats was attenuated (ME Fundytus et al, NeuroReport 9: 731-735 (1998)) . It has also been demonstrated that the collapse of mGluRl antisense oligonucleotides alleviates both neuropathic pain and inflammatory pain (ME Fundytus et al, British Journal of Pharmacology 132: 354-367 (2001); ME Fundytus et al, Pharmacology, Biochemsitry.; Behavior 73: 401-410 (2002)). Small antagonistic molecules. for attenuated pain mGluR5 in animal models in vivo are described in, for example, K. Walker et al, Neuropharmacology 40: 1-9 (2000) and A. Dogrul et al, Neuroscience Letters 2S2L-115-118 (2000)) . Traditionally, nociceptive pain has been managed by administration of non-opioid analgesics, such as acetylsalicylic acid, magnesium choline trisalicylate, acetaminophen, ibuprofen, fenoprofen, diflusinal, and naproxen; or opioid analgesics, including morphine, hydromorphone, methadone, levorphanol, fentanyl, oxycodone, and oxymorphone. Id. In addition to the treatments indicated above, neuropathic pain, which may be difficult to treat, has also been treated with anti-epileptics (eg, gabapentin, carbamazapine, valproic acid, topiramate, phenytoin), NMDA antagonists (eg, ketamine, dextromethorphan), topical lidocaine (for post-herpetic neuralgia), and tricyclic anti-depressants (eg, fluoxetine, sertraline, and amitriptyline).
Urinary incontinence ("Ul") is uncontrollable urination, usually caused by instability of the detrusor muscle of the bladder. Ul affects people of all ages and levels of physical health, both in the health area and in the community as a whole. Physiological contractions of the bladder are produced in large part by the acetylcholine-induced stimulation of post-ganglionic muscarinic receptors in the soft muscles of the bladder. Treatments for Ul include the administration of drugs with relaxing bladder properties, which help to control the over activity of the detrusor muscle of the bladder. For example, anticholinergics such as propantheline bromide and glycopyrrolate, and combinations of mild muscle relaxants such as a combination of racemic oxybutynin and dicyclomine or an anticholinergic, have been used to treat Ul (See, eg, A. Wein, Urol Clin. N. Am. 22: 557-577 (1995); Levin et al., J. Urol. 128: 396-398 (1982); Cooke et al, S. Afr. Med. J. 63: 3 (1983); R.K. Mirakhur et al, Anesthesia 38: 1195-1204 (1983)). However, these drugs are not effective in patients with non-inhibited bladder contractions. The administration of anticholinergic drugs represents the main basis in this type of treatment. However, none of the commercially available drug treatments for Ul has achieved total success in all Ul patient classes, nor has treatment been achieved without significant adverse side effects. For example, drowsiness, dry mouth, constipation, blurred vision, headache, tachycardia, and cardiac arrhythmia, related to the anticholinergic activity of traditional anti-UI drugs, can occur frequently and adversely affect patient compliance. However, despite the prevalence of anticholinergic effects in many patients, anticholinergic drugs are currently prescribed to patients with Ul. The Merck Manual of Medical Information 631-634 (R. Berkow ed., 1997). About 1 to 10 people develop an ulcer. Ulcers occur as a result of an imbalance between acid-secretory factors, also known as "aggressive factors," such as stomach acid, pepsin and Helicobacter pylori infection, and local mucosal protective factors, such as bicarbonate, mucosal secretion and prostaglandins
The treatment of ulcers typically involves reducing or inhibiting aggressive factors. For example, antacids such as aluminum hydroxide, magnesium hydroxide, sodium bicarbonate and calcium bicarbonate can be used to neutralize stomach acids. However, antacids can cause alkalosis, producing nausea, headache and weakness. Antacids can also interfere with the absorption of other drugs into the bloodstream and cause diarrhea. H2 antagonists, such as cimetidine, ranitidine, famotidine and nizatidine, are also used to treat ulcers. H2 Antagonists promote the healing of ulcers by reducing gastric acid and the secretion of digestive enzymes produced by histarnins and other H2 antagonists in the stomach and duodenum. However, H2 antagonists can cause breast enlargement and impotence in men, mental changes
(especially in elderly people), headache, dizziness, nausea, myalgia, diarrhea, rash and fever. Inhibitors H "1", K + - ATPase such as omeprazole and lansoprazole are also used to treat ulcers. Inhibitors H +, K + - ATPase inhibit the production of enzymes used by the stomach to secrete acids. Side effects associated with H +, K + - ATPase inhibitors include nausea, diarrhea, abdominal colic, headache, dizziness, drowsiness, skin rash and transient elevation of plasma aminotransferase activity.
Sucralfate is also used to treat ulcers. Sucralfate adheres to epithelial cells and is thought to form a protective layer at the base of an ulcer to promote its healing. However, sucralfate can cause constipation, dry mouth and interfere with the absorption of other drugs. Antibiotics are used when Helicobacter pylori is the main cause of the ulcer. Frequently, antibiotic therapy is coupled with the administration of bismuth compounds such as bismuth subsalicylate and colloid bismuth citrate. It is believed that bismuth compounds increase mucosal secretion and HCO3", inhibit peptic activity and act as an antibacterial against H. pylori, however, ingestion of bismuth compounds can produce high concentrations of Bi + plasma and can interfere With the absorption of other drugs, prostaglandin analogs, such as misoprostatic, inhibit acid secretion and stimulate mucous and bicarbonate secretion and are also used to treat ulcers, especially ulcers in patients requiring non-steroidal anti-inflammatory drugs. , effective oral doses of prostaglandin analogs can produce diarrhea and abdominal pains.Also, some prostaglandin analogs are abortive.Carhexolone, a mineral corticoid, can also be used to treat ulcers.Carhexoxone seems to alter the composition and amount of mucosa, thus increasing the mucosal barrier, however, carbenoxolone, it can produce Na + and fluid retention, hypertension, hypokalemia and impaired glucose tolerance. Muscarinic cholinergic antagonists such as pirenzapine and telenzapine can also be used to reduce acid secretion and treat ulcers. Side effects of muscarinic cholinergic antagonists may include oral dryness, blurred vision and constipation. The Merck Manual of Medical Information 496-500 (R. Berkow ed., 1997) and Goodman and Gilman's The Pharmacological Basis of
Therapeutics 901-915 (J. Hardman and L. Limbird eds., 9th ed.1996).
Inflammatory bowel disease (IBD) is a chronic disorder in which the intestine becomes inflamed, often producing abdominal pain and diarrhea. The two classes of IBD are Crohn's disease and ulcerative colitis. Crohn's disease, which may include regional enteritis, granulomatous ileitis, and ileocolitis, is a chronic inflammation of the intestinal wall. Crohn's disease occurs equally in both sexes and is more common in Jews with Western European ancestry. Most cases of Crohn's disease begin before the age of 30 and most begin between 14 and 24 years of age. The disease usually affects the total thickness of the intestinal wall. Usually, the disease affects the lower portion of the small intestine (ileum) and the large intestine, but it can occur anywhere in the digestive tract. The first symptoms of Crohn's disease are chronic diarrhea, pain from abdominal cramping, fever, loss of appetite and weight loss. Complications associated with Crohn's disease include the development of intestinal obstructions, abnormal connection channels (fistulas) and abscesses. The risk of cancer in the large intestine increases in people with Crohn's disease. Frequently, Crohn's disease is associated with other disorders such as gallstone, inadequate absorption of nutrients, amyloidosis, arthritis, episcleritis, aged stomatitis, erythema nodosa, pyoderma gangrenosum, ankylosing spondylitis, sacroiliitis, uveitis, and primary sclerose cholangitis. There is no known treatment for Crohn's disease.
Cramps and diarrhea, side effects associated with Crohn's disease, can be relieved with anticholinergic drugs, diphenoxylate, loperamide, deodorized opium dye or codeine. Generally, the drug is administered orally before the
meals. A wide range of antibiotics are usually administered to treat the symptoms of Crohn's disease. The antibiotic metranidazole is frequently administered when the disease affects the large intestine or causes abscesses and fistulas, "around the anus. However, prolonged use of metranidazole can damage the nerves,. resulting in a tingling sensation in the arms and legs. Sulfasalazine and chemically related drugs can suppress mild inflammation, especially in the large intestine. However, these drugs are less effective in severe sudden inflammations. Corticosteroids, such as prednisone, reduce
fever and diarrhea as well as abdominal pain and sensitivity. However, a prolonged corticosteroid therapy inevitably results in serious side effects such as high blood sugar, increased risk of infection, osteoporosis, fluid retention, and skin fragility. Drugs such as azathioprine and mercaptopurine can either compromise the immune system and are frequently effective in patients with Crohn's disease who do not respond to other drugs. However, these drugs generally need between 3 to 6 months before producing benefits and can cause serious side effects such as allergy, pancreatitis and low white cell counts. When Crohn's disease causes the bowel to become clogged or when 5 abscesses or fistulas do not heal, surgery may be necessary to remove diseased sections of the intestine. However, surgery does not cure the disease, and inflammation usually returns when the bowel is reattached. In almost half of the cases, a second surgery is necessary. The Merck Manual of Medical Information 528-530 (R. Berkow ed., 1997).
Ulcerative colitis is a chronic disease in which the large intestine becomes inflamed and ulcerated, producing episodes of diarrhea with bleeding, abdominal pain and fever. Ulcerative colitis usually starts between 15 and 30 years; However, a small group of people have their first attack between 50 and 70 years. Unlike Crohn's disease, ulcerative colitis never affects the small intestine and does not affect the total thickness of the intestine. The disease usually begins in the rectum and sigmoid colon and eventually extends partially or completely through the large intestine.
The cause of ulcerative colitis is not known. The treatment of ulcerative colitis is aimed at controlling inflammation, reducing symptoms and replacing lost fluids and nutrients. Irritable bowel syndrome ("IBS") is a mobility disorder of the entire gastrointestinal tract, which causes abdominal pain, constipation, and / or diarrhea. IBS affects three times more women than men. There are two main types of IBS. The first type, spastic colon type, is commonly triggered by eating and usually produces constipation and diarrhea with pain. Mucus usually appears in the stool. Pain may occur in attacks of constant weak pain, usually in the lower abdomen. The person suffering from spastic colon IBS may experience swelling, gas, nausea, headache, fatigue, depression, anxiety and difficulty concentrating. The second type of
IBS usually produces diarrhea without pain or constipation. Diarrhea can begin "suddenly and with extreme urgency." Diarrhea often occurs after a meal and sometimes immediately after awakening.The treatment of IBS generally involves modifications in the diet of the patient with IBS. patient with IBS avoid beans, cabbage, sorbitol and fructose. A diet low in fat and high in fiber can also help some patients with IBS. Physical activity on a regular basis can also help keep the gastrointestinal tract working correctly. Drugs such as? n Propanthelin that decrease the function of the gastrointestinal tract are not generally effective in treating IBS. Antidiarrheal drugs, such as diphenoxylate and loperamide, help with diarrhea. The Merck Manual of Medical Information 525-526 (R. Berkow ed., 1997).
Certain pharmaceutical agents have been administered to treat addictions. US Patent No. 5,556,838 to Mayer et al. describes the use of non-toxic blocking agents NMDA co-administered with an addictive substance to prevent the development of tolerance or withdrawal symptoms. U.S. Patent No.
. No. 574,052 to Rose et al. describes the co-administration of an addictive substance with an antagonist to partially block the pharmacological effects of the substance. The
U.S. Patent No. 5,075,341 to Mendelson et al. describes the use of an opiate agonist / antagonist mixture to treat addictions to cocaine and opiates. U.S. Patent No. 5,232,934 to Downs describes the administration of
3-phenoxypyridine to treat addiction. U.S. Patent No. 5,039,680 and 5,198,459 to Imperato et al. describes the use of a serotonin antagonist to treat a chemical addiction. U.S. Patent No. 5,556,837 to Nestler et.
'al. describes how BDNF or NT-4 growth factors are infused to inhibit or reverse adaptive neurological changes that correlate with behavioral changes in an addict. U.S. Patent No. 5,762,925 to Sagan discloses implanting adrenal medullary cells encapsulated in the central nervous system of the animal to inhibit the development of opioid intolerance. U.S. Patent No. 6,204,284 to Beer et al. describes (±) -l- (3,4-dichlorophenyl) -3-azabicyclo [3.1.0] racemic hexane for use in the prevention or alleviation of a withdrawal syndrome resulting from drug addiction and for
-. "The treatment of chemical dependencies. Without treatment, Parkinson's disease evolves into a rigid akinetic state where patients are unable to take care of themselves. Death occurs frequently as a result of complications resulting from immobility, including aspiration pneumonia or pulmonary embolism. Drugs commonly used for the treatment of Parkinson's disease include carbidopa / levodopa, pergolide, bromocriptine, selegiline, amantadine, and trihexyphenidyl hydrochloride. However, the need for drugs useful for the treatment of Parkinson's disease and with an improved therapeutic profile persists. 0 Anxiety is a fear, apprehension or panic of imminent danger commonly accompanied by restlessness, tension, tachycardia and dyspnea. Currently, benzodiazepines are the most used anti-anxiety agents for generalized anxiety disorders. However, benzodiazepines carry the risk of producing cognitive impairments and specialized motor functions, particularly in the elderly, which can cause confusion, delirium and falls with fractures. Sedatives are also commonly prescribed to treat anxiety. Azapirones, such as buspirone, are also used to treat moderate anxiety, however, azapirones are less useful in treating severe anxiety accompanied by panic attacks.
Epilepsy is a disorder characterized by the tendency to have recurrent attacks. Examples of drugs used to treat seizures and epilepsy include .carbamazepine, ethosuximide, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone, volproic acid, trimethadione, benzodiazepines, gabapentin, lamotrigine,? -vinyl GABA, acetazolamide, and felbamate. However, anti-seizure drugs can have side effects such as drowsiness; hyperactivity; hallucinations; inability to concentrate; central and peripheral nervous system toxicity, such as nystagmus, ataxia, diplopia, and vertigo; gingival hyperplasia; gastrointestinal disturbance such as nausea, vomiting, epigastric pain, and anorexia; endocrine effects such as inhibition of antidiuretic hormone, hyperglycemia, glycosuria, osteomalacia; and hypersensitivity such as scarlatiniform rash, morbilliform rash, Stevens-Johnson syndrome, systemic lupus erythematosus, and hepatic necrosis; and hematological reactions such as red cell aplasia, agranulocytosis, thrombocytopenia, aplastic anemia and megaloblastic anemia. The Merck Manual of Medical Information 345-350 (R. Berkow ed., 1997). The symptoms of heart attacks vary depending on the part of the affected brain.
Symptoms include loss or abnormal feeling in an arm or leg or side of the body, weakness or paralysis of an arm or leg or side of the body, partial loss of vision or hearing, double vision, dizziness, slurred speech, difficulty thinking about the correct word or saying it, inability to recognize parts of the body, unusual movement, loss of bladder control, imbalance, falls and fainting. Symptoms may be permanent and may be associated with coma or stupor. Examples of drugs for treating heart attacks include anticoagulants such as heparin, drugs that dissolve clots such as streptokinase or tissue plasminogen activator, and drugs that reduce swelling such as mannitol or corticosteroids. The Merck Manual of Medical Information 352-355 (R. Berkow ed., 1997). Itching in an unpleasant sensation that induces scratching. Usually, pruritus is treated by ultraviolet B or PUVA phototherapy or by therapeutic agents such as naltrexone, nalmefene, danazol, tricyclics and antidepressants. Selective antagonists of the metabotropic glutamate receptor 5 ("mGluR5") have been shown to exert an analgesic activity in the animal model in vivo (K. Walker et al, Neuropharmacology 40: 1-9 (2000) and A. Dogrul et al, Neuroscience Letters, 292 (2): 115-118 (2000)). Selective antagonists of the mGluR5 receptor have also been shown to exert anxiolytic and anti-depressant activity in the animal model in vivo (E. Tatarczynska et al, Br. J. Pharmacol. 132 (7): 1423-1430 (2001) and PJ.M. Will et al, Trends in Pharmacological Sciences 22 (7): 331-37 (2001)). Selective antagonists of the mGluR5 receptor have also been shown to exert anti-Parkinson activity in vivo (KJ Ossowska et al, Neuropharmacology 41 (4): 413-20 (2001) and PJ.M. Will et al, Trends in Pharmacological Sciences 22 (7 ): 331-37 (2001)). There is, however, a clear need in the art for compounds that are useful for treating or preventing pain, Ul, an ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, infarction, attack, a pruritic condition, psychosis, cognitive disorder, memory deficit, restricted brain function, Huntington's disease, amyotrophic lateral sclerosis ("ALS"), dementia, retinopathy, muscle spasm, migraine, vomiting, dyskinesia, or depression.
The mention of any reference in Section 2 of the present application should not be considered as an admission that such reference is prior art to the present application.
3. SUMMARY OF THE INVENTION
The present invention comprises compounds of the formula (1):
(r >
(I)
and pharmaceutically acceptable salts thereof, wherein:
Ari is
Ar2 is
RI is -H, -halo, -CH3, -CN, -NO2, -OH, -OCH3, -HG2, -C (halo) 3, -CH (halo) 2, or -CH2 (halo); each R2 is independently:
(a) -halo, -OH, -NH2, -CN, or -NO2; (b) - (C? -C? o) alkyl, - (C2-C10) alkenyl, - (C2-C1o) alkynyl, - (C3-C! o) cycloalkyl, - (C8-C1) bicycloalkyl, - ( C8-C14) tricycloalkyl, - (C5-C8) cycloalkenyl, - (C8-C14) bicycloalkenyl, - (C8-C14) tricycloalkenyl, - (3- to 7-bodies) heterocycle, or - (7- to 10-) ? s) bicycloheterocycle, each of which is substituted or not with one or more groups 5; or
(c) -phenyl, -naphthyl, - (C14) aryl or - (5- to 10-cells) heteroaryl, each of which is substituted or unsubstituted with one or more R6 groups; each R3 is independently:
(a) -halo, -OH, -NH2; -CN, or -NO2; (b) - (C? -C? o) alkyl, - (C2-C10) alkenyl, - (C2-C10) alkynyl, - (C3-C10) cycloalkyl, - (Cg-C1) bicycloalkyl, - (C8-) C14) xriccycloalkyl, - (C5-C10) cycloalkenyl, - (C8-C? 4) bicycloalkenyl, (C8-C? 4) tricycloalkenyl, - (3- to 7-well) heterocycle, or - (7- to 10- cuef? s) bicycloheterocycle, each of which is substituted or not with one or more R5 groups; or
(c) -phenyl, -nanel, - (C14) aryl or - (5- to 10 -acids) heteroaryl, each of which is substituted or not with one or more Re groups;
each R4 is -H, -CN, - € (O) O (C? -CL) a] quiL, or -C (O) NH ((C1-C4) alkyl; each R5 is independently -CN, -OH, - (C? -C6) alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, -halo, -N3, -NO2, -N (R7) 2, -CH = NR7, -NR7OH, - OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O) 2R7;
each Rd is independently - (-C ^ alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, - (C3C8) cycloalkyl, - (C5-C8) cycloalkenyl, -phenyl, - (3- to 5) -trues) heterocycle, -C (halo) 3, ~ CH (halo) 2, -CH2 (halo), -CN, -OH, -halo, -N3, -NO2, N (R7) 2, -CH = NR7 , -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (0) 2R7;
each R7 is independently -H, - (C2-C6) alkenyl, - (C2-C6) alkynyl, - (C3-C8) cycloalkyl, - (C5-C8) cycloalkenyl, -phenyl, - (3- to 5-cos ) heterocycle, -C (halo) 3, -CH (halo) 2, or CH 2 (halo);
each Rs is independently - (-C ^ alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, - (C3-C8) cycloalkyl, - (C5-C8) cycloalkenyl, -phenyl, - (3- at 5-ca) s, heterocycle, -C (halo) 3, -CH (halo) 2, -CH2 (halo), -CN, -OH, -halo, -N3, -NO2, -N (R7) 2 , -CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S ( O) 2R7, each halo is independently -F, -Cl, -Br, or -I;
m is an integer in a range from 0 to 2; n is an integer in a range from 0 to 3; p is an integer in a range from 0 to 2;
q is an integer in a range from 0 to 6; r is an integer in a range from 0 to 5; Y
s is an integer in a range from 0 to 4.
The invention further comprises compounds of the formula (11):
(II)
and pharmaceutically acceptable salts thereof, wherein
Arts
Ar2 is
Ri is -H, -halo, -CH3, -CN, -NO2, -OH, OCH3, NH2, -C (halo) 3, -CH (halo) 2, or -CH2 (halo); each R2 is independently: (a) -halo, -OH, -NH2, -CN, or -NO2;
(b) - (C? -C? o) alkyl, - (C2-C] .o) alkenyl, - (C2-C1o) alkynyl, - (C3-C? o) cycloalkyl, - (C8-C14) bicycloalkyl , - (C8-C14) tricycloalkyl, - (C5-C8) cycloalkenyl, - (Cg-C14) bicycloalkenyl, - (C8-C14) tricycloalkenyl, - (3- to 7-well) heterocycle, or - (7- a 10-cells) bicycloheterocycle, each of which is substituted or not with one or more R5 groups; or (c) -phenyl, -naphthyl, - (C? 4) aryl or - (5- to 10 -copes) heteroaryl, each of which is substituted or not with one or more Re groups; each R3 is independently: (a) -halo, -OH, -NH2, -CN, or -NO2; (b) - (C] -C10) alkyl, - (C2-C1o) alkenyl, - (C2-C10) alkynyl, - (C3-C1o) cycloalkyl, - (C8-C14) bicycloalkyl, - (Cs-C14) tricycloalkyl, - (C5-C1o) cycloalkenyl, - (C8- C14) bicycloalkenyl, - (C8-C14) tricycloalkenyl, - (3- to 7-chain) heterocycle, or - (7- to 10-line) bicycloheterocycle, each one of which is substituted or not with one or more groups
R5; or (c) -phenyl, -naphthyl, - (C? 4) aryl or - (5- to 10-well) heteroaryl, each of which is substituted or unsubstituted with one or more R6 groups; each R4 -H, -CN, -C (O) O (C? -C4) alky or -C (O) NH ((C? -C4) alkyl); each R5 is independently -CN, -OH, - (C? -C6) alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, -halo, -N3, -NO2, -N (R7) 2 , -CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S ( O) 2R7; each Re is independently - (C? -C6) alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, - (C3-C8) cycloalkyl, - (C5-C8) cycloalkenyl, -phenyl, - ( 3- to 5-cells) heterocycle, -C (halo) 3, -CH (halo) 2, -CH 2 (halo), -CN, -OH, -halo, -N 3, -NO 2, N (R 7) 2, -CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O 2R7;
each R7 is independently -H, - (Ci-Cß-alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, - (C3-C8) cycloalkyl, - (C5-C8) cycloalkenu, -phenyl, - ( 3- to 5-cells) heterocycle, -C (halo) 3, -CH (halo) 2, or CH2 (halo), each R8 is independently - (-Cejalquü, - (C2-C6) alkenyl, - (C2- C6) alkynyl, ~ (C3-C8) cycloalkyl, - (C5-C8) cycloalkenyl, -phenyl, - (3- to 5-cells) heterocycle, C (halo) 3, -CH (halo) 2, -CH2 ( halo), -CN, -OH, -halo, -N3, -NO2, -N (R7) 2, -CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O ) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O) 2R7; each halo is independently -F, -Cl, -Br, or -I; m is a whole number in a range from 0 to 2, n is an integer in a range from 0 to 4, p is an integer in a range from 0 to 2, q is an integer in a range from 0 to 6, r is a whole number in a range from 0 to 5, and s is an integer in a range from 0 to 4. A compound of formula (I) or (H) or a pharmaceutically acceptable salt thereof (a "Nitro Compound (cyano ) vin ilpiperazine ") is useful to treat or prevent pain, Ul, ulcer ulcer, IBD, IBS, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, infarction, an attack, a pruritus condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Korea of Huntington, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, or depression
(each being a "Condition") in an animal.
The invention also relates to. compositions containing an effective amount of a Nitro (cyano) vinyl piperazine Compound and a pharmaceutically acceptable carrier. The compositions are useful for treating or preventing a Condition in an animal.
The invention also relates to methods for treating a Condition, comprising administering to an animal, in need thereof, an effective amount of a
Nitro (cyano) vinylpiperazine compound.
The invention further relates to methods for preventing a Condition, which comprises administering to an animal in need thereof an effective amount of a Nitro (cyano) vinyl piperazine Compound.
The invention further relates to methods for inhibiting the function of the Vanilloid Receptor 1 ("VR1") in a cell, which comprises contacting a cell capable of expressing VR1 with an effective amount of a Nitro (cyano) vinyl piperazine Compound.
The invention further relates to methods for inhibiting mGluR5 function in a cell, which comprises contacting a cell capable of expressing mGluR5 with an effective amount of a Nitro (cyano) vinylpiperazine Compound.
The invention further relates to methods for inhibiting the function of the metabotropic glutamate receptor 1 ("mGluRl") in a cell, which comprises contacting a cell capable of expressing mGluRl with an effective amount of a Kitro (cyano) vinylpiperazine Compound. The invention further relates to methods for preparing a composition comprising the step of mixing a Nitro (cyano) vinyl piperazine Compound and a pharmaceutically acceptable carrier or excipient.
The invention further relates to a kit comprising a container containing an effective amount of Nitro (cyano) vinyl piperazine Compound. The present invention can be understood in greater depth through the following detailed description and illustrative examples, which are intended to exemplify non-limiting embodiments of the invention.
4. DETAILED DESCRIPTION OF THE INVENTION
4. 1 Nitro (cyano) vinyl piperazine Compound of Formula (I) As indicated above, the present invention comprises Nitro (cyano) vinyl piperazine Compounds of Formula (I)
(I)
wherein Arl3 Ar2, R3, X, and m are defined above for Nitro (cyano) vinylpiperazine compounds of the formula (I).
In one modality, Ar! it is a pyridyl group. In another embodiment, Ari is xm pyrimidinyl group.
In another embodiment, Aii is xm pyrazinyl group. In another embodiment, Arj is xm pyridazinyl group.
In another modality, A? It is a thiadiazolyl group.
In another embodiment, At2 is a benzoimidazolyl group.
In another embodiment, At2 is a benzothiazolyl group.
In another embodiment, At2 is a benzooxazolyl group.
In another modality, X is O. In another modality, Ar2 is
In another modality, Ar2 is
jj hw.
In another modality, t2 is
In another modality, Ar2 is
In another modality, Ar2 is
In another modality, Ar2 is
In another modality, Ar2 is
In another modality, m is 0.
In another modality, m is 1. In another modality, m is 2. In another modality, m is 3. In another modality, n is 0. In another modality, n is 1. In another modality, n is 2. In another modality, n is modality, n is 3. In another modality, p is 0. In another modality, p is 1. In another modality, p is 2. In another modality, or is 0. In another modality, r is 0. In another modality, r is 1. In another mode, r is 2. In another mode, r is 3.
In another modality, r is 4. In another modality, r is 5. In another modality, q is 0. In another modality, q is 1.
In another modality, q is 2. In another modality, q is 3. In another modality, q is 4. In another modality, q is 5. In another modality, q is 6. In another modality, s is 0. In another modality, s is 0. modality, s is 1. In another modality, s is 2. In another modality, s is 3. In another modality, s is 4. In another modality, Ri is - H. In another modality, Ri is -halo. In another modality, RÍ is -Cl. In another modality, R i is -Br. In another modality, R.}. is -I.
In another modality, R \ is -F. In another modality, R! is -CH3. In another embodiment, R \ is - CN. In another modality, it is -NO2.
In another embodiment, Rt is -OH.
In another embodiment, Rt is -OCH3.
In another modality, RÍ is -NH2.
In another embodiment, RÍ is -C (halo) 3.
In another embodiment, Rt is -CH (halo) 2.
In another embodiment, Ri is -CH2 (halo).
In another embodiment, Rt is -CF3.
In another embodiment, n or p is 1 and R2 is -halo, -OH, -NH2, -CN, or -NO2.
In another embodiment, nop is 1 and R2 is - (CrC10) alkyl, - (C2-C10) alkenyl, - (C2-C10) alkynyl, - (C3-C1o) cycloalkyl, - (C8-C1) bicycloalkyl, - ( C5-C8) cycloalkenyl, - (C8-C? 4) bicycloalkenyl, - (C8-C14) tricycloalkenyl, - (3- to 7-well) heterocycle, or - (7- to 10-well) bicycloheterocycle, each of which is substituted or not with one or more R5 groups.
In another embodiment, n or p is 1 and R 2 is -phenyl, -naphthyl, - (C 14) aryl or - (5- to 10 -acids) heteroaryl, each of which is substituted or not with one or more Re groups.
In another embodiment, m is 1 and R3 is -halo, -OH, -NH2, -CN, or -NO2. In another embodiment, m is 1 and R3 is - (C1-C10) alkyl, - (C2-C10) alkenyl, - (C2-C10) alkynyl, - (C3-C1o) cycloalkyl, - (C8-C14) bicycloalkyl, - (C8-C14) 1-cycloalkyl, - (C5-C10) cycloalkenyl, - (C8-C1) bicycloalkenyl, - (C8-C14) tricycloalkenyl, - (3- to 7-well) heterocycle, or - (7- to 10) (c) bicycloheterocycle, each of which is substituted or not with one or more groups R5, In another embodiment, m is 1 and R3 is -phenyl, -naphthyl, - (C? 4) aryl or - (5- a 10-) heteroaril, each imo of which is substituted or not with one or more RÓ groups.
In another embodiment, m is 1 and R3 is - (C1-C10) alkyl.
In another embodiment, m is 1, R3 is (- (C1-C1o) alkyl, and the carbon atom to which the R3 group is attached is in the (R) configuration.
In another embodiment, m is 1, R3 is (- (C? -C?) Alkyl, and the carbon atom to which the group R3 is attached is in the (S) configuration.
In another embodiment, m is 1 and R3 is -CH3. In another embodiment, m is 1, R3 is -CH3, and the carbon atom to which the group R3 is attached is in the (R) configuration.
In another embodiment, m is 1, R3 is -CH3, and the carbon atom to which group 3 is
find attached is in the configuration (S).
In another modality, m is 1 and R3 is -halo.
In another mode, m is 1 and R3 is -Cl.
In another mode, m is 1 and R3 is -Br.
In another mode, m is 1 and R3 is -I.
In another mode, m is 1 and R3 is -F.
In another modality, R4 is -H.
In another modality, t is -CN.
In another embodiment, R 4 is -C (O) O ((C 1 -C 4) alkyl.
In another embodiment, ^ is - (C (O) NH ((C? -C4) alkyl). In another embodiment, Ar2 is a benzothiazolyl group and s is 1. In another embodiment, Ar2 is a benzoimidazolyl group and s is 1.
In another embodiment, Ar2 is a benzooxazolyl group and s is 1.
In another modality, Ar2 is
ys is 1. In another mode, Ar2 is
and s is 1. In another mode, Ar2 is
and r is 1. In another modality, At2 is
yqes 1.
In another modality, Ar2 is
and res 1. In another modality, Ar2, is
and res 1. In another modality, Ar2 is
and res 1.
In another embodiment, A ^ is a pyridyl group, m is 0, and At2 is a benzothiazolyl group. In another embodiment, Ari is a pyridyl group, m is 0, and Ar 2 is a benzooxazolyl group. In another modality, Ar! is xm pyridyl group, m is 0, and At 2 is a benzoimidazolyl group. In another modality, Ar! is a pyridyl group, m is 0, and Ar2 is
In another embodiment, Aii is a pyridyl group, m is 0, and Ar2 is
In another modaliadd, Ari is a pyridyl group, m is 0, and Ar2 is
In another embodiment, it is a pyridyl group, m is 0, and Ar2 is
In another embodiment, Ai \ is a pyridyl group, m is 0, and Ar2 is
In another modality, Ar! is a pyridyl group, m is 0, and Ar2 is
In another modality, Ar! is xm pyridyl group, m is 0, and Ar2 is
In another embodiment, Ar1 is a group, pyridyl, r is 1, m is 0, Ar 2 is
and R8 is a - (dC ^ alkyl) In another embodiment, the - (CrC ^ alkyl is substituted on the para-position of the phenyl group.) In another embodiment, the - (C1-C6) alkyl is a tert-butyl group. another embodiment, the - (C.! - Ce) alkyl is a tert-butyl group and is substituted in the phenyl group paraposition In another embodiment, the - (dC ^ alkyl is a? propyl group. another embodiment, the - (C1-C6) alkyl is a wo-propyl group and is substituted in the para-position of the phenyl group.
In another embodiment, Aii is a pyridyl group, r is 1, m is 0, At2 is
and R8 ¿s -CF3. In another embodiment, CF3 is substituted in the ara-position of the phenyl group.
In another embodiment, Arl is a pyridyl group, r is 1, m is 0, Ar2 is
and Rg is -halo. In another embodiment, the -halo is substituted in the p-group position. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and it is substituted in the / > ara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the p ara-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and is substituted in the ara-position of the phenyl group.
In another modality, Ar! is xm pyrazinyl group, m is 0, and Ar2 is xm benzothiazolyl group.
In another embodiment, Aii is xm pyrazinyl group, m is 0, and Ar2 is a benzooxazolyl group. In another embodiment, Ax \ is a pyrazinyl group, m is 0, and At2 is a benzoimidazolyl group.
In another embodiment, Aii is a pyrazinyl group, m is 0, and Ar2 is
In another modality, Ax? is xm pyrazinyl group, m is 0, and A12 is
In another modality, Ar! is xm pyrazinyl group, m is 0, and Ar2 is
11 ^ - (R8) s In another embodiment, An is a pyrazinyl group, m is 0, and Ar2 is In another embodiment, An is xm pyrazinyl group, m is 0, and Ar2 is In another embodiment, A is xm pyrazinyl group , m is 0, and Ar2 is In another embodiment, An is xm pyrazinyl group, m is 0, and Ar2 is In another embodiment, An is a pyrazinyl group, m is 0, and Ar2 is
and Rg is xm - (C1-C6) alkyl. In another embodiment, the - (QC ^ alkyl and substituted in the para-position of the phenyl group) In another embodiment, the - (C? -C6) alkyl is a tert-butyl group In another embodiment, the - (C C6) alkyl is a tert-butyl group and is substituted at the p-group position of the phenyl group.In another embodiment, the - (dC ^ alkyl is x m-propyl group. - (C1-Ce) alkyl is a so-propyl group and is substituted on the other-position of the phenyl group.
In another embodiment, An is a pyrazinyl group, r is 1, m is 0, Ar2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the /? Ara-position of the phenyl group.
In another embodiment, Ar1 is xm pyrazinyl group, r is 1, m is 0, Ar2 is
and Rg is -halo. In another modality, the -halo is replaced in the > ara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and it is substituted in the ara-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and it is substituted in the j? Ara-position of the phenyl group. In another modality, - halo is -I. In another modality, -halo is -I and is substituted in the ra-position of the phenyl group. In another embodiment, -halo is -F and is substituted in the ara-position of the phenyl group.
In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is a benzothiazolyl group. In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is a benzooxazolyl group. In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is a benzoimidazolyl group. In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is
In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is
In another embodiment, A is a pyrimidinyl group, m is 0, and Ar2 is In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is In another embodiment, An is xm pyrimidinyl group, m is 0, Ar2 is In another embodiment, An is a pyrimidimyl group, m is 0, Ar2 is In another embodiment, An is xm pyrimidinyl group, m is 0, Ar2 is In another embodiment, An is a pyrimidinyl group, m is 0, Ar2 is
and Rs is a - (d-C6) alkyl. In another embodiment, the - (dC 6) alkyl is substituted on the other-position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (dC ^ alkyl is a tert-butyl group and is substituted in the paraposition of the phenyl group In another embodiment, the - (d-C6) alkyl is xm wo-propyl group. - (C? -C6) alkyl is x? Propyl group and is substituted on the ara-position of the phenyl group.
In another modality, Ar! is a pyrimidinyl group, r is 1, m is 0, Ar2 is
and R-8 is -CF3. In another embodiment, -CF3 is substituted on the other-position of the phenyl group.
In another embodiment, An is a pyrimidinyl group, r is 1, m is 0, Ar2 is
and Rs is -halo. In another embodiment, the -halo is substituted in the p-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another embodiment, -halo is -Br and is substituted in the s ^ ra-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the para-position of the phenyl group. In another modality, -halo is -F. In another modality, -halo is -F and it is substituted in the para-position of the phenyl group.
In another embodiment, An is a pyridazinyl group, m is 0, and Ar 2 is a benzothiazolyl group.
In another embodiment, An is a pyridazinyl group, m is 0, and Ar2 is a benzoolyl group.
In another embodiment, An is a pyridazinyl group, m is 0, and Ar2 is a benzoimidazolyl group.
In another embodiment, Ar1 is a pyridazinyl group, m is 0, and Ar2 is
In another embodiment, An is a pyridazinyl group, m is 0, and Ar2 is
In another embodiment, An is x pyridazinyl group, m is 0, and Ar2 is In another embodiment, Ar! is a pyridazinyl group, m is 0, and Ar2 is
In another embodiment, An is xm pyridazinyl group, m is 0, Ax2 is
In another embodiment, An is xm pyridazinyl group, m is 0, At2 is
In another embodiment, An is xm pyridazinyl group, m is 0, Ar2 is
In another embodiment, An is a pyridazinyl group, r is 1, m is 0, Ar2 is
and R8 is a - (dC6) alkyl. In another embodiment, he - (C! -C6) alkyl is substituted at the p-group position. In another embodiment, the - (-Ce ^ alkyl is a tert-butyl group In another embodiment, the - (dC6) alkyl is a tert-butyl group and is substituted at the para-position of the phenyl group. In another embodiment, the - (dC6) alkyl is an iso-propyl group and is substituted in the para-position of the phenyl group.
In another embodiment, An is xm piradizinyl group, r is 1, m is 0, Ar2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the para-position of the phenyl group.
In another modality, Ar! is a piradizinyl group, r is 1, m is 0, Ar2 is
and Rs is -halo. In another embodiment, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and is substituted in the s < zra-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the s < zra-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the para-position of the phenyl group. In another embodiment, An is a thiadiazolyl group, m is 0, and Ar2 is xm benzothiazolyl group.
In another embodiment, An is xm thiadiazolyl group, m is 0, and At 2 is a benzoolyl group.
In another embodiment, An is xm thiadiazolyl group, m is 0, and Ar2 is a benzoimidazolyl group. In another embodiment, An is xm thiadiazolyl group, m is 0, and Ar2 is
In another embodiment, A is a thiadiazolyl group, m is 0, and Ar2 is
In another embodiment, An is a tiazolyl group, m is 0, and Ar2 is
In another embodiment, An is a thiadiazolyl group, m is 0, and Ar2 is
In another embodiment, An is a thiadiazolyl group, m is 0, and At2 is
In another modality, Ar! is a thiadiazolyl group, m is 0, and Ar2 is In another embodiment, An is xm thiadiazolyl group, m is 0, and Ar2 is In another embodiment, An is a thiadiazolyl group, r is 1, m is 0, Ar2 is
and Rs is a - (d-C6) alkyl. In another embodiment, the - (C1-C6) alkyl is substituted at the position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group and is substituted at the para-position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a wo-propyl group. In another embodiment, the - (d-C6) alkyl is a so-propyl group and is substituted in the para-position of the phenyl group.
In another embodiment, A is a thiadiazolyl group, r is 1, m is 0, At2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the para-position of the phenyl group.
In another embodiment, An is a thiadiazolyl group, r is 1, m is 0, A12 is
and R8 is -halo. In another embodiment, the -halo is substituted in the para-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another embodiment, -halo is -Br and is substituted in the s-ra-position of the phenyl group. In another modality, -halo is -I. In another embodiment, -halo is -I and it is substituted in the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the para-position of the phenyl group. In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is a benzothiazolyl group. In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is a benzooxazolyl group. In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group.
In another embodiment, An is a pyridyl group, m is 1, 3 is -CH3, and Ar2 is
In another embodiment, An is xm pyridyl group, m is 1, R3 is -CH3, and At2 is
In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and At is
* your? vn N - (R8).
In another embodiment, An is xm pyridyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and At2 is In another embodiment, An is a pyridyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is a - (dC ^ alkyl) In another embodiment, the - (d-C6) alkyl is substituted at the p-aryl group position In another embodiment, the - (d-C6) alkyl is a tert-butyl group In another embodiment, the - (d-C6) alkyl is a tert-butyl group and is substituted in the para-position of the phenyl group In another embodiment, the - (C1-C6) alkyl is a ws-propyl group. In another embodiment, the - (d-C6) alkyl is an SO-propyl group and is substituted at the para-position of the phenyl group.
In another embodiment, An is a pyridyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rs is -CF3. In another embodiment, -CF3 is substituted at the sixth position of the phenyl group.
In another embodiment, An is a pyridyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rs is -halo. In other. modality, the -halo is substituted in the para-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another embodiment, -halo is -Br and is substituted in the s ^ ra-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the para-position of! phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and is substituted in the ara-position of the phenyl group. In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is xm benzothiazolyl group. In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is a benzooxazolyl group. In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group.
In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is xm pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is xm pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, Ar! is xm pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, A is xm pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, Ar! is xm pyrazinyl group, r is 1, m is 1, 3 is -CH3, Ar2 is
and Rs is a - (d-C6) alkyl. In another embodiment, the - (C1-Ce) alkyl is substituted at the position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group and is substituted at the para-position of the phenyl group. In another embodiment, the - (C1-C6) alkyl is a so-propyl group. In another embodiment, the - (C! -C6) alkyl is a z'50-propyl group and is substituted at the para-position of the phenyl group.
In another embodiment, An is a pyrazinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rs is -CF3. In another embodiment, -CF3 is substituted in the s < zra-position of the phenyl group.
In another embodiment, An is a pyrazinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and R8 is -halo. In another embodiment, the -halo is substituted in the s ^ ra-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another embodiment, -halo is -Br and is substituted in the s-ra-position of the phenyl group. In another modality, - halo is -I. In another embodiment, -halo is -I and is substituted in the s ^ ra-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the para-position of the phenyl group. In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is a benzothiazolyl group.
In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is a
benzooxazolyl group.
In another modality, Ar! is a pyrimidinyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group.
In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is
• In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, An is xm pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, An is xm pyrimidmyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and At2 is
In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, Ar! is xm pyrimidinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and R8 is a - (dC6) alkyl. In another embodiment, the - (C1-C6) alkyl is substituted at the "position of the phenyl group. In another embodiment, the - (C? -C6) alkyl is a tert-butyl group. In another embodiment, the - (C1-C6) alkyl is a tert-butyl group and is substituted at the para-position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a z '? O-propyl group. In another embodiment, the - (dC6) alkyl is a zosopropyl group and is substituted at the para-position of the phenyl group.
In another modality, Ar! is a pyrimidinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and R8 is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
In another embodiment, An is a pyrimidinyl group, r is 1, m is 1, 3 is -CH3, Ar2 is
and Rs is -halo. In another embodiment, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the ara-position of the phenyl group. In another modality, -halo is -F. In another embodiment,.-Halo is -F and is substituted in the laa7-a-position of the phenyl group. In another modality, Ar! is xm pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is a benzothiazolyl group.
In another embodiment, An is xm pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is a benzooxazolyl group.
In another embodiment, An is xm pyridazinyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group. In another embodiment, Ar1 is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
wyuv
In another embodiment, An is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is xm pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, Ar1 is xm pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is xm pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridazinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rs is a - (C1-C6) alkyl. In another embodiment, the - (C1-C6) alkyl is substituted at the position of the phenyl group. In another embodiment, it is a tert-butyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group and is substituted in the phenyl group. In another embodiment, the - (C? -C6) alkyl is a z '? O-propyl group. In another embodiment, the - (d-C ^ alkyl) is a zsO-propyl group and is substituted in the parent-position of the phenyl group.
In another embodiment, An is a pyridazinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
In another embodiment, An is a pyrazinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is -halo. In another embodiment, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the ara-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the para-position of the phenyl group.
In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is a benzothiazolyl group. In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is a benzooxazolyl group. In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group. In another embodiment, An is xm thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is xm thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is jjl hRA
In another embodiment, Ar1 is a thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is xm thiadiazolyl group, m is 1, R3 is -CH3, and Ar is In another embodiment, An is xm thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, An is a thiadiazolyl group, r is 1, m is 1, R3 is -CH3, Ar is and R8 is a - (d-C6) alkyl. In another embodiment, the - (dC ^ alkyl is substituted in the paraposition of the phenyl group In another embodiment, the - (C? -C6) alkyl is a tert-butyl group. -C6) alkyl is xm tez-butyl group and is substituted at the p-group position sara.In another embodiment, the - (d-C6) alkyl is a zss-propyl group.In another embodiment, the - (d- C6) alkyl is a wo-propyl group and is substituted in the para-position of the phenyl group.
In another embodiment, An is a thiadiazolyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and R8 is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
. In another modality, Ar! is a thiadiazolyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and R8 is -halo. In another embodiment, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another embodiment, -halo is -I and is substituted in the para-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the para-position of the phenyl group.
4. 2 COMPOUNDS MTRO (CIANOWI LPIPERAZINA DE LA FORMULA (Yes
'
The present invention also comprises Nitio (cyano) vmylpiperazine Compounds
of the formula (11)
(LD
j5 where An, At2, R3, R4 and m are defined above for the Compounds
Nitro (cyano) vinylpiperazine of the formula (H). In one embodiment, An is a pyridyl group. In another embodiment, An is a pyrimidinyl group. In another embodiment, An is a pyrazinyl group. 0 In another modality, Ar! It is a pyridazinyl group. In another embodiment, An is a thiadiazolyl group. In another embodiment, Ar2 is a bezoimidazolyl group. In another embodiment, Ar2 is a benzothiazolyl group. In another embodiment, Ar2 is a benzooxazolyl group.
In one modality, A12 is
In another modality, Ar2 is
In another modality, Ar2 is
In another modality, At is
In another modality, At2 is In another modality, Ar2 is
In another modality, Ar2 is
In another modality, m is 0. In another modality, m is 1. In another modality, m is 2. In another modality, n is 1. In another modality, n is 2. In another modality, n is 3. In otia modality, p is 0. In another modality, p is 1. In another modality, p is 2. In another modality, r is 0. In another modality, r is 1. In another modality, r is 2. In another modality, r is 3.
In another modality, r is 4. In another modality, r is 5. In another modality, q is 0. In another modality, q is 1. In another modality, q is 2. In another modality, q is 3. In another modality, modality, q is 4. In another modality, q is 5. In another modality, q is 6. In another modality, s is 0. In another modality, s is 1. In another modality, s is 2. In another modality, s is 3. In another mode, s is 4. In another mode, R \ is -halo. In another modality, R? is -Cl. In another modality, Rt is -Br. In another modality, R \ is -I.
In another mode, Ri is -F. In another modality, Ri is -CH3. In another embodiment, R i is -CN. In another mode, Ri is -NO2. In another mode, Ri is -OH. In another mode, Ri is -OCH3.
In another modality, R! is -C (halo) 3.
In another embodiment, Ri is -CH (halo) 2. In another embodiment, Rt is -CH (halo).
In another embodiment, R i is -CF3. In another embodiment, n or p is 1 and R2 is -halo, -OH, -NH2, -CN, or -NO2. In another embodiment, nop is 1 and R2 is - (d-C10) alkyl, - (C2-C10) alkenyl, - (C2-C10) alkynyl, - (C3-C0) cycloalkyl, - (C8-C14) bicycloalkyl, - (C8-C? 4) tricycloalkyl, - (C5-C8) cycloalkenyl, - (Cg-C? 4) bicycloalkenyl, - (Cg-C? 4) tricycloalkenyl, - (3- to 7- cuef? s ) heterocycle, or - (7- to 10-cells) bicycloheterocycle, each of which is
substituted or not with one or more R5 groups.
In another embodiment, n or p is 1 and R2 is -phenyl, -naphthyl, - (C14) aryl or - (5- to 10-cells) heteroaryl, each of which is substituted or unsubstituted with one or more radical groups.
-, - In another mode, m is 1 and R3 is -halo, -OH, -NH2j -CN, or -NO2.
In another embodiment, m is 1 and R3 is - (C1-C10) alkyl, - (C2-C? O) alkenyl, - (C2-C10) alkynyl, - (C3-C? O) cycloalkyl, - (Cg-) C? 4) bicycloalkyl, - (Cg-C14) tricycloalkyl, - (C5-C10) cycloalkenyl, - (C8-C14) bicycloalkereryl, - (C8-C14) tricycloalkenyl, - (3- to 7- cuef? S) heterocycle, or - (7- to 10-cells) bicycloheterocycle, each of which is substituted or not with one or more R5 groups.
In another embodiment, m is 1 and -R3 is -phenyl, -naphthyl, - (C14) aryl or - (5- to 10-ca) heteroaryl, each of which is substituted or not with one or more groups Re.
~ - In another embodiment, m is 1 and R3 is - (d-C10) alkyl.
In another embodiment, m is 1, R3 is (- (d-d0) alkyl, and the carbon atom to which the group R3 is attached is in the (R) configuration.
In another embodiment, m is 1, R3 is - (C? -C?) Alkyl, and the carbon atom to which the group R3 is attached is in the (S) configuration. 5 In another embodiment, m is 1 and R3 is -CH3.
In another embodiment, m is 1, R3 is -CH3, and the carbon atom to which the group R3 is attached is in the (R) configuration.
In another embodiment, m is 1, R3 is -CH3, and the carbon atom to which the group R3 is attached is in the (S) configuration.
In another modality, m is 1 and R3 is -halo.
In another mode, m is 1 and R3 is -Cl.
In another mode, m is 1 and R3 is -Br.
In another mode, m is 1 and R3 is -I.
In another mode, m is 1 and R3 is -F.
In another modality, R4 is -H. In another embodiment, R4 is -CN.
In another embodiment, R 4 is -C (O) O (C 1 -C 4) alkyl.
In another embodiment, R4 is -C (O) NH ((d-C4) alkyl).
In another embodiment, Ar2 is xm benzothiazolyl group and s is 1.
In another embodiment, Ar2 is a benzoimidazolyl group and s is 1.
In another embodiment, Ar2 is a benzooxazolyl group and s is 1.
In another modality, At2 is
and s is 1. In another modality, Ar2 is
and s is 1. In another mode, Ar2 is
yr is 1. In another mode, Ar? is
and q is 1.
In another modality, At2 is
and r is 1. In another mode, Ar2, is
and r is 1. In another mode, Ar2 is
and r is 1. In another embodiment, An is a pyridyl group, m is 0, and Ar2 is a benzothiazolyl group. In another modality, Ar! is a pyridyl group, m is 0, and Ar2 is a benzooxazolyl group.
In another embodiment, A is a pyridyl group, m is 0, and Ar2 is a benzoimidazolyl group. In another modality, An is a pyridyl group, m is 0, and Ar2 is
In another modality, An is a pyridyl group, m is 0, and Ar2 is
In another modaliadd, An is a pyridyl group, m is 0, and Ar2 is
In another embodiment, An is a pyridyl group, m is 0, and Ar2 is
In another modality, An is a pyridyl group, m is 0, and Ai2 is
In another modality, Ar! is a pyridyl group, m is 0, and Ar2 is
In another embodiment, An is a pyridyl group, m is 0, and At2 is
In another embodiment, An is a pyridyl group, r is 1, m is 0, Ar 2 is
and R8 is a - (dC6) alkyl. In another embodiment, the - (dC 6) alkyl is substituted at the position of the phenyl group. In another embodiment, the - (C1-C6) alkyl is a tert-butyl group. In another embodiment, the - (d-C6) alkyl is xm tert-butyl group and is substituted at the parent-position of the phenyl group. In another embodiment, the - (C1-Ce) alkyl is a zso-propyl group. In another embodiment, the - (C? -C6) alkyl is xm? Ss-propyl group and is substituted in the parent-position of the phenyl group.
In another mode, An is a pyridyl group, r is 1, m is 0, Ar2 is
and R8 is -CF3. In another embodiment, -CF3 is substituted in the ara-position of the phenyl group.
In another embodiment, An is a pyridyl group, r is 1, m is 0, At2 is
and R8 is -halo. In another modality, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the sara-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the para-position of the phenyl group. .
In another modality, Ar! is a pyrazinyl group, m is 0, and Ar2 is xm benzothiazolyl group.
In another embodiment, Aii is a pyrazinyl group, m is 0, and Ar2 is a benzooxazolyl group. In another embodiment, Axi is a pyrazinyl group, m is 0, and Ax2 is a benzoimidazolyl group. In another embodiment, An is a pyrazinyl group, m is 0, and Ar2 is
In another embodiment, An is a pyrazinyl group, m is 0, and Ar2 is
In another embodiment, An is xm pyrazinyl group, m is 0, and Ar2 is
In another modality, Ar! is xm pyrazinyl group, m is 0, and Ar2 is In other modality, An is a pyrazinyl group, m is 0, and Ar2 is
In another embodiment, An is a pyrazinyl group, m is 0, and Ar2 is In another embodiment, An is a pyrazinyl group, m is 0, and Ar2 is In another embodiment, Ar1 is a pyrazinyl group, r is 1, m is 0, Ar2 is and Rs is a - (d-C6) alkyl. In another embodiment, the - (dC 6) alkyl is substituted at the position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (C? -C6) alkyl is a tert-butyl group and is substituted in the sara-position of the phenyl group. In another embodiment, the - (C! -C6) alkyl is a z'jo-propyl group. In another embodiment, the - (d-C6) alkyl is an iso-p-p-tyl group and is substituted at the p-p-group position.
In another modality, An is a pyrazinyl group, r is 1, m is 0, At2 is
and Rs is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
In another embodiment, An is a thiadiazolyl gxupo, r is 1, m is 0, A 2 is
and R8 is -halo. In another embodiment, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another modality, -halo is -Cl and is substituted in the ara-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another embodiment, -halo is -I and is substituted in the para-position of the phenyl group. In another modality, -halo is -F. In another modality, -halo is -F and is substituted in lasa? * -position of the phenyl group. In another modality, Ar! is a pyrimidinyl group, m is 0, and Ar2 is a benzothiazolyl group.
In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is a benzooxazolyl group.
In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is a benzoimidazolyl group. In another embodiment, An is xm pyrimidinyl group, m is 0, and Ar2 is
In another embodiment, An is xm pyrimidinyl group, m is 0, and Ar2 is
In another modality, An is a pyrimidinyl group, m is 0, and Ar2 is
¡L ^ - (8) e In another modality, An is a pyrimidinyl group, m is 0, and Ar2 is
In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is
In another embodiment, Ai \ is xm pyrimidinyl group, m is 0, and Ar2 is In another embodiment, An is a pyrimidinyl group, m is 0, and Ar2 is In another embodiment, An is a pyrimidinyl group, r is 1, m is 0, Ar2 is
and RB is a - (d-C6) alkyl. In another embodiment, the - (d-C6) alkyl is substituted in the para-position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (d-C6) alkyl, is a tert-butyl group and is substituted in the para-position of the phenyl group. In another embodiment, the - (d-Ce) alkyl is a z'so-propyl group. In another embodiment, the - (dC6) alkyl is a z'ss-propyl group and is substituted in the paraposition of the phenyl group.
In another embodiment, An is a pyrimidinyl group, r is 1, m is 0, Ar2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
In another modality, An is a pyrimidinyl group, r is 1, m is 0, Ax2 is
and Rs is -halo. In another embodiment, the -halo is substituted in the para-position of the phenyl group. In another modality, -halo is -Cl. In another modality, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another embodiment, halo is -Br and is substituted in the parent-position of the phenyl group. In another mode, - 5 halo is -I. In another modality, -halo is -I and is substituted in the ara-position of the phenyl group. In another modality, -halo is -F. In another modality, -halo is -F and it is substituted in the para-position of the phenyl group. In another embodiment, An is a pyridazinyl group, m is 0, and Ar2 is a group? n benzothiazolyl. In another embodiment, An is xm pyridazinyl group, m is 0, and Ar 2 is a benzooxazolyl group. In another embodiment, An is a pyridazinyl group, m is 0, and Ar2 is a benzoimidazolyl group.
In another modality, An is a pyridazinyl group, m is 0, and Ar2 is
In another modality, An is a pyridazinyl group, m is 0, and Ax2 is
In another embodiment, A is a pyridazinyl group, m is 0, and Ar2 is In another embodiment, An is a pyridazinyl group, m is 0, and Ar2 is
In another modality, A is a gxupo pyridazinyl, m is 0, and Ar2 is
In another modality, An is a pyridazinyl group, m is 0, and Ax2 is In another modality, An is a pyridazinyl group, m is 0, and Ax2 is
In another embodiment, An is a pyridazinyl group, r is 1, m is 0, Ax2 is
and Rg is a - (d-C6) alkyl. In another embodiment, the - (C! -C6) alkyl is substituted at the position of the phenyl group. In another embodiment, the - (d-Ce) alkyl is a tert-butyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group and is substituted in the parent-position of the phenyl group. In another embodiment, the - (C? -C6) alkyl is a so-propyl group. In another embodiment, the - (C? -C6) alkyl is an iso-propyl group and is substituted in the parent group of the phenyl group.
In another embodiment, An is a pyridazinyl group, r is 1, m is 0, Ax2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
In another embodiment, An is a pyridazinyl group, r is 1, m is 0, Ar2 is
and R8 is -halo. In another modality, the -halo is substituted in the para-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the para-position of the phenyl group. In another modality, -halo is -F. In another modality, -halo is -F and it is substituted in the la / 'a-position of the phenyl group. In another embodiment, An is a thiadiazolyl group, m is 0, and Ar 2 is a benzothiazolyl group. In another embodiment, An is a thiadiazolyl group, m is 0, and Ar 2 is a benzooxazolyl group. In another embodiment, An is xm thiadiazolyl group, m is 0 and Ar2 is a benzoimidazolyl group.
In another embodiment, An is a thiadiazolyl group, m is 0, and Ar2 is
In another embodiment, it is a thiadiazolyl group, m is 0, and Ar 2 is another form, An is a thiadiazolyl group, m is 0, and Ar 2 is another form, An is a thiadiazolyl group, m is 0, and Ar 2 is
In another embodiment, An is a thiadiazolyl group, m is 0, and Ar2 is
In another modality, Ar! is a thiadiazolyl group, m is 0, and Ar2 is
In another embodiment, Art is a thiadiazolyl gxupo, m is 0, and Ar2 is
In another embodiment, An is a thiadiazolyl group, r is 1, m is 0, Ar2 is
and Rs is a - (d-C6) alkyl. In another embodiment, the - (dC6) alkyl is substituted in the para-position of the phenyl group. In another embodiment, the - (C? -C6) alkyl is a tert-butyl group. In another embodiment, the - (C? -Ce) alkyl is xm tert-butyl group and is substituted in the parent group of the phenyl group. In another embodiment, the - (d-C-Jak alkyl is a z-so-propyl group.) In another embodiment, the - (C? -C6) alkyl is an iso-propyl group and is substituted in the sara-position of the phenyl group.
In another embodiment, An is a thiadiazolyl group, r is 1, m is 0, Ar2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
In another embodiment, An is a thiadiazolyl group, r is 1, m is 0, Ar2 is
and Rg is -halo. In another modality, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo.es -Br. In another modality, -halo is -Br and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the sara-position of the phenyl group. In another modality, -halo is -F. In another modality, -halo is -F and it is substituted in the para-position of the phenyl group. In another modality, Ar! is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is a benzothiazolyl group.
In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and AX2 is a benzooxazolyl group.
In another modality, Ax! is a pyridyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group. In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, An is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is
• jv wi
In another modality, Ax is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, Ax! is a pyridyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is xm pyridyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridyl group, r is 1, m is 1, R3 is -CH3, Ax2 is
and Rg is a - (C1-C6) alkyl. In another embodiment, the - (dC 6) alkyl is substituted at the para-position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (dC6) alkyl is a tert-butyl group and is substituted in the phenyl group. In another embodiment, the - (C! -C6) alkyl is a zosopropyl group. In another modality, the - (d-C6) alkyl is a so-propyl group and is substituted in the sara-position of the phenyl group.
In another modality, Ar! is a pyridyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and R8 is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
In another modality, An is a pyridyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rs is -halo. In another embodiment, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Bx and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the sara-position of the phenyl group. In another modality, -halo is -F. In another modality, -halo is -F and it is substituted in the para-position of the phenyl group.
In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is a benzothiazolyl group. In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is a benzooxazolyl group. In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group. In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, Axt is xm gxupo pyrazinyl, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, An is a pyrazinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, An is xm pyrazinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is and Rg is a - (d-Ce quil.) In another embodiment, the - (C1-C6) alkyl is substituted at the para-position of the Phenyl group In another embodiment, the - (C! -C6) alkyl is a tert-butyl group.In another embodiment, the - (d-C6) alkyl is a tert-butyl group and is substituted at the phenyl group In another embodiment, the - (C1-C6) alkyl is a z.so-propyl group.In another embodiment, the - (d-C6) alkyl is a z.so-propyl group and is substituted in the -position of the phenyl group.
In another modality, An is a pyrazinyl group, r is 1, m is 1, R3 is -CH3, Ax2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted at the p-group position.
In another modality, An is a pyrazinyl group, r is 1, m is 1, R3 is -CH3, Ax2 is
and Rg is -halo. In another modality, the -halo is substituted in the ara-position of the phenyl group. In another modality, -halo is -Cl. In another modality, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and it is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the ara-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the para-position of the phenyl group. In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ax2 is a benzothiazolyl group. In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is xm gxupo benzooxazoliol. In another modality, Ax! is a pyrimidinyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group. In another embodiment, An is a pyrimidinyl gxupo, m is 1, R3 is -CH3, and Ax2 is
In another embodiment, An is a pyrimidinyl gxupo, m is 1, R3 is -CH3, and Ax2 is
In another modality, it is a gxupo piximidinyl, m is 1, R3 is -CH3, and Ar2 is
'• suyin. ll ~ (R8) s In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and At2 is
In another embodiment, An is xm pyrimidinyl group, m is 1, R3 is -CH3, and Ax2 is In another embodiment, An is a pyrimidinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, Ax! is a gxupo piximidinyl, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is a - (d-C6) alkyl. In another embodiment, the - (dC6) alkyl is substituted in the para-position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (C1-C6) alkyl is a tert-butyl group and is substituted in the second position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a z'sO-pxopyl group. In another embodiment, the - (d-C6) alkyl is a so-propyl group and is substituted in the para-phenyl group.
In another embodiment, An is a pyrimidinyl group, r is 1, m is 1, R is -CH 3, Ar 2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the parent-position of the phenyl group.
In another embodiment, An is a pyrimidinyl group, r is 1, m is 1, R3 is -CH3, Ax2 is
and Rs is -halo. In another embodiment, the -halo is substituted in the sara-position of the phenyl group. In otia modahdad, -halo is -Cl. In another modality, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another embodiment, halo is -Br and is substituted in the parent-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and it is substituted in the sara-position of the phenyl group. In another modality, -halo is -F. In another modality, -halo is -F and it is substituted in the para-position of the phenyl group. In another modality, Ar! is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is a
benzothiazolyl group. & In another modality, Ar! is a pyridazinyl group, m is 1, R3 is -CH3, and Ax2 is a benzooxazolyl group.
In another embodiment, An is a pyridazinyl group, m is 1, R3 is -CH3 and Ar2 is a benzoimidazolyl group.
In another embodiment, An is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, An is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another mode, An is my pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is In another embodiment, Axi is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, An is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, Ar! is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is In other mode, An is a pyridazinyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, AXI is a pyridazinyl group, r is 1, m is 1, 3 is -CH3, Ar2 is
and Rg is a - (C? -C6) alkyl. In another embodiment, the - (C! -C6) alkyl is substituted at the position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group and is substituted in the sara-position of the phenyl group. In another embodiment, the - (C! -C6) alkyl is a so-propyl group. In another embodiment, the - (d-Ce) alkyl is a zosopropyl group and is substituted in the ara-position of the phenyl group.
In another modality, An is a pyridazinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is -CF3. In another embodiment, -CF3 is substituted in the sara-position of the phenyl group.
In another embodiment, An is a pyridazinyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is -halo. In another modality, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another embodiment, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and it is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and is substituted in the para-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the para-position of the phenyl group. In another embodiment, An is xm thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is a benzothiazolyl group. In another embodiment, An is xm thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is a benzooxazolyl group. In another embodiment, An is xm thiadiazolyl group; m is 1, R3 is -CH3 and Ax2 is a benzoimidazolyl group.
In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is
In another embodiment, it is a thiadiazolyl group, m is 1, R3 is -CH3, and Ax2 is In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ax2 is In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ax2 is
In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ax2 is
In another embodiment, An is a thiadiazolyl group, m is 1, R3 is -CH3, and Ax2 is
In another embodiment, Axi is a thiadiazolyl group, m is 1, R3 is -CH3, and Ar2 is
In another modality, An is a thiadiazolyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is a - (d-C6) alkyl. In another embodiment, the - (dC 6) alkyl is substituted at the position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a tert-butyl group. In another embodiment, the - (C1-C6) alkyl is a tert-butyl group and is substituted in the parent-position of the phenyl group. In another embodiment, the - (d-C6) alkyl is a z '^ o-propyl group. In another embodiment, the - (d-Ce) alkyl is a z'so-propyl group and is substituted in the sara-position of the phenyl group.
In another modality, An is a thiadiazolyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is -CF3. In another modality, -CF3 is substituted in the parent-position of the phenyl group.
In another modality, An is a thiadiazolyl group, r is 1, m is 1, R3 is -CH3, Ar2 is
and Rg is -halo. In another embodiment, the -halo is substituted in the sara-position of the phenyl group. In another modality, -halo is -Cl. In another modality, -halo is -Cl and is substituted in the para-position of the phenyl group. In another modality, -halo is -Br. In another modality, -halo is -Br and is substituted in the sara-position of the phenyl group. In another modality, -halo is -I. In another modality, -halo is -I and it is substituted in the sara-position of the phenyl group. In another modality, -halo is -F. In another embodiment, -halo is -F and it is substituted in the p-group position.
4. 3
Certain compounds Niteo (cyano) vinylpiperazine can have asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. This invention relates to the use of all optical isomers and stereoisomers of the Nitio (cyano) vinylpiperazine Compounds, and mixtures thereof, and to all pharmaceutical compositions and methods of treatment which may employ or contain them.
The Nitro (cyano) vinylpiperazine Compounds have a double bond to which a group R4 and a group Ar2-NH- are linked, each of which can be cis or trans sex relative to one otio. Accordingly, the present invention comprises Nitio (cyano) vinylpipexazine Compounds wherein the R4 group and the Ar2-NH- group are trans relative to each other, and all mixtures thereof. Formula (I) and (H) are intended to comprise: (i) Nitro (cyano) vinyl piperazine compounds wherein the group _t and group 10 Ar2-NH- are trans relative to each other, (ii) Nitro compounds (cyano) ) vinylpiperazine in
where the group R and the group Ar2-NH- are cis xelative with each other, and (iii) all mixtures thereof.
In the Nitio (cyano) vinylpiperazine Compounds, each R3 group can be attached to a
, - carbon atom of the piperazino ring. In a fashion, the Compounds
Niteo (cyano) vinylpiperazine have only one group R3j sto es, m = l, and that group R3 is attached to the nitrogen atom adjacent to the carbon atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group. In another embodiment, the Compound
Nitro (cyano) vinylpiperazine has only one group R3 and that group R3 is attached to a carbon atom 0 adjacent to the nitrogen atom attached to the group -C (NHAx2) = C (CN) (R4) or to group -C (NHAx2) = C (NO2) (R4).
In another embodiment, two R3 groups are attached to a single carbon atom of the piperazine ring. In another embodiment, a group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl group, pyrimidinyl, pyrrazinyl, pyridazinyl, or thiadiazolyl and other group R3 is attached to a carbon atom adjacent to the nitrogen atom. adjunct of the gupo -C (NHAr2) = C (CN) (R4) or to the group -C (NHAr2) = C (NO2) (R). In another modality, the Niteo Compound (cyano) vinyl piperazine has two R3 groups, that is, m = 2, each attached to a different carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group. In another embodiment, the Compound Nitium (cyano) vinyl piperazine has two R3 groups, each attached to a different carbon atom adjacent to the carbon atom attached to the group-C (NHAr2) = C (CN) (R4) or to the group - C (NHAr2) = C (NO2) (R4).
In one embodiment, wherein the Nitro (cyano) vinyl piperazine Compound has one or two R3 groups, a carbon atom to which the R3 group is attached has the (R) configuration. In another embodiment, wherein the Nitro Compound (cyano) vinyl piperazine has one or two R3 groups, a carbon atom to which the group R3 is attached has the configuration (S). In another embodiment, the Nitro (cyano) vinylpiperazine Compound has x or two R3 groups and at least one of the carbon atoms to which the R3 group is attached has the (R) configuration. In another modaliadd, the Compound Nitro (cyano) vinylpiperazine has one or two R3 groups, and at least one of the carbon atoms to which a group R3 is attached has the configuration (S).
In another embodiment, the Niteo (cyano) vinylpiperazine Compound has one or two R3 groups, a R3 group is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, and carbon to which the group R3 is attached is in the Configuration (R). In another embodiment, the Compound Nitium (cyano) vinyl piperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which the Group R3 is attached is in the Configuration (RL), and.R3 is - (d-C4) alkyl, substituted or not with one or more halo groups. In another embodiment, the Nitro (cyano) vinylpiperazine Compound has one or two R3 groups, a R3 group is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon at which group R3 is attached was in Configuration (R) and 3 is -CH3. In another embodiment, the Nitro (cyano) vinylpiperazine Compound has one or two R3 groups, a R3 group is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon at which group R3 is attached was in the Configuration (R) and R3 is -CF3. In another embodiment, the Nitro Compound (cyano) vinyl piperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which the Group R3 is attached is in the Configuration (R), and R3 is -CH2CH3.
In another embodiment, the Compound Nitium (cyano) vinyl piperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group -C (NHAr2) = C (CN) (R4) or to the group -C (NHAr2) = C (NO2) (R4), and the carbon to which the group R3 is attached is found in the Configuration (R). In another embodiment, the Compound Niteo (cyano) vinylpiperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to group-C (NHAr2) or to the group -C (NHAr2) = C (NO2) (R4), and the carbon to which the group R3 is attached was in the Configuration (R) and R3 is - (d-C4) alkyl, substituted or not with one or more halo groups. In another embodiment, the Nitro Compound (cyano) vinyl piperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the gxupo -C (NHAr2) = C (CN) (R4) or to the group -C (NHAx2) = C (NO2) (R4), the carbon to which the group R3 is attached is found in the Configuration (R) and R3 -CH3. In another embodiment, the Compound Niteo (cyano) vinylpiperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen attached to the group -C (NHAr2) = C (CN) (R4) or to the group -C (NHAr2) = C (NO2) (R4), the carbon to which the group R3 is attached was in the Configuration (R) and R3 is -CF3. In another embodiment, the Nitro Compound (cyano) vinyl piperazine has one or two R3 groups, a group 3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group -C (NHAr2) = C (CN) (R?) or to the group -C (NHAr2) = C (NO2) (R4), and the carbon to which the group R3 is attached is found in the Configuration (R) and R3 - CH2CH3.
In another embodiment, the Compound Nitium (cyano) vinylpiperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pixazinyl, pyridazinyl, or thiadiazolyl group, and carbon to which the group R3 is attached was in the Configuration (S). In another modality, the Compound Nitro (cyano) vinylpiperazine has one or two R3 groups, a group
R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pixazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which the R3 group is attached is found in the Configuration (S), and R3 is - ( C? -C4) alkyl, substituted or unsubstituted with one or more halo groups. In another embodiment, the Nitro Compound (cyano) vinyl piperazine has one or two R3 groups, a R3 group is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon at which group R3 is attached was in the Configuration (S) and R3 is -CH3. In another embodiment, the Compound Nitium (cyano) vinyl piperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nytogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon at which group R3 is attached is in the Configuration (S) and R3 is -CF3. In another embodiment, the Compound Niteo (cyano) vinylpiperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which the Group R3 is attached was in the Configuration (S), and R3 is -CH2CH3.
In another embodiment, the Compound Nitium (cyano) vinyl piperazine has one or two R3 groups, xm group R3 is attached to a carbon atom adjacent to the nytogen atom attached to the group -C (NHAr2) = C (CN) (R) or to the group -C (NHAr2) = C (NO2) (R4), and the carbon to which the group R3 is attached was in the Configuration (S). In another embodiment, the Nitro Compound (cyano) vinyl piperazine has one or two R3 groups, a group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group -C (NHAx2) = C (CN) (R or gxupo -C (NHAr2) = C (NO2) (R4), and the carbon to which the group R3 is attached was in the Configuration (S) and R3 is - (d-C4) alkyl, substituted or not with one or more halo groups In another embodiment, the Compound Nitium (cyano) vinylpipexazine has one or two R3 groups, one group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group -C (NHAr2) = C (CN) (R4) or to the group -C (NHAr2) = C (NO2) (R4), the carbon to which the group R3 is attached was in the Configuration (S) and R3 -CH3 In another modality, the Nitium Compound ( cyano) vinylpiperazine has one or two g3P3 R3, a group R3 is attached to a carbon atom adjacent to the nitrogen attached to the group -C (NHAr2) = C (CN) (R4) or the group -C (NHAr2) = C ( NO2) (R4), the carbon to which the R3 group is ad together it is in the Configuration (S) and R3 is -CF3. In another embodiment, the Compound Nitium (cyano) vinyl piperazine has one or two groups R3, xm group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group -C (NHAr2) = C (CN) (E) or to the group -C (NHAr2) = C (NO2) (R4), and the carbon to which the group R3 is attached was in the Configuration (S) and R3 -CH2CH3.
In another embodiment, the Compound Nitium (cyano) vinylpiperazine has only one group
R3, the group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, and the carbon to which the R3 group is attached is found in the Configuration (R). In another modality, the
Compound Nitium (cyano) vinylpiperazine has only one R3 group, the R3 group is attached to a carbon atom adjacent to the nytogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl group, pyridazinyl, or thiadiazolyl, the carbon to which the group R3 is attached is found in the Configuration (R), and R3 is - (C? -C4) alkyl, substituted or unsubstituted with one or more halo groups. In another embodiment, the Nitro Compound (cyano) vinylpiperazine has only one R3 group, the R3 group is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which group R3 is attached was in Configuration (R) and R3 is -CH3.
In another embodiment, the Compound Nitium (cyano) vinyl piperazine has only one group R3, the group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which group R3 is attached was in Configuration (R) and R3 is -CF3. In another embodiment, the Compound Nitium (cyano) vinyl piperazine has only one group R3, the group R3 is attached to a carbon atom adjacent to the nitrogen attached to the pyridyl group, p rimidinyl, pixazinyl, pixidazinyl, or thiadiazolyl, the carbon to which the Group R3 is attached was in the Configuration (R), and R3 is -CH2CH3.
In another embodiment, the Nitro Compound (cyano) vinylpiperazine has only one group
R3, the group R3 is attached to a carbon atom adjacent to the nucleotide atom attached to the group -C (NHAr2) = C (CN) (R4) or to the group -C (NHAr2) = C (NO2) (R4), and the carbon to which the R3 group is attached is found in the Configuration (R). In another embodiment, the Compound Nitium (cyano) vinyl piperazine has only one R3 group, the group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group -C (NHAr2) = C (CN) (R4) or group -C (NHAr2) = C (NO2) (R4), and the carbon to which the group
R3 is attached is in the Configuration (R) and R3 is - (d-C) alkyl, substituted or not with one or more halo groups. In another embodiment, the Nitro Compound (cyano) vinyl piperazine has only one R3 group, the R3 group is attached to a carbon atom adjacent to the nytogen atom attached to the group -C (NHAr2) = C (CN) (R4) or group -C (NHAr2)
= 0 1 ^ 0 ^ (1 ^), the carbon to which the group R3 is attached is in the Configuration (R) and R3 --CH3. In another embodiment, the Nitro Compound (cyano) vinyl piperazine has only one R3 group, the R3 group is attached to a carbon atom adjacent to the nitrogen attached to the group -C (NHAr2) = C (CN) (R) or the group - C (NHAr2) ^ (NO ^ ÍR ^, the carbon to which gxupo R3 is attached is in the Configuration (R) and R3 is -CF3. In another embodiment, the Compound TSfitio (cyano) vinylpiperazine has only one R3 group , the group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group-C (NHAx2) = C (CN) (R4) or to the gxupo -C (NHAx2) = C (NO2) (R4), and the carbon to which the group R3 is attached is found in the Configuration (R) and R3 -CH2CH3.
In another embodiment, the Compound Nitium (cyano) vinyl piperazine has only one group R3, the group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, and the carbon at which group R3 is attached was in the Configuration (S). In another embodiment, the Compound Nitium (cyano) vinyl piperazine has only one group R3, the group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which the group R3 is attached is in the Configuration (S), and R3 is - (d-C4) alkyl, substituted or not with one or more halo groups. In another embodiment, the Niteo (cyano) vinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the nytogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which the group R3 is attached is in the Configuration (S) and R3 is -CH3.
In another embodiment, the Niteo (cyano) vinylpiperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the nitrogen atom attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which The R3 GXupo is attached in the Configuration (S) and R3 is -CF3. In another embodiment, the Nitro (cyano) vinyl piperazine Compound has only one R3 group, the R3 group is attached to a carbon atom adjacent to the nitrogen attached to the pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, or thiadiazolyl group, the carbon to which the group R3 is attached was in the Configuration (S), and R3 is -CH2CH3.
In another embodiment, the Compound Nitium (cyano) vinylpiperazine has only one group R3, the group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group -C (NHAr2) = C (CN) (R4) or group -C (NHAr2) ^ (NO ^^), and the carbon to which the group R3 is attached is listed in the Configuration (S). In another embodiment, the Compound Nitium (cyano) vinyl piperazine has only one group R3, the group R3 is attached to a carbon atom adjacent to the nytogen atom attached to the group-C (NHAr2) = C (CN) (R4) or group -C (NHAr2) = C (NO2) (R4), and the carbon to which the group R3 is attached was in the Configuration (S) and R3 is - (dC) alkyl, substituted or not with one or more groups halo. In another modality, the Compound Nitio (cyano) vinylpiperazine
has only one group R3, the group R3 is attached to a carbon atom adjacent to the nitrogen atom attached to the group -C (NHAr2) = C (CN) (R4) or to the group -C (NHAr2) = C (N? 2) (Rt), the carbon to which the group R3 is attached is found in the Configuration (S) and R3 -CH3. In another embodiment, the Compound Nitium (cyano) vinylpiperazine has only one group R3, the group R3 is attached to a carbon atom adjacent to the nitrogen attached to the
group -C (NHAr2) = C (CN) (R) or the group -C (NHAr2) = C (NO2) (R4), the carbon to which the group R3 is attached was in the Configuration (S) and R3 is -CF3. In another embodiment, the Compound Nitium (cyano) vinyl piperazine has only one group R3, the group R3 is attached to a carbon atom adjacent to the nytogen atom attached to the group -
C (NHAr2) = C (CN) (R4) or to gxupo -C (NHAx2) = C (NO2) (R4), and the carbon to which the group
R3 is attached in the Configuration (S) and R3 -CH2CH3. i The links represented by a line *? / w | in the Compounds
Nitro (cyano) vinylpiperazine of the Formula (I) and Formula (II) mean that the group t and the
group Ar2 can be cz ', s relative one with ote, trans relative one with otio, or a mixture of the cis and trans isomers.
4. 4 NITROÍCIAN COMPOUNDS INILOPYTAZINE ILLUSTRATIVES Nitro (cyano) vinylpiperazine compounds are listed below in Tables 1-7.
For the chemical structure represented, for example, at the beginning of each of Tables 1-7, a is independently 0 or 1. When a = 0, the group in position "a" is -H. When a = 1, the group in the "a" (Rsa) position is other than -H, that is, it is Rg. Table 1
(? D
and pharmaceutically acceptable salts thereof, wherein:
"a" means that R3 is -H3 .. "b" means that R3 is -CH3 and the Compound Nitio (cyano) vinylpiperazine is racemic. "c" means that R3 is -CH3 and the carbon atom to which R3 is attached was in the (R) configuration. "d" means that R3 is -CH3 and the carbon atom to which R3 is attached is in the (S) configuration.
Table 2 and pharmaceutically acceptable salts thereof, wherein:
"a" means that R3 is -H3. "b" means that R3 is -CH3 and the Compound Niteo (cyano) vinylpiperazine is racemic.
"c" means that R3 is -CH3 and the carbon atom to which R3 is attached is in the (R) configuration. "d" means that R3 is -CH3 and the carbon atom to which R3 is attached is in the (S) configuration. "Table 3
and pharmaceutically acceptable salts thereof, wherein:
'15 20 25
"a" means that R3 is -H3. "b" means that R3 is -CH3 and the Compound Niteo (cyano) vinylpiperazine is racemic. . "c" means that R3 is -CH3 and the carbon atom to which R3 is attached is in the (R) configuration. - n "d" means that R3 is -CH3 and the carbon atom to which R3 is attached was in the configuration (S).
Table 4
(YOU
And pharmaceutically acceptable salts thereof, wherein:
"a" means that R3 is -H3. "b" means that R3 is -CH3 and the Compound Niteo (cyano) vinylpiperazine is racemic.
"c" means that R3 is -CH3 and the carbon atom to which R3 is attached was in the (R) configuration. "d" means that R3 is -CH3 and the carbon atom to which R3 is attached is listed in the (S) configuration.
Table 5 (vp)
and pharmaceutically acceptable salts thereof, wherein:
: 'a' means that R3 is -H3.
"b" means that R3 is -CH3 and the Compound Niteo (cyano) vinylpiperazine is racemic. "c" means that R3 is -CH3 and the carbon atom to which R3 is attached was in the (R) configuration. "d" means that R3 is -CH3 and the carbon atom to which R3 is attached is listed in the (S) configuration.
Table 6
(HIV) and pharmaceutically acceptable salts thereof, wherein:
"a" means that R3 is -H3. "b" means that R3 is -CH3 and the Compound Nitio (cyano) vinylpiperazine is racemic.
"c" means that R3 is -CH3 and the carbon atom to which R3 is attached is in the (R) configuration. "d" means that R3 is -CH3 and the carbon atom to which R3 is attached is listed in the (S) configuration.
Table 7
(DO
and pharmaceutically acceptable salts thereof, wherein:
"a" means that R3 is -H3. "b" means that R3 is -CH3 and the Compound Nitio (cyano) vinylpiperazine is racemic.
"c" means that R3 is -CH3 and the carbon atom to which R3 is attached was in
the configuration (R). "d" means that R3 is -CH3 and the carbon atom to which R3 is attached is in n the configuration (S).
4. 4 Definitions
According to the use granted in this document, the terms used above have the meaning: 5"- (C1-C1o) alkyl" means a straight or branched chain of non-cyclic hydrocarbon having from 1 to 10 carbon atoms. Representative linear chain - (d-do) alkyl includes -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, -n-hexyl, -n-heptyl, -n-octyl, -n- nonyl, and -n-decyl. Representative branching - (C1-C1o) alkyl includes -z'so-propyl, -sec-butyl, -z'-butyl, -tert-butyl, -z'so-pentyl, -neo-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1, 1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-methylhexyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 1,2-dimethylpentyl, 1,3-dimethylpentyl, 1,2-dimethylhexyl, 1,3-dimethylhexyl, 3,3-dimethylhexyl,
1,2-dimethyl-heptyl, 1,3-dimethylheptyl, and 3,3-dimethylheptyl.
"- (d-C6) alkyl" means a straight or branched chain of non-cyclic hydrocarbon having from 1 to 6 carbon atoms. Representative linear chain - (d-C6) alkyls includes -methyl, -ethyl, -n-propyl, -n-butyl, -n-pentyl, and -n-hexyl. Representative branched - (d-C6) alkyls includes -z'so-propyl, -sec-butyl, -z'-butyl, -tert-butyl, -z'so-pentyl, -neo-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1-ethylbutyl, 2-ethylbutyl, 3-ethylbutyl, 1, 1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, and 3,3-dimethylbutyl.
"- (C2-C10) alkeny" means a straight or branched chain of non-cyclic hydrocarbon having from 2 to 10 carbon atoms including at least one carbon-carbon double bond. Linear and branched chain representative (C2-C10) alkenyl includes -vinyl, -allyl, -1-butenyl, -2-butenyl, -z'-butynyl, -1-pentynyl, -2-pentenyl, -3-methyl- l-butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, -1-hexenyl, -2-hexenyl, -3-hexenyl, -1-heptenyl, -2-heptenyl, - 3-heptenyl, -1-octenyl, -2-octenyl, -3-octenyl, -1-nonenyl, -2-nonenyl, -3-nonenyl, -1-decenyl, -2-decenyl, -3-decenyl and the like .
"- (C2-C6) alkenyl" means a straight or branched chain of non-cyclic hydrocarbon having from 2 to 6 carbon atoms and including at least one carbon-carbon double bond. Representative linear and branched chain (C2-Ce) alkenyl includes -vinyl, -allyl, -1-butenyl, -2-butenyl, -z'-butynyl, -1-pentenyl, -2-pentenyl, -3-methyl- 1 -butenyl, -2-methyl-2-butenyl, -2,3-dimethyl-2-butenyl, -1-hexenyl, 2-hexenyl, 3-hexenyl and the like.
"- (C2-do) alkynyl" means a straight or branched chain of non-cyclic hydrocarbon having from 2 to 10 carbon atoms and including at least one carbon-carbon triple bond. Representative linear or branched chain - (C2-do) alk mTs includes -. acetylenyl, -propynyl, -1-butynyl, -2-butynyl, -1 -pentinyl, -2-pentynyl, -3-methyl-1-butynyl, -4-pentynyl, -1-hexyl, -2-hexynyl, - 5-Hexynyl-1-heptynyl-2-heptynyl -6-heptynyl-1-octynyl, -2-octynyl, -7-octynyl, -1-nonynyl-2-noninyl, -8-noninyl, -1- 5 decolor, -2-decinyl, -9-decinyl and the like.
"- (C2-C6) alkynyl" means a straight or branched chain of non-cyclic hydrocarbon having from 2 to 6 carbon atoms and including at least one carbon-carbon triple bond. Linear and branched chain (C2-Ce) alkynyl includes -acetylenyl, 10 -propynyl, -1-butynyl, -2-butynyl, -1-pentynyl, -2-pentynyl, -3-methyl-1-butynyl, -4- pentinyl, -1-hexyl, -2-hexinyl, -5-hexinyl and the like. "- (C3-C10) cycloalkyl" means a saturated cyclic hydrocarbon having from 3 to 10 carbon atoms. (C3-C10) Representative cycloalkyls are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, and cyclodecyl. "- (C3-Cg) cycloalkyl" means a saturated cyclic hydrocarbon having from 3 to 8 carbon atoms. (C3-Cg) Representative cycloalkyls include -cyclopropyl, -cyclobutyl, -cyclopentyl, -cydohexyl, -cycotheptyl, and -cyclooctyl.
"- (Cg-C14) bicycloalkyl" means a bicyclic hydrocarbon ring system having from 8 to 14 carbon atoms and at least one saturated cyclic alkyl ring. - (C 8 -C 14) Representative bicycloalkyl include -indanyl, -1,2,3,4-tetiahydronaphthyl, -5,6,7,8-tetiahydronaphthyl, -perhydronaphthyl and the like.
je "- (Cg-C14) tricycloalkyl" means a tri-cyclic hydrocarbon ring system having from 8 to 14 carbon atoms and at least one saturated cyclic alkyl ring. - (Cg-C14) representative tricycloalkyl include -pyrenyl, -1,2,3,4-tetrahydxoantiacenyl, -perhydroanthracenyl -aceantienyl, -1,2,3,4-tetranidropenanthrenyl, -5,6,7,8-tetrahydrophenantienyl, -perhydrofenantrenyl and the like.
"- (C5-C10) cycloalkenyl" means a non-axomatic cyclic hydrocarbon with al
minus a carbon-carbon double bond in the cyclic system and from 5 to 10 carbon atoms. (C5-C1o) representative cicloalquenils include -cyclopentenyl, cyclopentadienyl, -cycloheptenyl, -cycloheptadienyl, -cycloheptatrienyl, -cyclooctenyl, - cycloheptatrienyl, -ciclooctenilo, -cyclooctadienyl, -cyclooctatrienyl, -ciclooctatetiaenilo, -10 cyclononenyl, -cyclononadienyl, -cyclodecenyl, -cyclodecadienyl and the like.
"- (C5-C8) cycloalkenu" means a non-aromatic cyclic hydrocarbon having at least one carbon-carbon double bond in the cyclic system and from 5 to 8 carbon atoms.
(C5-Cg) Representative cycloalkenyl include -cyclopentenyl, -cyclopentadienyl,
, r-cyclohexenyl, -cyclohexadienyl, -cycloheptenyl, -cycloheptadienyl, -cycloheptatrienyl,
Cyclooctenyl, cyclooctadienyl, cyclooctatrienyl, cyclooctatetraenyl and the like.
"- (Cg-C14) bicycloalkenü" means a bi-cyclic hydrocarbon ring system having at least xm double carbon-carbon bond in each ring and from 8 to 14 carbon atoms. . - (C8-C14) Representative bicycloalkenyls include -indenyl, -pentalenyl, -0-naphthalenyl, -azenyl, -heptalenyl, -1,2,7,8-teteahidronaphthalenyl and the like.
"- (C8-C14) tricycloalkenu" means a tri-cyclic hydxocaxbono ring system
having at least one carbon-carbon double bond in each ring and from 8 to 14 carbon atoms. - (C8-C14) representative tricycloalkenyl include -anthracenyl, -phenanthrenyl, 5-phenylenyl, -cenaphthalenyl, as-indacenyl, s-indacenyl and the like.
"- (3- to 7-cells) heterocycle" or "- (3- to 7-cells) heterocycle" means xm 3- to 7-chain monocyclic heterocyclic ring which is either saturated, unsaturated, non-aromatic, or aromatic. A 3- or 4-stranded heterocycle can contain up to 3 heteroatoms, a 5-stranded heterocycle can contain up to 4 heteroatoms, a 6-stranded heterocycle can contain up to 6 heteroatoms, and a 7-stranded heterocycle can contain up to 7 heteroatoms. Each heteroatom is independently selected from nitrogen, which can be quaternized; oxygen; and sulfur, including sulfoxide and sulfone. The - (3- to 7-well) heterocycle can be attached by means of a nitrogen or carbon atom. - (3- to 7-cations) representative heterocycles include pyridyl, furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, thiadiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, morpholinyl, pyrrolidinonyl, pixrolidinyl, piperidinyl, piperazinyl, hydantoinyl, valerolactamyl, oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydroxypyranyl, teteratedipixindinyl, tetrahydropyrimidinyl, tetiahydrothiophenyl, tetiahydrothiopyranyl and the like.
"- (3- to 5-caffeine) heterocycle" or "- (3- to 5-chain) heterocycle" means a 3- to 5-chain monocyclic heterocyclic ring which is either saturated, unsaturated, non-aromatic, or aromatic. A 3- or 4-chain heterocycle can contain up to 3 heteroatoms, and a 5-chain heterocycle can contain up to 4 heteroatoms. Each heteroatom is independently selected from nitrogen, which can be quaternized; oxygen; and sulfur, including sulfoxide and sulfone. The - (3- to 5-cells) heterocycle can be attached by means of a nitrogen or carbon atom. - (3- to 5-cells) representative heterocycles include furyl, thiophenyl, pyrrolyl, oxazolyl, imidazolyl, thiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, triazinyl, pyrrolidinonyl, pyrrolidinyl, hydantoinyl, oxyranyl, oxetanyl, tetrahydrofuranyl, tetiahydrothiophenyl, and the like.
"- (7- to 10-words) bicycloheterocycle" or "- (7- to 10-words) bicycloheterocycle" means a 7- to 10-bicyclic heterocyclic ring which is either saturated,
unsaturated non-aromatic, or aromatic. A - (7- to 10-cells) bicycloheterocycle contains from 1 to 4 heteroatoms independently selected from nitrogen, which may be quaternized; oxygen; and sulfur, including sulfoxide and sulfone. The bicycloheterocycle - (7- to 10-caffeine) can be attached by means of a nitrogen or caxone atom. - (7- to 10-cells) Representative bicycloheterocycles include -quinolinyl, -isoquinolinyl, -chromonyl, -coumarinyl, -indolyl, -indolizinyl, -benzo [b] furanyl, -benzo [b] thiophenyl, -indazolyl, -purinyl, -4H-quinolizinyl, -isoquinolyl, -quinolyl, -phthalazinyl, -naphthyridinyl, -carbazolyl, -β-carbolinyl and the like.
, - "- (C14) aryl" means a 14-carbon aromatic carbocyclic moiety such as -antrile or -phenanthryl.
"- (5- to 10-cells) heteroaryl" means xm aromatic heterocyclic ring of 5 to 10 cores, including both mono- and bicyclic ring systems, wherein at least one carbon atom of one or both rings is substituted with a heteroatom 0 independently selected from nitrogen, oxygen and sulfur. In one embodiment, one of the - (5- to 10-story) heteroaryl rings contains at least one carbon atom. In another embodiment, both rings of the 5- (5- to 10-chain) heteroaryl contain at least one carbon atom. - (5- to 10-cells) Representative heteroarils include pi idyl, fxaryl, 5-benzofuranyl, thiophenyl, benzothiophenyl, quinolinyl, pyrrolyl, indolyl, oxazolyl,
benzoxazolyl, imidazolyl, benzimidazolyl, thiazolyl, benzothiazolyl, isoxazolyl, pyrazolyl, isothiazolyl, pyridazinyl, pyrimidyl, pyrimidinyl, thiadiazolyl, triazinyl, cinnolinyl, phthalazinyl and quinazolinyl.
"-CH2 (halo)" means a methyl group in which one of the hydrogens of the methyl group has been replaced with a halogen. Representative -CH2 (halo) groups include -CH2F, -CH2C1, -CH2Br, and -CH2L
"-CH (halo) 2" means a methyl group in which two of the hydrogens of the methyl group have been replaced with a halogen. Representative -CH (halo) 2 groups include -CHF2, -CHC12, -CHBr2, -CHBrCl, -CHC1I, and -CHI2.
"-C (halo) 3" means a methyl group in which each xmo of the hydrogens has been replaced with xm halogen. Representative -C (halo) 3 groups include -CF3, -CCI3, -CBr3, and -CI3. "-Halogen" or "-halo" means -F, -Cl, -Br, or -I.
The phrase "pyridyl group" means
where R1; R2, and n are defined above for the Nitro (cyano) vinylpiperazine Compounds of the formulas (I) and (II).
The phrase "pyrazinyl group" means,
wherein Rls R2, and p are defined above for the Nitio (cyano) vinylpiperazine Compounds of formulas (I) and (H).
The phrase "pyrimidinyl group" means
wherein Rl5 R2, and p are defined above for the itio (cyano) vinyl piperazine Compounds of the formulas (I) and (U).
The phrase "pyridazinyl group" means
wherein Rl5 R2, and p are defined above for the itio (cyano) vinyl piperazine Compounds of formulas (I) and (II).
The phrase "thiadiazolyl group" means
wherein Ri is defined above for the Nitro (cyano) vinyl piperazine Compounds of formulas (I) and (TI). The phrase "2- (3-chloropyridyl)" means
The phrase "2- (3-fluoropyridyl)" means
The phrase "2- (3-methylpyridyl)" means
The phrase "2- (3-CF3-pyridyl)" means
The phrase "2- (3-CHF2-pyridyl)" means
The phrase "2- (3-hydroxypyridyl)" means
The phrase "2- (3-nitropyridyl)" means
The phrase "2- (3-cyanopyridyl)" means
The phrase "2- (3-bromopyridyl)" means
The phrase "2- (3-odopyridyl)" means
The phrase "4- (5-chloropyrimidinyl)" means
The phrase "4- (5-methylpyrimidinyl)" means
The phrase "4- (5-fluoropyrimidinyl)" means
The phrase "2- (3-chloropyrazinyl)" means
The phrase "2- (3-mitilpyrazinyl)" means The phrase "2- (3-fluoropyrazinyl)" means
The phrase "3- (4-chloropyridazinyl)" means
The phrase "3- (4-methypyridazinyl)" means
The phrase "3- (4-fluoropyridazinyl)" means The phrase "5- (4-chlorothiadiazolyl)" means
The phrase "5- (4-methylthiadiazolyl)" means The phrase "5- (4-fluorothiadiazolyl)" means The phrase "benzoimidiazolyl group" means
wherein Rs and s are defined above for the Nitio (cyano) vinylpiperazine Compounds of the formulas (I) and (H). The phrase "benzothiazolyl group" means
wherein R8 and s are defined above for the compounds Nitio (cyano) vinylpiperazine or of the formulas (I) and (D). The phrase "benzooxazolyl group" means
wherein Rs and s are defined above for the Nitro (cyano) vinyl piperazine Compounds of formulas (I) and (? L). The phrase "piperazine ring" means
The term "animal," includes, but is not limited to, a cow,. monkey, chimpanzee, baboon, horse, sheep, pig, chicken, turkey, quail, cat, dog, rat, mouse, guinea pig and human. The phrase "pharmaceutically acceptable salt," according to the use herein given, is any pharmaceutically acceptable salt that can be prepared from a Nitium (cyano) vinyl piperazine Compound, including a salt formed from an acid and a basic functional group, such as a group of nytogen, from one of the Niteo (cyanp) vinylpiperazine Compounds. Exemplary salts include, but are not limited to, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, phosphonic acid, isonicotinate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, s-toluenesulfonate and gt; and pamoate (that is, salts 1, -methylene-bis- (2-hydroxy-3-naphthoate)). The term "pharmaceutically acceptable salt" also includes a salt prepared from xm Nitro (cyano) vinyl piperazine compound having an acidic functional group, such as a functional carboxylic acid group, and a pharmaceutically acceptable inorganic or organic base. Suitable bases include, but are not limited to, alkali metal hydroxides such as sodium, potassium and lithium; alkali metal hydroxides such as calcium and magnesium; hydroxides of other metals such as aluminum and zinc; ammonia and organic amines, such as mono-, di-, hydroxy-substituted or unsubstituted, or trialkylamines; dicyclohexyl amine; tributyl arnine; pyridine;
N-methyl, N-ethyl amine; diethyl amine; triethyloamine; lower mono-, bis-, or tris- (2-hydroxy-amines), such as mono-, bis-, or tris- (2-hydroxyethyl) amine,
2-hydroxy-tert-butylamino, or tris- (hydroxymethyl) methyloamine, N, N-di-lower alkyl-N- (lower hydroxy-lower alkyl) -amines, such as N, N-dimethyl-N- (2- hydroxyethyl) amine, or tri- (2-hydroxyethyl) amine; N-methyl-D-glucamine; and amino acids such as arginine, lysine and the like.
The phrase "effective amount," used in connection with a Nitro (cyano) vinylpiperazine Compound means an amount effective to: (a) treat or prevent a Condition; or (b) inhibit the VR1, mGluR1, or mGluR5 function in a cell. The phrase "effective amount," used in connection with another therapeutic agent means an amount to provide the therapeutic effect of the therapeutic agent. When a first group is "substituted with one or more" second groups, one or more hydrogen atoms of the first group is replaced with a corresponding number of second groups. In one embodiment, each carbon atom of a first group is independently substituted with one or two second groups. In another mode, each carbon atom is independently substituted with only a second group. The term "Ul" means urinary incontinence.
The term "IBD" means inflammatory bowel disease.
The term "IBS" means irritable bowel syndrome.
The term "ALS" means lateral amyotrophic sclerosis.
The term "DMF" means dimethylformamide.
The term "DIEA" means di-zso-propylethyl amine.
The term "DIC" means di-z'so-propylcarbodimide.
The phrases "treatment of", "tiatar" and the like include the alleviation or amelioration of a Condition or symptom thereof.
In one embodiment, treating includes inhibiting, for example, decreasing the overall frequency of episodes of a Condition or symptoms thereof. The phrases, "prevention of," "preventing" and the like include avoiding the onset of a Condition or symptom thereof.
4. 6 Methods for Preparing Nitiof Ciano) Vinylpiperazine Compounds The Nitro (cyano) vinylpiperazine Compounds can be prepared using conventional oxigenic synthesis or by means of the following illustrative methods shown in the following schemes.
4. 6.1 Methods for Preparing the Niteo (cyano) vinylpiperazine Compounds of Formula I.
The Niteo (cyano) vinylpiperazine Compounds of Formula (I) can be obtained by the following illustrative method illustrated below in Scheme 1.
Scheme 1
Cyano (niteo) vinylpiperazine compounds of the formula (I)
wherein Arl, Ar2, R3, R4, and m are defined above for the Nitio (cyano) vinylpiperazine Compounds of the formula (I). For example, a DMF solution of isothiocyanate A (2.5 mmol) and nitrile B is allowed to react in the presence of DIEA (2.5 mmol) at a temperature of about 25 ° C for about 16 h to provide a DMF solution. of a compound of formula C. A compound of formula D (3 mmol) and DIC (4.5 mmol) is then added to the DMF solution of the compound of formula C and the resulting solution is allowed to stir at a temperature of about 25. ° C for about 16 h. The solvent is then removed under reduced pressure to provide a residue. The residue is then purified using flash column matography (silica gel eluted with a gradient of 5:95 ethyl acetate: hexane at 20:80 ethyl acetate: hexane) to provide the Compound
Cyano (nitro) vinylpiperazine of the Formula (I). Typically, the Compound
Cyano (nitio) vinylpiperazine of the formula (I) is obtained as a mixture of the isomer wherein the group R4 and the group Ar2-NH- are cis relative to one another and the isomer wherein the group R4 and the group Ax2-NH they are trans xelative one with otio. The individual czs and trans isomers can be separated using methods known to those skilled in the art. Representative methods for separating the cis and trans isomers include, but are not limited, to recrystallization and column chromatography. If the group An of the compound of formula D is substituted with a hydroxyl or amine group or -R3 is a hydroxyl group or amine, the hydroxyl group or amine can be protected using a suitable protecting group, using methods known to those skilled in the art. art, before the compound of formula D is reacted with a compound of formula C. Suitable protecting groups include, but are not
limited to, methyl ether, methoxymethyl ether, methoxythiomethyl ether, 2-methoxyethoxymethyl ether, bis (2-chloroethoxy) ethyl ether, tetrahydropyranyl ether, tetiahydrothiophenyl ether, 4-methoxytetehydropyranium ether, methoxytetrahydrothiopyranyl ether, tetiathermofofuranyl ether, tetiathermothrifophilyl ether, 1-ethoxyethyl ether , 1-methyl-1-methoxyethyl ether, 2- (phenylenyl ether), tert-butyl ether, allyl ether, benzyl ether, o-nitrobenzyl ether, triphenylmethyl ether, o-naphthyldiphenylmethyl ether, s-methoxydifsnilmethyl ether, 9- (9) phenyl-10-oxo) -xenxyl ether (tritylone), trimethylsilyl ether, so-propyldimethylusyl ether, tert-butyldimethylsilyl ether, tert-butyldiphenylsilyl ether, thiibenzilyl ether, tris-propyl silyl ether, formate ester, acetate ester, thioloroacetate ester , phenoxyacetate ester, ester-so-butyrate, ester pivaloate, adamanttoate ester, benzoate ester, 2,4,6-trimethyl ester (mesitoate), methyl carbonate, 2,2,2-trichlorocarbonate, allil carbonate, s- Nitiphenyl carbonate, benzyl carbonate,
S-nitrobenzyl carbonate, S-benzylthiocarbonate, N-phenylcarbamate, nitrate ester, and ester. 2,4-dinitrophenylsulfenate (See, for example, T. W. Greene et al, Protective Groups in
Organic Synthesis, 17-200 (3d ed, 1999)). Suitable protecting groups for an amine include, but are not limited to, 1, l-dimethyl-2,2,2-trichloroethyl carbamate, 1-methyl-1- (4-biphenyloyl) ethyl carbamate, 2-thiimethylsilyl ethyl carbamate, 9- fluorenylmethyl carbamate and tert-butyl carbamate (TW Greene et al, Protective Groups in Organic Synthesis, 494-653
(2d ed.1991)).
Isothiocyanates, Ax2NCS (A), are commercially available or can be prepared by methods known to those skilled in the art (See, eg, J. March, Advanced Organic Chemistry Reactions, Mechanisms, and Structure All, 429, 670 , 904, and 930 (4th ed., 1992)).
The nitriles (B) are commercially available or can be prepared by methods known to those skilled in the art. The nitrile (B) wherein Rt is -CN was commercially available from Sigma-Aldrich, St. Louis, MO (www.sigma-aldrich.com). The nitriles (B) wherein Rt is -C (O) O (C1-C4) alkyl or -C (O) NH ((d-C4) alkyl) can be obtained by reacting an alcohol of formula R9OH or an amine of Formula R9NH2, wherein R9 is a C? -C4 alkyl group with a cyanoacetyl halide. In one embodiment, the cyanoacetyl halide is cyanoacetyl chloride (Cl-C (O) CH2CN). Cyanoacetyl halides can be obtained from cyanoacetic acid (commercially available from Sigma-Aldrich.) Methods for dissolving acid halides from carboxylic acids are known to those skilled in the art and are described in J. March, Advanced Organic Chemistry, Reactions Mechanisms, and Structure 437-8 (4th ed., 1992) For example, halide acids can be prepared by reacting the carboxylic acid with thionyl chloride, bromide, or iodide.An acid chloride can also be prepared by reacting a carboxylic acid with phosphorous trichloride or tribromide. Acid chloride can also be prepared by reacting the carboxylic acid with PI13P in carbon tetrachloride An acid fluoride can be obtained by reacting a carboxylic acid with cyanuric fluoride.
The Compound of formula D can be obtained according to what is illustrated in Scheme 2:
Scheme 2 wherein Rls R2, R3, m, n, and p are defined above for the thio (cyano) vinylpiperazine compounds of the formula (I) and X is a halogen. In one embodiment, X is bromide, chloride, or iodide.
For example, a compound of formula E1-E5 (of about 20 xmol) is activated with a compound of formula F (about 27.5 mmol) in 15 ml of dimethyl sulfoxide in the presence of triethylamine (about 30 xmol). , optionally with heat, for about 24 hours to provide a compound of formula D1-D5. The compound of formula D1-D5 can be isolated from the reaction mixture and purified. In one embodiment, the compound of formula D1-D5 is purified using column chromatography or recrystallization. If the compound of formula F is substituted with a hydroxyl or amine group, the hydroxyl group or amine can be protected using a suitable protecting group, using methods known to those skilled in the art, before being reacted with a compound of formula E1 -E5.
Suitable protecting groups include, but are not limited to, those described above.
Compounds of formula E and F are commercially available or can be prepared by methods known to those skilled in the art. The compound of formula F wherein m is 0 was commercially available from Sigma-Aldrich.
4. 6.2 Methods for Preparing Nitro (cyano) vinyl piperazine Compounds of the Formula (ID The Nitio (cyano) vinylpiperazine Compounds of the formula (II) wherein R 4 is -H can be obtained by the following illustrative method illustrated in Scheme 3:
Cyan (nitrio) vinyl piperazine compound of the Formula (H)
wherein An, Ar2, R3, Rt, and m are defined above for the Nitio (cyano) vinylpiperazine Compounds of the formula (H).
For example, xma amine ethanol solution Ar NH 2 (G) (1 mmol) and a compound of formula H are allowed to react at a temperature of about 70 ° C for up to 15 h to provide an ethanol solution of a compound of formula J. A compound of formula D (1.2 mmol) is then added to the ethanol solution of a compound of formula J and the resulting solution is allowed to recirculate for a period of 15 h. The solvent is then removed under reduced pressure to provide a residue. The residue is then purified using column chromatography (silica gel eluted with a gradient of 20:80 ethyl acetate: hexane at 50:50 ethyl acetate: hexane) to give the Compound Cyan (nitio) vinyl piperazine of the Formula (JL). Typically, the cyano (nitrio) vinylpiperazine Compound of the formula (II) is obtained as a mixture of the isomer wherein the group R4 and in group Ar2-NH are cis relative to one with otio and the isomer wherein the group R4 and the group Ar2-NH are relative trans xmo with otio. The individual cis and trans isomers can be separated using methods known to those skilled in the art. Representative methods for separating the cz's and trans isomers include, but are not limited to, recrystallization and chromatography on colurhna. The Nitio (cyano) vinylpiperazine Compounds of the formula (II) wherein 4 is -CN can be obtained using a procedure analogous to that used to prepare Nitio (cyano) vinylpiperazine Compounds of the formula (I) wherein 4 is -CN, as is described above in Schemes 1 and 2, except that a compound of the formula O 2 N -CH 2 -CN is used instead of the compound of the formula B. The compound of the formula O 2 N -CH 2 -CN can be obtained by reacting sodium cyanide with bromonitromethane O 2 N- CH2-Br, (commercially available from Sigma-Aldrich), in DMF at 70 ° C. The Nitro (cyano) vinylpiperazine Compounds of the formula (p) wherein R 4 is -C (O) O (d-C 4) alkyl or -C (O) NH ((C 1 -C 4) alkyl) can be obtained using an analogous procedure to that used to prepare Nitio (cyano) vinylpiperazine Compounds of the formula (I) wherein R4 is C (O) O (d-C4) alkyl or -C (O) NH ((d-C4) alkyl), respectively, as described above in Schemes 1 and 2, except that a compound of formula O2N-CH2-C (O) O (dC) alkyl or -C (O) NH ((dC) alkyl), respectively, is used instead of the compound of the formula B. The compound of the formula O2N-CH2-C (O) O (dC) alkyl can be obtained by reacting a niteoacetyl halide with an alcohol of R9OH wherein R9 is a dC alkyl group. The compound of formula 2N-CH2-C (O) (NHd-C) alkyl can be obtained by reacting a nitroacetyl halide with an amine of formula R9NH2 wherein R9 is a d-C4 alkyl group. Nitioacetyl halides can be obtained from nitroacetic acid using methods known to those skilled in the art include, but not limited to, the methods described above for prepaxax acid halide. Nitroacetic acid can be obtained by hydrolyzing methyl nitroacetate (commercially available from Sigma-Aldrich) using methods known to those skilled in the art. Certain Nitro (cyano) vinylpiperazine compounds may have one or more asymmetric centers and therefore exist in different enantiomeric and diastereomeric forms. A Nitio (cyano) vinylpiperazine Compound may be in the form of an isomer or an optical diastereomer. Therefore, the invention comprises Nitro (cyano) vinylpiperazin compounds and their uses as described herein in the form of their optical isomers, diastereomers, and mixtures thereof, including a racemic mixture. Optical isomers of the Nitro (cyano) vinylpiperazine Compounds can be obtained by known techniques such as chiral chromatography or diastereomeric salt formation from an optimally active acid or base. In addition, one or more hydrogen, carbon or other atoms of a Compound
Nitium (cyano) vinylpiperazine can be replaced with an isotope of hydrogen, carbon or other atoms. Such compounds, encompassed by the present invention, are useful as a research and diagnostic tool in studies of pharmacokinetic metabolism and in assays.
4. 7 THERAPEUTIC USES OF THE NITRO COMPOUND (VINYLPIPERAZINE CELL)
According to the invention, the Nitio (cyano) vinylpiperazine Compounds are administered to an animal in need of treatment or prevention of a Condition.
In one embodiment, an effective amount of a Nitium (cyano) vinyl piperazine Compound can be used to thiatar or prevent a tiatable or preventable condition by means of inhibiting VR1. Examples of treatable or preventable conditions by inhibiting VR1 include, but are not limited to, pain, Ul, ulcer, IBD, and IBS.
In another embodiment, an effective amount of a Nitio (cyano) vinylpiperazine Compound can be used to treat or prevent a condition treatable or preventable by means of the inhibition of mGluR5. Examples of conditions treatable or preventable by the inhibition of mGluR5 include, but are not limited to, pain, addictive disorders, Parkinson's disease, parkinsonism, anxiety, pruritic condition, and psychosis. In another embodiment, an effective amount of a Nitro (cyano) vinyl piperazine Compound can be used to thiatar or prevent any tiatable or preventable condition by inhibiting mGluRl. Examples of conditions that are treatable or preventable by inhibiting mGluRl include, but are not limited to, pain, Ul, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, infarction, an attack, a pruritus condition , psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's disease, ALS, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia, and depression.
The Nitio (cyano) vinylpiperazine Compounds can be used to treat or prevent acute or chronic pain. Examples of pain treatable or preventable using the Compound Nitro (cyano) vinyl piperazine include, but are not limited to, cancer product dolox, labor pain, pain from myocardial infarction, pancreatic pain, pain from colic, post-operative pain, pain headache, muscle pain, arthritic pain, and pain associated with periodontal disease, including gingivitis and periodontitis. The Nitro (cyano) vinylpiperazine Compounds can also be used to treat or prevent pain associated with inflammation or with an inflammatory disease in an animal. Said pain may occur where there is an inflammation of the tissue of the body, which may be a local inflammatory response and / or a systemic inflammation. For example, the Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent pain associated with inflammatory diseases, including, but not limited to: organ transplant rejection, reoxygenation injury resulting from organ transplantation (see Grupp et al, J. Mol Cell Cardiol 31: 297-303 (1999)) including, but not limited to, heart, lung, liver or kidney transplantation; chronic inflammatory diseases of the joints, including arthritis, rheumatic arthritis, osteoariritis and bone diseases associated with increased bone resorption; Inflammatory bowel diseases, such as ileitis, ulcerative colitis,
Barret and Crohn's disease; inflammatory diseases of the lungs, such as asthma, respiratory distress syndrome in adults, and chronic airway obstruction disease; inflammatory diseases of the eye, including corneal dystrophy, trachoma, onchocerciasis, uveitis, sympathetic ophthalmitis and endophthalmitis; chronic gum diseases, including gingivitis and periodontitis; tuberculosis; leprosy; inflammatory diseases of the kidney, including uraemic complications, glomerulonephritis and nephrosis;
inflammatory diseases of the skin, including sclerodermatitis, psoriasis and eczema; inflammatory diseases of the central nervous system, including chronic demyelinating diseases of the central nervous system, multiple sclerosis, neurodegeneration related to AIDS and Alzheimer's disease, infectious meningitis, encephalomyelitis, Parkinson's disease, Huntington's disease, lateral amyotrophic sclerosis and viral or auto encephalitis immune; autoimmune diseases, including Type I and Type II diabetes mellitus; diabetic complications, including, but not limited to, diabetic cataract, glaucoma, retinopathy, nephropathy (such as microaluminuria and progressive diabetic nephropathy), polyneuropathy, mononeuropathies, autonomic nauropathy, gangrene of the feet, atherosclerotic arterial coronary disease, peripheral arterial disease, hyperglycemic coma -non-ketosal hyperosmolar, foot ulcer, joint problems, and skin or mucosal involvement (such as an infection, an area with pimples, a pure diabetic infection or lipid necrosis); immunocomplex vasculitis and systemic lupus erythematosus (SLE); inflammatory diseases of the heart, such as cardiomyopathy, ischemic heart disease, hypercholesterolemia, and atherosclerosis; as well as other diseases that may have significant inflammatory components, including preclaimsia, chronic liver failure, brain and spinal cord trauma, and cancer. The Compounds
Nitro (cyano) vinylpiperazine can also be used to tiatar or prevent pain associated with an inflammatory disease that can, for example, sex a systemic inflammation of the body, exemplified by gram-positive or gram-negative shock, hemorrhagic or anaphylactic shock, or shock product of chemotherapy for cancer in response to pro-inflammatory cytokines, for example, shock associated with pro-inflammatory cytokines. Such a shock can be induced, for example, a chemotherapeutic agent administered as a treatment for cancer. The Niteo (cyano) vinylpiperazine Compounds can be used to treat or prevent UT. Examples of Ul treatable or preventable using Compounds
Nitium (cyano) vinylpiperazine include, but are not limited to, impulsive incontinence, stress incontinence, overflow incontinence, neurogenic incontinence, and total incontinence. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent an ulcer. Examples of treatable or preventable ulcers using Nitio (cyano) vinyl piperazine compounds include, but are not limited to, duodenal ulcer, gastric ulcex, marginal ulcer, ulcer to the esophagus or ulcer produced by stress.
The Niteo (cyano) vinylpiperazine Compounds can be used to treat or prevent IBD, including Crohn's disease and ulcerative colitis.
The Niteo (cyano) vinylpiperazine Compounds can be used to treat or prevent IBS. Examples of treatable or elusive IBS using Compounds
Nitium (cyano) vinylpipexazine include, but are not limited to, spastic colon type IBS and predominant constipation IBS.
The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent an addictive disorder, including but not limited to, an eating disorder, an impulse control disorder, an alcohol-related disorder, a nicotine-related disorder, a disorder related to amphetamines, cannabis-related disorder, a cocaine-related disorder, a hallucinogen-related disorder, inhalant-related disorders and an opioid-related disorder, all of which are sub-classified below. Eating disorders include, but are not limited to Bulimia Nervosa, Non-Purgative Type; Nervous Bulimia, Purgative Type; Anorexy; and Eating Disorders of another form not specified (NOS). Impulse control disorders include, but are not limited to Intermittent Explosive Disorder, Kleptomania, Pyromania, Impulsive Gambler, Trichotillomania, and Impulse Control Disorders other than specified (NOS). Alcohol-related disorders include, but are not limited to, Alcohol-Induced Psychotic Disorder with Delusions, Alcohol Abuse, Alcohol Poisoning, Alcohol Abstinence, Delirium from Alcohol Poisoning, Alcohol Abstinence Delirium, Persistent Dementia Induced by Alcohol Alcohol, Alcohol-induced persistent amnestic disorder, Alcohol dependence, Alcohol-induced mood disorders, Psychotic disorders with alcohol-induced hallucinations, Alcohol-induced Anxiety disorders, Alcohol-induced sexual dysfunction, Sleeping disorders induced by alcohol Alcohol and Other Alcohol-Induced Disorders Not Otherwise Specified (NOS). Disorders related to Nicotine include, but are not limited to, Nicotine
Dependence, Nicotine Withdrawal, and Nicotine-Related Disorders Not Otherwise Specified (NOS). Disorders related to Amphetamines include, but are not limited to Amphetamine Dependence, Amphetamine Abuse, Amphetamine Intoxication, Amphetamine Withdrawal, Amphetamine Intoxication Delirium, Psychotic Disorder with Pox Induced Amphetamine Disorder, Psychotic Disorder with Amphetamine Induced Hallucinations, Mood Disorder Amphetamine-Induced, Amphetamine-Induced Anxiety Disorder, Amphetamine-Induced Sexual Dysfunction, Amphetamine-Induced Sleeping Disorder, and Other Unspecified Amphetamine Related Disorders (NOS). Disorders related to Canabis include, but are not limited to, Cannabis
Dependence, Cannabis Abuse, Cannabis Intoxication, Cannabis Delirium Intoxication, Pysicotic Disorder with Cannabis Delusions, Psychotic Disorders with Cannabis-Induced Hallucinations, Cannabis-Induced Anxiety Disorder, and Cannabis-Related Disorders of Other Form Not Otherwise Specified ( US). Cocaine-related disorders include, but are not limited to, cocaine Dependence, Cocaine abuse, Cocaine poisoning, Cocaine abstinence, Cocaine poisoning rant, Psychotic disorder with cocaine-induced delusions, Psychotic disorders with hallucinations Cocaine-induced, disorders Psychic
Cocaine-Induced, Cocaine-Induced Anxiety Disorder, Sexual Dysfunction
Cocaine-Induced, Cocaine Induced Sleeping Disorder, and Other Unspecified Cocaine-Related Disorders (NOS). Disorders related to hallucinogens include, but are not limited to, Hallucinogenic Dependence, Hallucinogenic Abuse, Hallucinogenic Intoxication,
Hallucinogenic Abstinence, Hallucinogenic Intoxication Delirium,
Persistent Perception by Hallucinogen (Flashbacks), Psychotic disorder with delusions
Induced by hallucinogen, Psychotic disorder with hallucinations Induced by
Hallucinogen, hallucinogen-induced mood disorder, Anxiety disorder
Induced by Hallucinogen, Hallucinogen-Induced Sexual Dysfunction, Hallucinogen-Induced Sleep Disorder, and other hallucinogen-related disorders of other than unspecified form (NOS). Disorders related to Inhalants include, but are not limited to, Inhalant Dependence, Inhalant Abuse, Inhalant Poisoning, Inhalant Poisoning Delirium, Inhalant Induced Psychotic Disorder, Psychotic Disorder with Inhalant Induced Alucinations, Induced Anxiety Disorder by Inhalants, and disorders related to Inhalants other than unspecified (NOS). Opioid-related disorders include, but are not limited to, Opioid Dependence, Opioid Abuse, Opioid Withdrawal, Opioid Intoxication, Opioid Intoxication Delirium, Psychotic Disorder with Opioid Induced Delusions, Psychotic Disorder with Opioid Induced Alloys, Disorder from
Anxiety Induced by Opioids, and other disorders of other form not specified (NOS).
The Nitio (cyano) vinylpiperazine Compounds can be used to treat or prevent Parkinson's disease, parkinsonism and the symptoms associated with Parkinson's disease.
Parkinson's and parkinsonism, including but not limited to, bradykinesia, muscle rigidity, resting tremors and impaired postural balance. The Nitio (cyano) vinylpiperazine Compounds can be used to treat or prevent generalized or severe anxiety and symptoms associated with anxiety, including, but not limited to, agitation, tension, tachycardia, dyspnea; depression, including depression
"neurotic" chronic; panic disorder; agoraphobia and other specific phobias; eating disorders; and personality disorders. Theo (cyano) vinylpiperazine Compounds can be used to treat or prevent epilepsy, including but not limited to partial epilepsy, generalized epilepsy, and symptoms associated with epilepsy, including, but not limited to, simple partial attacks, jacksonian attacks, complex partial seizures (psychomotor), seizures (grand mal or tonic-clonic seizure) ), petit mal attacks (absence), and status epilepticus. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent infarcts, including, but not limited to, ischemic infarcts and hemorrhagic infarcts. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent an attack, including, but not limited to, infantile spasms, febrile seizures and epileptic seizures. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent a pruritic condition, including, but not limited to, itching product of dry skin, scabs, dermatitis, hepathema, atopic dermatitis, pruritus vulvae et ani, milaria, insect bite, pediculosis, contact dermatitis, drug reactions, urticaria, urticarial pregnancy, psoriasis, lichen planus, lichen simplex chronicus, exfoliating dermatitis, folliculitis, pemphigoid hullosa, or dermatitis caused by contact with fiberglass. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent psychosis, including but not limited to, schizophrenia, including paranoid schizophrenia, hebephrenic or disorganized schizophrenia, catatonic schizophrenia, undifferentiated schizophrenia, schizophrenia of the negative subtype or deficit, and non-deficit schizophrenia; a delirium disorder, including illusory erotomatic subtype disorder, delusional illusory subtype disorder, illusory jealous subtype disorder, persecution delusional subtype disorder, and somatic delirium subtype disorder; and brief psychosis.
The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent a cognitive disorder, including but not limited to delirium and dementia such as multi-infarct dementia, pugilistic dementia, dementia caused by AIDS, and dementia caused by Alzheimer's. The Nitro (cyano) vinyl piperazine Compounds can be used to treat or prevent a memory deficit, including but not limited to dissociated amnesia and fleeting dissociation. The Niteo (cyano) vinylpiperazine Compounds can be used to treat or prevent restricted brain functions, including, but not limited to, that caused by surgery or organ transplant, restricted supply of blood to the brain, injury to the spinal cord, injury to the head , hypoxia, cardiac arrest or hypoglycemia. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent Huntington's disease. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent ALS. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent retinopathy, including but not limited to atherosclerotic retinopathy, atherosclerotic diabetic retinopathy, hypertensive retinopathy, non-proliferating retinopathy and proliferating retinopathy. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent a muscle spasm.
The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent a migraine including, but not limited to, migraine without aura ("common migraine"), migraine with aura ("classic migraine"), migraine without headache, basilar migraine , migraine
familial hemiplegic, migraine infarction, and migraine with prolonged aura.
The Nitio (cyano) vinylpiperazine Compounds can be used to treat or prevent
vomiting, including but not limited to, vomiting product of nausea, dry vomiting (retching)
. . , and regurgitation. The Nitio (cyano) vinylpiperazine Compounds can be used to treat or prevent dyskinesia, including but not limited to, tardive dyskinesia and biliary dyskinesia. The Nitro (cyano) vinylpiperazine Compounds can be used to treat or prevent
or depression, including but not limited to severe depression and bi-polar disorder. Without wishing to be bound by theory, the Requesters believe that the Compounds
Niteo (cyano) vinylpiperazine are antagonists for VR1. The invention also relates to methods for inhibiting VR1 function in a cell which comprises contacting a cell capable of expressing VR1 with an effective amount of a Niteo (cyano) vinyl piperazine Compound to inhibit VR1 function in the cell. East
The method can be used in vitro, for example, as an assay to select cells capable of expressing VR1 and, therefore, useful as part of an assay to select compounds useful for thiazing or preventing pain, UL.a ulcer, IBD, or IBS. The method is also useful for inhibiting VR1 function in a cell in vivo, in animal xm (eg, human xm), by contacting a cell in an animal with an effective amount of a
Nitro (cyano) vinylpiperazine compound. In one embodiment, the method is useful to treat or
prevent pain in an animal that needs it. In another modality, the method is useful
to tiatar or prevent Ul in an animal that needs it. In another embodiment, the method is useful to treat or prevent an ulcer in an animal in need thereof. In another modality, the method is useful to treat or prevent IBD in an animal that needs it. In another modality, the method is useful to tiatar or prevent IBS in an animal that needs it.
Examples of cells capable of expressing VR1 include, but are not limited to, neuronal, cerebral, kidney, urothelial cells, and bladder tissue. Methods for studying VR1 expressing cells are known in the art.
Without-} wishing to be limited by theory, the Applicants believe that the Nitio (cyano) vinylpiperazine Compounds are antagonists for mGluR5.
The invention further relates to methods for inhibiting mGluR5 function in a cell which comprises contacting a cell capable of expressing mGluR5 with an effective amount of a Nitro (cyano) vinyl piperazine Compound to inhibit mGluR5 function in the cell. This method can be used in vitro, for example, as an assay to select cells capable of expressing mGluR5 and, therefore, they are useful as part of an assay for selecting compounds useful for tiatar or preventing pain, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, a pruritus condition, or psychosis. The method is also useful for inhibiting mGluR5 function in a cell in vivo, in an animal (eg, a human), by contacting a cell in an animal with an effective amount of a Nixro Compound (cyano) vinyl piperazine to inhibit mGluR5 function in the cell. In one embodiment, the method is useful to tiatar or prevent pain in an animal that needs it. In another embodiment, the method is useful for treating an addictive disorder in an animal in need thereof. In another embodiment, the method is useful for tiatar or preventing Parkinson's disease in an animal that needs it.
In another modality, the method is useful to treat or prevent parkinsonism in an animal that needs it. In another modality, the method is useful to treat or prevent anxiety in an animal that needs it. In another embodiment, the method is useful for treating or preventing an itching condition in an animal in need of it. In another modality, the method is useful to tiatar or prevent psychosis in an animal that needs it.
Examples of cells capable of expressing mGluR5 are the neuronal and glial cells of the central nervous system, particularly the brain, especially in the nucleus accumbens. Methods for studying cells expressing mGluR5 are known in the art.
Without wishing to be bound by theory, Applicants believe that the Nitio (cyano) vinyl piperazine Compounds are antagonists for mGluRl.
The invention also relates to methods for inhibiting mGluRl function in a cell, which comprises contacting a cell capable of expressing mGluRl with an effective amount of a Nitio (cyano) vinylpiperazine Compound in order to inhibit mGluRl function in the cell. This method can be used in vitro, for example, as an assay to select cells capable of expressing mGluRl and, therefore, they are useful as part of an assay for selecting compounds to tiatar or prevent pain, Ul, an addictive disorder, Parkinson's disease , parkinsonism, anxiety, epilepsy, stroke, an attack, a pruritus condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's disease, ALS, dementia, retinopathy, muscle spasm, migraine, vomiting , dyskinesia, or depression. The method is also useful for inhibiting mGluRl function in a cell in vivo, in an animal (eg, a human), by contacting a cell in an animal with an effective amount of a Compound.
Niteo (cyano) vinylpiperazine. In one embodiment, the method is useful to tiatar or prevent pain in an animal that needs it. In another embodiment, the method is useful to treat or prevent Ul in an animal in need thereof. In another mode, the method is useful to tiatar or prevent an addictive disorder in an animal that needs it. In another modality, the method is useful to treat or prevent Parkinson's disease in an animal that needs it. In another modality, the method is useful to treat or prevent parkinsonism in an animal that needs it. In another modality, the method is useful to tiatar or prevent anxiety in an animal that needs it. In another modality, the method is useful to tiatar or prevent epilepsy in an animal that needs it. In another modality, the method is useful for treating or preventing a heart attack in an animal that needs it. In another modality, the method is useful to treat or prevent an attack on an animal that needs it. In another modality, the method is useful to tiatar or prevent a pruritus condition in an animal that needs it. In another modality, the method is useful to tiatar or prevent psychosis in an animal that needs it. In another embodiment, the method is useful to treat or prevent a cognitive disorder in an animal that needs it. In another modality, the method is useful to tiatar or prevent a memory deficit in an animal that needs it. In another modality, the method is useful to tiatar or prevent restricted brain function in an animal that needs it. In another modality, the method is useful to tiatar or prevent Hxmtington's Korea in an animal that needs it. In another embodiment, the method is useful for treating or preventing ALS in an animal, which needs it. In another embodiment, the method is useful for treating or preventing dementia in an animal in need thereof. In another modality, the method is useful to treat or prevent retinopathy in an animal that needs it. In another embodiment, the method is useful to treat or prevent a muscle spasm in an animal in need thereof. In another embodiment, the method is useful to treat or prevent a migraine in an animal that needs it. In another modality, the method is useful to tiatar or prevent vomiting in an animal that needs it. In another embodiment, the method is useful to treat or prevent dyskinesia in an animal in need thereof. In another embodiment, the method is useful for tiatar or preventing depression in an animal that needs it.
Examples of cells capable of expressing mGluR1 include, but are not limited to, neurons from the Purkinje cerebellum, Purkinje cell (punctate) cells, spinal cord (s) cells of the cerebellum; neurons and neurophil cells of the olfactory bulb glomerulus; cells of the superficial layer of the cerebral cortex; hippocampal cells; thalamic cells; superior coliculus cells; and cells of the core of the spinal cord, triglyminal spinal cord. Methods for studying cells expressing mGluRl are known in the art.
4. 8 THERAPEUTIC / PROPHYLACTIC ADMINISTRATION AND COMPOSITIONS OF THE INVENTION i Due to their activity, the Nitro (cyano) vinyl? Iperazine Compounds are advantageously useful in veterinary and human medicine. As described above, the Niteo (cyano) vinyl piperazine Compounds are useful for treating or preventing a Condition in an animal in need thereof.
When administered to an animal, the Nitro (cyano) vinylpiperazine Compounds can be administered as a component of a composition comprising a pharmaceutically acceptable carrier. The present compositions, which comprise a Nitro (cyano) vinylpiperazine Compound, can be administered orally. The Nitio (cyano) vinyl piperazine Compounds of the invention can also be administered by any other convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous coatings (e.g., oral, rectal, mucosa). and intestinal mucosa, etc.) and can be administered in conjunction with another activated therapeutic agent. The administration can be systemic or local. Several delivery systems are known, for example, encapsulation in liposomes, microparticles, microcapsules, capsules, etc., and can be used to administer the Compound Nitium (cyano) vinylpiperazine.
Methods of administration include, but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, oral, sublingual, intiacerebral, inteavaginal, teansdermal, rectal, inhalation, or topical, particularly to the ears, nose, eyes or skin. The mode of administration is left to the discretion of the physician. In most instances, the administration xesultaxá in the release of Compound Nitio (cyano) vinylpiperazine to the blood system.
In specific modalities, it may be desirable to administer the Compounds
Nitium (cyano) vinylpiperazine locally. This can be achieved, for example, and not by limitation, by local infusion during surgery, topical application, for example, together with a bandage disposed in the wound after surgery, by injection, by means of a catheter, by means of a suppository or enema, or by means of an implant, said implant being of a porous, non-porous or gelatinous material, including membranes, such as silastic membranes, or fibers. In certain modalities, it may be desirable to introduce the Compounds
Nitium (cyano) vinylpiperazine to the central nervous system or gastrointestinal tract through any suitable route, including intiaventiicular, intrathecal, and epidural injection, and enema. Intraventricular injection can be facilitated through an intiaventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.
Pulmonary administration may also be employed, for example, by the use of an inhaler or nebulizer, and formulation with an aerosolizing agent, or via perfusion in a fluorocarbon or synthetic pulmonary surfactant. In certain modalities, the
Nitio (cyano) vinylpiperazine compounds can be formulated as suppositories, with traditional binders and excipients such as triglycerides. In another embodiment, the Nitio (cyano) vinylpiperazine Compounds can be delivered in a vesicle, in particular a liposome (see Langer, Science 249: 1527-1533 (1990) and Treat et al, Liposomes in the Therapy of Influent Disease and Cancer 317-327 and 353-365 (1989)). In yet another mode, the Niteo (cyano) vinylpiperazine Compounds can be delivered under a controlled delivery system or sustained delivery system (see, for example, Goodson, in Medical Applications of Contiolled Relay, supra, vol.2, pp. 115- 138 (1984)). Other systems of controlled and sustained delivery discussed in the publication of
Langer, Science 249: 1527-1533 (1990) can be used. In one embodiment, a bowler can be used (Langer, Science 249: 1527-1533 (1990), Sefton, CRC Crit Ref Biomed, Eng. 14: 201 (1987), Buchwaid et al., Surgery 88: 507 ( 1980), and Saudek et al, N. Engl.
Med. 321. "574 (1989).) In another embodiment, polymeric materials can be used (see
Medical Applications of Controlled Relays (Langer and Wise eds., 1974); Controlled
Drug Bioavailability, Drug Product Design and Performance (Smolen and Ball eds.,
1984); Ranger and Peppas, J. Macromol Sci. Rev. Macromol Chem. 23:61 (1983); Levy et al, Science 228: 190 (1985); During et al, Ann. Neurol. 25: 351 (1989); and Howard et al,
J. Neurosurg. 71: 105 (1989)). In yet another modality, a controlled or sustained system may be placed near a target of the Nitio (cyano) vinyl piperazine Compounds, for example, the spinal column, brain or gastrointestinal tract, such that only a fraction of the dose is required. systemic In one embodiment, the pharmaceutically acceptable carrier is an excipient. Such a pharmaceutical excipient may be a liquid such as water or an oil, including those of petroleum, animal, vegetable or synthetic origin, such as peanut / peanut oil, soybean oil, mineral oil, sesame oil and the like. The pharmaceutical excipient may be saline, acacia gum, gelatin, starch paste, talcum, keratin, colloidal silica, urea and the like. In addition, auxiliary agents, stabilizers, thickeners, lubricants and colorants can be used. In one embodiment, the pharmaceutically acceptable excipient is listed as sterile when administered to an animal. Water is a particularly useful excipient when the Compound Niteo (cyano) vinyl piperazine is administered intravenously. Salt solutions and aqueous dextiosa and glycerol solutions can also be used as liquid excipients, particularly for injectable solutions.
Suitable pharmaceutical excipients also include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycexol monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene, glycol , water, ethanol and the like. The present composition, if desired, may also contain minor amounts of moisturizing or emulsifying agents, or pH buffers. The present compositions may take the form of solutions, suspensions, emulsions, tablets, pills, pellets, capsules, capsules containing liquids, powders, sustained release formulations, suppositories, emulsions, aerosols, sprays, suspensions, or any other form of use. suitable. In one embodiment, the composition was in the form of a capsule (see for example, U.S. Patent No. 5,698,155). Other examples of pharmaceutically suitable excipients are disclosed in Remington's Pharmaceutical Sciences 1447-1676 (Alfonso R. Gennaro ed., 19th ed., 1995), untitled by reference to this document. In one embodiment, the Nitro (cyano) vinylpiperazine Compounds are formulated according to ratin methods as a composition adapted for oral administration in humans. Compositions for oral delivery can be presented, for example, in the form of tablets, lozenges, aqueous or oily suspensions, granules, powders, emulsions, capsules, syrups or elixirs. Oxally-administered compositions may contain one or more agents, for example, sweetening agents such as fructose, aspartame or saccharin; savoring agents such as peppermint, oil of wintergreen or cherry; coloring agents; and preservative agents, to provide a pharmaceutically palatable preparation. Moreover, when in the form of a tablet or a pill, the composition can be coated to delay disintegration and absorption in the gastrointestinal tract thereby providing a sustained action over a prolonged period of time. Selective permeable membranes enveloping the osmotic release active compound are also suitable for compositions administered orally. In these last platforms, fluid from the environment enveloping the capsule is impregnated by the release compound, which swells to displace the agent or agents through an opening. These platforms can provide an essentially zero order release profile as opposed to instant profiles of immediate release formulations. A delayed release material such as glycerol monostearate or glycerol stearate may also be used. Oral compositions may also include standard excipients such as mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, and magnesium carbonate. In one embodiment, the excipients are pharmaceutical grade. In another embodiment, the Nitio (cyano) vinylpiperazine Compounds can be formulated for intravenous administration. Typically, compositions for oral administration comprise an aqueous isotonic buffer. Of necessary sex, the compositions may also include a solubilizing agent. Compositions for intravenous administration may optionally include a local anesthetic such as lignocaine to reduce pain at the site of injection. Generally, the ingredients are provided either separately or mixed in unit doses, for example, as a freeze-dried dry powder or water-free concentrate in a hermetically sealed container such as a blister or sachette indicating the amount of active agent. Where the Nitro (cyano) vinyl piperazine Compounds should be administered by infusion, these can be dispensed, for example, with an infusion bottle containing water or a pharmaceutically sterile pharmaceutical grade saline solution. Where the Nitro (cyano) vinyl piperazine Compounds should be administered by injection, an ampoule of sterilized water for injection or saline may be provided so that the ingredients can be mixed before being administered. The Nitio (cyano) vinyl piperazine Compounds can be administered by means of controlled release or sustained release or by delivery mechanisms known to those skilled in the art. Examples include, but are not limited to, those described in U.S. Patent Nos: 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,566, each of which is included in this document by reference. Such dosage forms can be used to provide sustained or sustained release of one or more active agents using, for example, hydroxopromopomethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination of them to provide the desired release in varying proportions. Suitable contiolated or sustained release formulations known to those skilled in the art, including those described herein, can be readily selected for use with the active ingredients of the invention. Accordingly, the invention encompasses suitable unit doses for oral administration, such as, but not limited to, tablets, capsules and soft capsules, adapted for sustained or sustained release. Controlled or sustained release pharmaceutical compositions may have a common goal of improving drug therapy over that achieved by non-controlled or non-sustained counterparts. In one embodiment, a sustained or sustained delivery composition comprises a minimum amount of a Nitro (cyano) vinyl piperazine Compound to thiart or prevent the Condition or symptom thereof in the minimum of time. The advantages of controlled or sustained release compositions include prolonged activity of the drug, decrease in the frequency of the dose, and greater compliance of the patient. Also, controlled or sustained release compositions can favorably affect the action starting time or other characteristics, such as blood levels of the Nitro (cyano) vinyl piperazine Compound, and thereby reduce the occurrence of adverse side effects. . Controlled or sustained release compositions can, in principle, release an amount of Nitro (cyano) vinylpiperazine Compound that will immediately produce the desired therapeutic or prophylactic effect, and gradually and continuously release other amounts of Nitium Compound (cyano) vinyl piperazine in order to maintain this level of therapeutic or prophylactic effectiveness during a prolonged period of time. To maintain a constant level of Compound N ith (cyano) vinyl piperazm in the cell, the Compound Nitium (cyano) vinyl piperazine can be released from its dosage form at a rate that replaces the amount of Compound Niteo (cyano) vinyl piperazine being metabolized and excreted of the cuefo. Sustained or sustained release of an active ingredient can be stimulated by various conditions, including, but not limited to, changes in pH, changes in temperature, concentration or availability of enzymes, concentration or availability of water, or other physiological or compound conditions . The amount of Compound Nitium (cyano) vinyl piperazine effective for the treatment or prevention of a condition can be determined by standard clinical techniques. Likewise, in vitro or in vivo assays can be optionally employed in order to help identify the optimal dose ranges. The precise dose to be used will also depend on the route of administration, and the seriousness of the condition and can be decided according to the criteria of a doctor and / or the circumstance of each animal. However, effective amounts of effective doses vary from about 0.01 mg / kg of coforal weight to about 2500 mg / kg of coforal weight, although typically they are 100 mg / kg of coforal weight or less. In one embodiment, the effective dose amount varies from about 0.01 mg / kg of coforal weight to about 100 mg / kg of coforal weight of a Compound Nitium (cyano) vinyl piperazine, in another embodiment, of about 0.02. mg / kg of coforal weight at about 50 mg / kg of coforal weight, and in another embodiment, about 0.025 mg / kg of coforal weight at about 20 mg / kg of coforal weight. In one embodiment, an effective dose amount is administered every 24 hours until the
Condition is contiolada. In another modality, an effective dose amount is administered every 12 hours until the condition is controlled. In another modality, an effective dose amount is administered every 8 hours until the Condition is discontinued. In another modality, an effective dose amount is administered every 6 hours until the Condition is discontinued. In another modality, the amount of effective dose is administered every 4 hours until Condition is controlled. The amount of effective dose described in this document refers to the total amount achnitized; that is, if more than one Nitium (cyano) vinyl piperazine Compound is administered, the effective dose amounts correspond to the total amount administered. Where a cell capable of expressing VR1, mGluR5 or mGluR1 is contacted with a Nitio (cyano) vinylpiperazine Compound in vitro, the amount effective to inhibit the receptor function VR1, mGluR5 or mGluR1 in a cell will typically vary between 0.01 μg or less. / L to about 5 mg / L, in one embodiment, from about 0.01 μg / L to about 2.5 mg / L, in another embodiment, from about 0.01 μg L to about 0, 5 mg / L, and in another embodiment, from about 0.01 μg / L to about 0.25 mg / L of a solution or suspension of a pharmaceutically acceptable carrier or excipient. In one embodiment, the volume of solution or suspension comprising the Compound
Niteo (cyano) vinylpiperazine is about 0.01 μL to about 1 mL. In another embodiment, the volume of solution or suspension is around 200 μL. Where a cell capable of expressing VR1, mGluR5, or mGhiR1 is contacted with a Nitium (cyano) vinylpiperazine Compound in vivo, the amount effective to inhibit the receptor function in a cell will typically vary between about 0.01 mg / kg of body weight. coforal at about 2500 mg / kg of coforal weight, although typically it varies from about 100 mg kg of coforal weight or less. In one embodiment, the effective dose amount ranges from about 0.01 mg / kg of coforal weight to about 100 mg / kg of coforal weight of a Niteo (cyano) vinyl piperazine Compound, in another embodiment, about 0.02. mg / kg of coforal weight at about 50 mg / kg of coforal weight, and in another modality, about 0.025 mg / kg of coforal weight at about 20 mg / kg of coforal weight. In one embodiment, an effective dose amount is administered every 24 hours. In another embodiment, an effective dose amount is administered every 12 hours. In another modality, an effective dose amount is administered every 8 hours. In another modality, an effective dose amount is administered every 6 hours. In another embodiment, an effective dose amount is administered every 4 hours. The Nitro (cyano) vinylpiperazine Compounds can be analyzed in vitro or in vivo for the desired therapeutic or prophylactic activity before being used in humans. Animal model systems can be used to demonstrate safety and efficacy.
The methods present for treating or preventing a Condition in an animal in need thereof may further comprise administration to the animal being treated a Nitium Compound (cyano) vinyl piperazine, or other therapeutic agent. In one embodiment, the other therapeutic agent is administered in an effective amount.
The methods present for inhibiting VR1 function in a cell capable of expressing VR1 may also comprise contacting the cell with an effective amount of another therapeutic agent.
The methods present for inhibiting mGluR5 function in a cell capable of expressing mGluR5 may further comprise contacting the cell with an effective amount of another therapeutic agent.
The methods present for inhibiting mGluRl function in a cell capable of expressing mGluRl may also comprise contacting the cell with an effective amount of another therapeutic agent. Effective amounts of other therapeutic agents are known to those skilled in the art. Nevertheless, it is within the scope of the skilled person, to determine the variation of the optimal effective amount of the other therapeutic agent. In one embodiment of the invention, when another therapeutic agent is administered to an animal, the minimum effective amount of the compound teo (cyano) vinylpiperazine is less than would be the minimum effective amount of not having administered the other therapeutic agent. In this modality, without being limited to theory, it is believed that the Nitio (cyano) vinylpiperazine Compounds and the other therapeutic agent act synergistically to tiate or prevent a Condition. The other therapeutic agent may be, but is not limited to, an opioid agonist, a non-opioid analgesic, a non-steroidal anti-inflammatory agent, an anti-migraine agent, a Cox-II inhibitor, an antiemetic, a β-blocker. -adrenergic, an anticonvulsant, an antidepressant, a Ca2 + channel blocker, an anticancer agent, an agent to tiatar or prevent Ul, an agent to teach or prevent an ulcer, an agent to tiatar or prevent IBD, an agent to treat or prevent IBS, an agent for tiatax addictive disorders, an agent for tiatar Parkinson's disease and parkinsonism, an agent to tiatar anxiety, an agent to tiatar epilepsy, an agent to treat a heart attack, an agent to thiatar an attack, an agent for treat xm pruritic condition an agent to treat psychosis, an agent to tittle Korea of Huntington, an agent to tiatar ALS, an agent to teach a cognitive disorder, an agent to teach a migraine, an agent for trafficking V vomiting, xm agent for teatar dyskinesia or an agent to treat depression and mixtures thereof. Examples of useful opioid agonists include, but are not limited to, alfentanil, allylprodin, alphaprodin, anileridin, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextiomoramide, dezocin, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimefeptanol , dimethyl thiambutane, dioxafethyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypetidine, isomethadone, ketobemidone, levorphanol, levofenacillinfuran, lofentanil, meperidine, meptazinol, metazocine, methadone, metopona, morphine, mirofin , nalbuphine, narcein, nicomorphine, norlevorphanol, normetadone, nalorphine, normorphine, nofipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, fenadoxone, fenomorphan, phenazocine, phenoperidine, piminodine, piritramide, proheptazine, promedol, properidin, propiram, prophoxydiphen, sufentanil Tilidine, tramadol, salts fa rmeaceutically acceptable thereof and mixtures thereof. In certain embodiments, the opioid agonist is selected from codeine, hydromorphone, hydrocodone, oxycodone, dihydrocodeine, dihydromorph, morphine, tramadol, oxymorphone, pharmaceutically acceptable salts thereof, and mixtures thereof. Examples of useful non-opioid analgesics include non-steroidal anti-inflammatory agents, such as aspirin, ibuprofen, diclofenac, naproxen, benoxaprofen, flurbiprofen, fenprofen, flubufen, ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin, pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen, thiaprofenic acid, fluprofen, bucilloxic acid, indomethacin, sulindac, tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid, tolfenamic acid, diflurisal, flufenisal , piroxicam, sudoxicam, isoxicam, and pharmaceutically acceptable salts thereof and mixtures thereof. Other suitable non-opioid analgesics include the following chemical classes, non-limiting analgesics, antipyretics, and non-steroidal anti-inflammatory drugs: derivatives of salicylic acids, including aspirin, sodium salicylate, magnesium choline trisalicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, and olsalazine; para-aminophenol derivatives including acetaminophen and phenacetin; type and indene acetic acids, including indomethacin, sulindac, and etodolac; heteroaryl acetic acids, including tolmetin, diclofenac, and ketorolac; antianilic acids (fenamates), including mefenamic acid and meclofenamic acid; enolic acids, including oxicams (piroxicam, tenoxicam), and pyrazolidinediones (phenylbutazone, oxifentartazone); and alkanones, including nabumetone. For a more detailed description of the NSAIDs, see Paul A. Insel, Analgesic-Antipyretic and Anti-inflammatory Agents and Drugs Employed in the Treatment of Gout, in Goodman & Gilman's The Pharmacological Basis of Therapeutics 617-57 (Perry B. Molinhoff and Raymond W. Ruddon eds., 9th ed.1996) and Glen R. Hanson, Analgesic, Antipyretic and Anti-Inflammatory Drugs in Remington: The Science and Practice of Pharmacy Vol II 1196-1221 (AR Gennaro ed., 19th ed., 1995) which are listed in full in this document by reference. Examples of useful Cox-II inhibitors and 5-lipoxygenase inhibitors, as well as combinations thereof, are described in U.S. Patent No. 6,136,839, which is incorporated herein by reference in its entirety. Examples of Cox-II inhibitors include, but are not limited to, rofecoxib and celecoxib.
Examples of useful anti-migraine agents include, but are not limited to, alpiropride, bromocriptine, dihydroergotamine, dolaseteone, ergocomin, ergocorninin, exgocriptine, ergonovine, ergot, ergotamine, flumedroxone acetate, fonazine, ketanserin, lisuride, lomerizine, methylergonovine, methysergide , metoprolol, naratriptan, oxetorone, pizotiline, propranolol, risperidone, rizatriptan, sumatriptan, timolol, teazodone, zolmitriptan, and mixtures thereof. The other therapeutic agent may be an antiemetic agent. Examples of useful antiemetic agents include, but are not limited to, metoclopromide, domperidone, procloferazine, promethazine, clofromazine, trimethobenzamide, ondansetiona, granisectone, hydroxyzine, acetylleucine monoethanolamine, alizapride, azasethione, benzquinamide, bietanautin, bromopride, buclizine, clebopride, cyclizine, dimeritachinate, diphenidol, dolasetiona, meclizine, metallatal, metopimazine, nabilone, oxyperendil, pipamizine, scopolamine, sulpiride, tetiahydrocannabinol, thiethylperazine, thioproperazine, tropisetron, and mixtures thereof. Examples of useful β-adrenergic blockers include, but are not limited to, acebutolol, alprenolol, amosulabol, arotinolol, atenolol, befunolol, betaxolol, bevantolol, bisoprolol, bopindolol, bucumolol, bufetolol, bufxxralol, buniteolol, bupranolol, butidrine hydrochloride, butofilolol. , carazolol, carteolol, carvedilol, celiprolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol, indenolol, labetalol, levobunolol, epindolol, metipranolol, metoprolol, moprolol, nadolol, nadoxolol, nebivalol, nifenalol, nipradilol, oxprenolol, penbutolol, pindolol, practolol , pronetalol, propranolol, sotalol, sulfinalol, talinolol, tertatolol, tilisolol, timolol, toliprolol, yxibenolol. Examples of useful anticonvulsants include, but are not limited to acetylpheneturide, albutoin, alloxidone, aminoglutethimide, 4-amine-3-hydroxybutyric acid, ateolactamide, beclamide, buramate, calcium bromide, carbamazepine, cinromide, clomethiazole, clonazepam, decimemide, dietdione, dimethadione, doxenithioin, eterobarb, etadione, ethosuximide, ethotoin, felbamate, fluoresone, gabapentin, 5-hydroxytryptophan, lamotrigine, magnesium bromide, magnesium sulfate, mephenytoin, mephobarbital, metarbital, metetoin, methsuximide, 5-methyl-5- (3 -phenyantiyl) -hydantoin,
3-methyl-5-phenylhydantoin, naxcobarbital, nimetazepam, nitrazepam, oxcarbazepine, parametadione, phenacemide, phenetarbital, pheneturide, phenobarbital, phensuximide, phenylmethylbarbituric acid, phenytoin, sodium fetenilate, potassium bromide, pregabalin, primidone, progabide, sodium bromide , solanum, strontium bromide, suclofenide, sultiam, tetiantoin, tiagabine, topiramate, trimethadione, valproic acid, valpromide, vigabatrin, and zonisamide. Examples of useful antidepressants include, but are not limited to, binedaline, caroxazone, citalopram, (S) -citalopram, dimethazan, fencamine, indalpine, indeloxazine cloxhydrate, ñofopam, nomifensm, oxytriptan, oxypertin, paroxetine, sertraline, thiazidem, teazodone, benmoxin. , iproclozide, iproniazid, isocarboxazid, nialamide, octamoxin, phenelzine, cotinine, rolicyprine, rolipram, maprotiline, metralindole, mianserin, mirtazepine, adinazolam, amitriptyline, amitriptilinoxida, amoxapine, butriptyline, clomipramine, demexiptiline, desipramine, dibenzepin, dimetacrine, dothiepin, doxepin , fluacizine, imipramine, imipramine N-oxide, iprindole, lofepramine, melitiaceno, metapramine, nortriptyline, noxiptilin, opipramol, pizotyline, propizepine, protriptyline, quinupramine, tianeptine, trimipramine, adrafinil, benactyzina, bupropion, butacetin, dioxadrol, duloxetine, etoperidone, febarbamate, femoxetine, fenpentadiol, fluoxetine, fluvoxamine, hematoporphyrin, hypericin, vofacetoperano, medifoxamina, milnacipran, minaprine, moclobemide, nefazodone, oxaflozane, piberalina, prolintano, pirisuccideanol, ritanserina, roxindole, chlorinated xubidium, sulpiride, tandospirone, tozalinone, tofenacin, toloxatone, thianylcypromine, L-tryptophan, venlafaxine, viloxazine, and zimeldine. Examples of Ca2 + channel blockers include, but are not limited to, bepridil, clentiazem, diltiazem, fendiline, gallopamil, mibefradil, prenylamine, semothiadil, terodiline, verapamil, amlodipine, aranidipine, barnidipine, benidipine, cilnidipine, efonidipine, eldipipine, felodipine, isradipine, lacidipine, lercanidipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine, nitiendipine, cinnarizine, flunarizine, lidoflazine, lomerizine, benciclane, etafenone, phanopharone, and perhexilin. Examples of useful anticancer agents include, but are not limited to, acivicin, aclarubicin, acodazole hydrochloride, acronine, adozelesin, aldesleukin, altretamine, ambomycin, ametantrone acetate, aminoglutethimide, amsacrine, anastrozole, anteamycin, asparaginase, asperlin, azacitidine, azetepa, azotomycin, batystatate, benzodepa, bicalutamide, bisantene hydrochloride, bisnafide dimesylate, bizelesin, bleomycin sulfate, brequinar sodium, biririmine, busulfan, cactinomycin, calusterone, caracemide, carbetimer, carboplatin, carmustine, carubicin hydrochloride, carzelesin, cedefingol, chlorambucil, cirolemycin , cisplatin, cladribine, chrysanthine mesylate, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin hydrochloride, decitabine, dexormaplatin, dezaguanine, dezaguanine mesylate, diazicuone, docetaxel, doxorubicin, doxorubicin hydrochloride, droloxifene, droloxifene cytite, dromostanolone propionate, duazomycin, edateexate , hydrochloride of eflomitin, elsamitiucina, enloplatina, empromato, epipropidina, epirubicin hydrochloride, erbulozole, esorabicin hydrochloride, estramustine, estramustine sodium phosphate, etanidazole, etoposide, etoposide phosphate, etoprine, fadrozole hydrochloride, fazarabine, fenretinide, floxuridine, fludarabine phosphate, fluorouracil, flurocitabine, fosquidone, fostriecin sodium, gemcitabine, gemcitabine hydrochloride, hydroxyurea, idarubicin hydrochloride, ifosfamide, ilmofosin, interleukin II (including recombinant intexleukin II or rLL2), interferon alfa-2a, interferon alfa-2b, interferon alfa-nl , interferon alfa-n3, interferon beta-I a, interferon gamma-I b, iproplatin, irinotecan hydrochloride, lanreotide acetate, letrozole, leuprolide acetate, liarozole hydrochloride, lomethexol sodium, lomustine, losoxantrone hydrochloride, masoprocol, maytansine, hydrochloride of mechlorethamine, megestiol acetate, melengestrol acetate, melphalan, menogaril, mercaptopurine, methotie xato, methotrexate sodium, metoprine, meturedepa, mitindomide, mitocarcin, mitochromin, mitogilin, mitomalcin, mitomycin, mitosper, mitotane, mitoxanthion hydrochloride, myophenolic acid, nocodazole, nogalamycin, ormaplatin, oxisurane, paclitaxel, pegaspargase, peliptmycin, pentamustine, peplomycin sulfate , perfosfamide, pipobroman, piposulfane, piroxantone hydrochloride, plicamycin, plomestan, porfimero sodium, porfiromycin, prednimustine, procarbazine hydrochloride, puromycin, puromycin hydrochloride, phazofurin, riboprine, rogletimide, safingol, safingol hydrochloride, semustine, simtiazene, sodium propafosate , sparsomycin, spirogermanium hydrochloride, spiromustine, spixoplatin, esteeptonigrin, esteeptozocin, sulphenurin, talisomycin, tecogalan sodium, tegafur, teloxantrone hydrochloride, temoporfin, teniposide, teroxirone, testolactone, thiamiprine, thioguanine, thiotepa, thiazofurine, tirapazamine, toremifene citrate, tiestolone acetate, triciri's phosphate bina, trimetrexate, trimetrexate glucuronate, triptorelin, tubulozole hydrochloride, uracil mustard, uredepa, vapreotide, verteporfin, vinblastine sulfate, vincristine sulfate, vindesine, vindesine sulfate, vinepidine sulfate, vinglicinato sulfato, vinleurosina sulfato, vinorelbine tartiato, vinrosidina sulfato, vinzolidina sulfato , vorozol, zeniplatina, zinostatin, zorubicin hydrochloride.
Examples of other anticancer drugs include, but are not limited to, 20-epi-l, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acrylic fulvene; adecipenol; adozelesina; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrografol; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; morphogenetic protein-1 anti-splitting; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; afidicolin glycinate; modulators of the apoptosis gene; regulators apoptosis; Apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azathirosine; Bacatin DI derivatives; balanol Batimastat; BCR / ABL antagonists; benzoclorins; benzoylstaurosporin; beta lactam derivatives; beta-aletine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantiene; bisaziridinyl espermine; bisnafide; bistiaten A; bizelesin; breflate; biririmine; budotitan; butionine sulfoximine; calcipotriol; calfostin C; camptothecin derivatives; canaripox B0-2; capecitabine; carboxamide-amine-triazole; carboxyamidotriazole; CaRest M3; CARN 700; inhidor derived from cartilage; carzelesin; inhibitors casein kinase (ICOS); castanospermine; cecropin B; cetrorelix; clorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine; clomiphene analogues; clotrimazole; colismicin A; colismicin B; combretastatin A4; analogous combretastatin; conagenina; crambescidin 816; crisnatol; cryptophycin 8; Cryptophycin A derivatives; Cure A; cyclopentantiaquinones; Cycloplatam; cipemycin; citaxabine ocphosphate; cytolytic factor; cytostatin; dacliximab; decitabine; deMdrodidemnin B; deslorelin; dexamethasone; dexiphosphamide; dexrazoxane; dexverapamil; diazicuone; didemnin B; didox; diethylonorspermine; dihydro-5-azacytidine; 9-dihydrotaxol; dioxamycin; diphenyl spiromustine; docetaxel; docosanol; dolasetiona; doxifluridine; dxoloxifene; dronabinol; duocarmicin SA; ebselen; ecomustine; edelfosin; Edrecolomab; eflomitin; elemene; emitefur; epirubicin; epristerida; estiamustine analogue; Estiogeho antagonists; Stiogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastima; Finasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphylline; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulina; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosin; ilomastat; imidazoacridones; imiquimod; immunostimulatory peptides; insulin-like factor-1 growth receptor inhibitor; interferon agonists; interferonase; interleukins; iobenguane; iododoxorubicin; 4-ipomeanol; iroplact; irsogladine; isobengazole; isohomohalicondrine B; itasetion; jasplakinolide; kahalalide F; lamelarine-N triacetate; lanreotide; Ieinamycin; lenograstima; lentinan sulfate; leptolstatin; letrozole; leukemia inhibitory factors; alpha leukocyte interferon; -leuprolide + estiogen + progesterone; leuprorelin; levamisole; liarozola; linear analogous polyamine; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricin; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; luteciu texafixin; lyophilin; lytic peptides; Maytansine; Handstatin A; marimastat; masoprocol; maspina; matrilysin inhibitors; inhibitors of metalloproteinase matrix; menogaril; merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; Uneven RNA of double slob; mitoguazone; mitolactol; mitomycin analogues; mitonafide; growth factor fibroblast mycotoxin; mitoxanthione; mofarotene; molgramostim; anticoclonal monoclonal, coronary human gonadotrophin; lipid monophosphoryl cell wall A + myobacterium sk; mopidamol; gene inhibitor for multiple drug resistance; therapy 1 -based suppressor of multiple tumors; anticancer agent of mustard; micaperoxida B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone + pentazocinea; napavina; naphthefin; nartograstim; nedaplatin; nemombicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; Nitric oxide modulators; nitroxide antioxidants; niteulin; O6-benzylguanine; octeeotide; okicenone; oligonucleotides; onapristone; ondanseteona; ondansetrone; oracine; oral cytokine inducer; ormaplatin; osaterone; Oxaliplatin; oxaunomycin; paclitaxel; analogous paclitaxel; paclitaxel derivatives; palauamine; palmitoihhizoxin; pamidronic acid; panaxitriol; panomiphene; parabactin; pazeliptina; pegaspargasa; peldesina; sodium pentosan polysulfate; pentostatin; pentrozole; perflubron; perfosfamide; perilyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocafine hydrochloride; pirarabicin; piritiexim; placetina A; placetina B; inhibidox of activadox plasminogen; platinum complexes; platinum compounds; platinum-triamine complexes; porfimer sodium; porphyromycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; A-based immune protein modulator; inhibitor of protein kinase C, microalgal; inhibitors of tyrosine phosphate protein; inhibitors of nucleoside purine phosphorylase; pufurinsa; pyrazoloacridine; conjugate of pyridoxylated hemoglobin plioxyethylene; raf antagonists; raltitiexed; ramosetron; inhibitors of ras famesil tiansferasa protein; ras inhibitors; ras-GAP inhibitor; demethylated reteliptina; rhenium Re 186 etidxonate; rhizoxin; ribozymes; RH retinamide; rogletimide; rohitukina; romurtida; roquinimex; Rubiginone Bl; ruboxil; safingol; saintopine; SarCNU; sarcophitol A; sargramostima; Sdi 1 mimetics; semustine;
inhibitor 1 derived from senescence; oligonucleotides sense; inhibitors of the translation signal; modulators of the translation signal; simple protein binding agent of the antigenic chain; sizofirana; Sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; Esparfosic acid; Spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; cell root inhibitor; inhibitors of root-cell division; stihadid; inhibitors of esteomelisin; Sulfinosine; vasoactive superactive antagonist of the intestinal peptide; suradista suramin; Swainsonin; synthetic glycosaminoglycans; talimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; Telurapyrilium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetiaclorodecaoxide; tetiazomina; Taliblastine; thiocoraline; thrombopoietin; mimetic theombopoietin; timalfasin; timopoietin antagonist receptor; thymotrinan; Hormone thyroid stimulant; ethyl ethyl etiopufurine; tirapazamine; bicyclic titanocene; topsentin; toremifene; totipotent factor of cellular root; Translation inhibitors; teetinoin; triacetyluridine; triciribine; trimethexate; triptorelin; tiopisetiona; turosteride; tyrosine kinase inhibitors; Tyrphostins; inhibitors
UBC; ubenimex; sine-derived urogenital growth inhibitory factor; urokinase antagonist receptor; vapxeotide; variolin B; vector system, erythrocyte gene therapy; velaresol; veramina; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zipiplatine; zilascorb; and zimatatin stimalamer. Examples of therapeutic agents useful for thiazing or preventing Ul include, but are not limited to, propantheline, imipramine, hyoscyamine, oxybutynin, and dicyclomin. Examples of therapeutic agents useful in treating or preventing an ulcer include antacids such as aluminum hydroxide, magnesium hydroxide, sodium bicarbonate, and calcium bicarbonate; sucralfate; bismuth compounds such as bismuth subsalicylate and bismuth subcytheate; H2 antagonists such as cimetidine, ranitidine, famotidine, and nizatidine; H +, K + - ATPase inhibitors such as omeprazole iansoprazole, and lansoprazole; carbenoxolone; misprostol; and antibiotics such as teteacicline, meteonidazole, thymidazole, clarithromycin, and amoxicillin. Examples of therapeutic agents useful for thiatar or preventing D3D include, but are not limited to, anticholinergic drugs; diphenoxylate; loperamide; deodorized opium dye; codeine; wide range of antibiotics such as methionidazole; sulfasalazine; olsalazine; mesalamine; prednisone; azathioprine; mercaptopurine; and methotrexate. Examples of therapeutic agents useful for thiazing or preventing IBS include, but are not limited to, propantheline; muscarin antagonist receptors such as pirenzapine, methoctiamine, ipratiopium, thioteopium, scopolamine, metscopolamine, homatiopine, homathiopine methyl bromide, and metanyl; and antidiarrheal drugs such as diphenoxylate and loperamide. Examples of therapeutic agents useful to thiatar or prevent an addictive disorder include, but are not limited to, methadone, desipramine, amantadine, fluoxetine, buprenorphine, an opiate agonist, 3-phenoxypyridine, levomethadyl acetate hydrochloride, and serotonin antagonists. Examples of therapeutic agents useful for treating or preventing the disease of
Parkinson's and parkinsonism include, but are not limited to, carbidopa / levodopa, pergolide, bromocriptine, ropinirola, pxamipexole, entacapone, tolcapone, selegiline, amantadine, and trihexyphenidyl hydrochloride. Examples of useful therapeutic agents for treating or preventing anxiety, include, but are not limited to, benzodiazepines, such as alprazolam, brotizolam, clordiazepoxide, clobazam, clonazepam, clorazepate, demoxepam, diazepam, estazolam, flumazenil, flurazepam, halazepam, lorazepam, midazolam , nitiazepam, nordazepam, oxazepam, prazepam, quazepam, temazepam, and triazolam; non-benzodiazepine agents, such as buspirone, gepirone, ipsaprione, thiospirone, zolpicone, zolpidem, and zaleplone; tranquilizers, such as barbiturates, for example, amobarbital, aprobarbital, butabarbital, butalbital, mephobarbital, methohexital, pentobarbital, phenobarbital, secobarbital, and thiopental; and propanediol carbomatos, such as meprobamate and tibamate. Examples of therapeutic agents useful for thiazing or preventing epilepsy include, but are not limited to carbamazepine, ethosuximide, gabapentin, lamotrignin, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, bemzodiaepines, gabapentin, lamotrigine,? -vinyl GABA, acetazolamide, and felbamate Examples of therapeutics useful for teaching or preventing infarcts include, but are not limited to, anticoagulants such as heparin, clot dissolving agents such as streptokinase or tissue plasminogen activator, swelling reducing agents such as mannitol or corticosteroids, and acetylsalicylic acid. Examples of therapeutic agents useful for thiazing or preventing an attack include, but are not limited to, carbamazepine, ethosuximide, gabapentin, lamotrignin, phenobarbital, phenytoin, primidone, valproic acid, trimethadione, bemzodiaepines, gabapentin, lamotrigine,? -vinyl GABA, acetazolamide. , and felbamate. Examples of therapeutic agents useful for thiazing or preventing a pruritic condition include, but are not limited to, naltiexono; nalmefene; Danazol; tricyclics such as amitriptyline, imipramine, and doxepin; antidepressants such as those indicated below, menthol; camphor, phenol, pramoxin, capsaicin, tar; steroids; and antihistamines.
Examples of therapeutic agents useful for thiatar or preventing psychosis include, but are not limited to, phenothiazines such as clofromazine cloxhydrate, mesylazine besylate, and toridazine hydrochloride; thioxanthenes such as chloroprothixene and thiothixene hydrochloride; clozapine; risperidone; olanzapine; quetiapine; quetiapine fumarate; haloperidol; haloperidol decanoate; loxapine succinate; molindone hydrochloride; pimozide; and ziprasidone. Examples of therapeutics useful for thiatar or preventing Huntington's disease include, but are not limited to, haloperidol and pimozide. Examples of therapeutic agents useful for thiazing or preventing ALS include, but are not limited to, baclofen, neuroteopic factors, riluzole, tizanidine, benzodiazepines such as clonazepam and dantrolene. Examples of therapeutic agents useful for thiazing or preventing cognitive disorders include, but are not limited to, agents for thiazing or preventing demensia such as tacrine; donepezil; ibuprofen; antisychotic dxogas such as thioridazine and haloperidol; and anti-depressant drugs such as those indicated below. Examples of therapeutic agents useful for treating or preventing a migraine include, but are not limited to, sumatriptan; methysergide; ergotamine; caffeine; and beta-blockers such as propranolol, verapamil, and divalproex. Examples of therapeutic agents useful for thiazing or preventing vomiting include, but are not limited to, 5-HT 3 antagonist receptors such as ondansetiona, dolasetron, graniseteone, and tropisethione; dopamine antagonist receptors such as procloferazine, tiethylperazine, clofromazine, metoclopramide, and domperidone; glucocorticoids such as dexamethasone; and benzodiazepines such as lorazepam and alprazolam.
Examples of therapeutic agents useful for thiazing or preventing dyskinesia include, but are not limited to, resephine and tetiabenazine. Examples of therapeutic agents useful for treating or preventing depression include, but are not limited to, tricyclic antidepressants such as amitriptyline, amoxapine, bupropion, clomipramine, desipramine, doxepin, imipramine, maprotiline, nefazadone, nortriptyline, protriptyline, thiazodone, thiipipramine, and venlaflaxin.; selective serotonin reukptake inhibitors, such as citalopram, (S) -citalopram, fluoxetine, fluvoxamine paroxetine, and setealine; monoamine oxidase inhibitors such as isocarboxazide, parguin, phenelzine, and thianylcypromine; and psychostimulants such as dextroamphetamine and methylphenidate. A Nitro (cyano) vinyl piperazine Compound and the other therapeutic agent may act together or, in one embodiment, synergistically. In one embodiment a Niteo (cyano) vinyl piperazine Compound is administered concurrently with another therapeutic agent, for example a composition comprising an effective amount of a Nitium Compound (cyano) vinyl piperazine and an effective amount of other therapeutic agent can be administered. Alternatively, a composition comprising an effective amount of a Nitium Compound (cyano) vinyl piperazine and a different composition comprising an effective amount of another therapeutic agent may be administered concurrently. In another embodiment, an effective amount of a Nitium Compound (cyano) vinyl piperazine may be administered before or after administration of an effective amount of another therapeutic agent. In this modality, the Compound Nitio (cyano) vinyl? Iperazine is administered while the other therapeutic agent exerts its therapeutic effect, or the other therapeutic agent is administered while the Compound Nitro (cyano) vinyl piperazine exerts its therapeutic effect to tiatar or prevent a Condition. . A composition of the invention is prepared according to a method comprising mixing a Compound Nitio (cyano) vinylpiperazine and a pharmaceutically acceptable carrier or excipient. The mixture can be achieved using known methods for mixing a compound (or salt) and a pharmaceutically acceptable carrier. In one embodiment the Nitro (cyano) vinyl piperazine Compound is present in the composition in an effective amount.
4. 9 KITS
The invention comprises kits that can simplify the administration of a Nitium (cyano) vinyl piperazine Compound to an animal. A typical kit of the invention comprises unit dose formulation of a Nitium (cyano) vinyl piperazine Compound. In one embodiment, the unit dose is a container, which can be sterile, containing an effective amount of a Niteo (cyano) vinyl piperazine Compound and a pharmaceutically acceptable carrier. The kit may additionally comprise a label or printed instructions instructing on the use of the Compound Nitro (cyano) vinyl piperazine to treat a Condition. The kit may further comprise a unit dose of another therapeutic agent, for example, a second container containing an effective amount of the other therapeutic agent and a pharmaceutically acceptable carrier or excipient. In another embodiment, the kit comprises a container containing an effective amount of a Nitium Compound (cyano) vinyl piperazine, an effective amount of another therapeutic agent, a pharmaceutically acceptable carrier or excipient. Examples of other therapeutic agents include, but are not limited to, those indicated above. Kits of the invention may further comprise a device useful for administering unit dosage forms. Examples of such devices include, but are not limited to, a syringe, a drip bag, a patch, an inhaler and an enema bag. The following examples are set forth to assist in the understanding of the invention and should not be construed as limiting the invention described and claimed herein. Such variations of the invention, including the substitution of all equivalents currently known or developed in the future, which would be within the scope of those skilled in the art, and changes in formulations or changes in experimental design, should be considered of the field of the invention herein uncovered.
. Examples
Examples 1-8 refer to the synthesis of illiterative Niteo (cyano) vinylpiperazine compounds. -
. 1 Example 1: Synthesis of Compound E14 (a)
2,3-dichloropyridine (5) (5g) and piperazine (6) (8 g, 04.5 mmol) (each of which was commercially available from Sigma-Aldrich) was dissolved in 70 mL of DMF. To the resulting solution was added DIEA (12.21 g, 94.5 mmol) and the resulting reaction mixture was allowed to stir at a temperature of about 150 ° C for up to 15 h. Water (100 mL) and ethyl acetate (150 mL) were added to the reaction mixture and the organic phase and the separated aqueous phases. The aqueous phase was extracted with ethyl acetate (about 100 mL / ext.) And the combined ethyl acetate layers. The combined ethyl acetate layers were then washed with water (50 mL), washed with brine (50 mL) and dried (Na2SO). The solvent was removed under reduced pressure to provide a residue that was purified using column chromatography (silica gel eluted with 20% methanol in ethyl acetate) to provide the compound of formula 4 (5.2 g, 81% yield)
4-Zso-β-aniline aniline (1) (0.5 g, 3.6 mmol) and 1,1-bis (methylthio) -2-nitroethylene (H) (0.61 g, 3.6 mmol) (commercially available from Sigma) -Aldrich) were dissolved in ethanol and the resulting solution heated to recirculating temperature for about 2 h. The solvent was removed under reduced pressure to provide a residue which was purified using column chromatography (silica gel with gradient elution of 10% ethyl acetate in hexane to 20% ethyl acetate in hexane) to provide xm compound of formula 3 as a yellow solid (85 mg, 93% delivery).
The compound of formula 3 and a compound of formula 4 were dissolved in 50 ml of ethanol and the resulting solution heated to recirculating temperature for about
2 h. Then, the solvent was removed under reduced pressure to provide a residue.
The residue was purified using column chromatography (silica gel with elution gradient of 20% atyl acetate in hexane to 50% ethyl acetate in hexane) to give Compound E14 (a) as a yellow solid (55 mg, 68% yield) . The identity of Compound E14 (a) was confirmed using 1H NMR and mass spectroscopy (MS).
Compound E14 (a): 1 H NMR (400 MHz CD3OD): d 1.3 (bs, 6H), 2.72 (m, HH), 3.33 (bd, 4H), 3.45 (bd, 4H) 6.72 (s, ÍH), 6.91 (m, ÍH), 7.15 (d, 2H), 7.26 (t, 2H), 7.75 (t, ÍH), 8.22 (t , lH), 11.09 (s, ÍH) ppm.
. 2 Example 2: Synthesis of the Compound The (a)
Compound El (a) was prepared by an analogous procedure to that used to prepare Compound E14 (a) except that 4-tert-butyl aniline (commercially available from Sigma-Aldrich) was used instead of 4-zso-propyl aniline. The identity of Compound E 1 (a) was confirmed using 1 H NMR and MS.
Compound El (a): * H NMR (400 MHz CD3OD): d 1.3 (s, 9H), 3.33-3.75 (bd, 4H),
3.40-3.45 (bd, 4H) 6.72 (s, ÍH), 6.91 (m, ÍH), 7.35 (d, 2H), 7.45 (t, 2H), 7, 65 (t, ÍH), 8.22 (t, 1H), 11.09 (s, lH) ppm.
MS (E?): M / z = 415 (m + l).
. 3 Example 3: Synthesis of Compound 4 Ka)
Compound 41 (a) was prepared by a procedure analogous to that used to prepare Compound El except that 4,5-dichloropyrimidino was used in place of 2,3-dichloropyridino. The identity of Compound E141 (a) was confixed using 1H NMR and
MS.
Compound E141 (a): * H NMR (400 MHz CD3OD): d 1.3 (s, 9H), 3.32-3.34 (bd, 4H), 3.35-3.36 (bd, 4H) 6.72 (s, ÍH), 7.25 (d, 2H), 7.45 (t, 2H), 7.99 (s, ÍH), 8.22 (s, ÍH), 11.19 (s) , ÍH) ppm.
MS (EI): m / z = 416 (m + l).
. 4 Example 4: Synthesis of Compound E7 (a
Compound E7 (a) was prepared by a procedure analogous to that used to prepare Compound E14 (a) except that 4-trifluoromethyl aniline was used in place of 4-z'so-propyl aniline. The identity of Compound E7 (a) was confirmed using 1H NMR and
MS.
Compound E7 (a): ^ NMR ^ OO MHz CD3OD): d 3.25-4.25 (bm, 8H), 5.68 (s, ÍH), 7.23 (m, 1H), 7.35 ( m, 2H), 7.88 (t, 2H), 7.91 (m, HH), 7.22 (t, HH), 10.01 (s, ÍH) ppm.
MS (EI): m / z = 427 (m + l).
. 5 Example 5: Synthesis of Compound E267fa
Compound E267 (a) was prepared by a procedure analogous to that used to make Compound El except that 4,5-dichloro-2-thia-1,3-diazole was used in place of 2,3-dichloropyridino. The identity of Compound E267 (a) was confirmed using 1H
NMR and MS.
Compound E267 (a): H NMR (400 MHz CD3OD): d 1.3 (s, 9H), 3.12-3.14 (bd, 4H), 3.25-3.26 (bd, 4H), 6.25 (s, ÍH), 7.15 (d, 2H), 7.45 (d, 2H), 11.20 (s, ÍH) ppm.
MS (EI): m / z = 422 (m + l).
. 6 Example 6: Synthesis of Elic Compound
Compound El (c) was prepared by a procedure analogous to that used to make Compound El except that (R) -2-methylpiperazine (commercially available from Sigma-Aldrich) was used in. place of piperazine. The identity of Compound El (c) was confirmed using 1H NMR and MS.
Compound El (c): * H NMR (400 MHz CD3OD): d 1.3 (s, 9H), 1.52 (t, 3H), 2.85-2.87 (bm, 2H), 3.25 -3.27 (bm, 3H), 3.68 (s, ÍH), 3.72 (s, ÍH), 6.58 (s, ÍH), 6.75 (m, ÍH), 7.12 ( m, 2H), 7.55 (t, 2H), 7.79 (t, ÍH), 8.25 (s, ÍH), 11.35 (s, ÍH) ppm.
MS (El): m / z = 429 (m + 1).
. 7 Example 7: Synthesis of Compound E43 (a)
Compound E43 (a) was prepared by a procedure analogous to that used to make Compound El except that 2-chloro-3-trifluoromethylpyridino was used in place of 2,3-dichloro-iridino. The identity of Compound E43 (a) was confirmed using 1H NMR and MS.
Compound E267 (a): H NMR (400 MHz CD3OD): d 1.35 (s, 9H), 3.54 (t, 4H), 3.60 (t, 4H), 6.55 (s, ÍH) , 7.12 (m, ÍH), 7.21 (t, 2H), 7.49 (t, 2H), 7.78 (d, ÍH), 8.45 (s, ÍH), 11.05 (s, ÍH) ppm.
MS (EI): m / z = 449 (m + l).
. 8 Example 8: Synthesis of Compound DI (a)
l l < a) tert-Butyl isocyanate, 5, (0.353 g, 2.5 mmol) (commercially available from Lancaster Chemicals of Windham, NH (www.lancastersvnthesis.com)): 4-tert-butyl isothiocyanate, 6, (commercially available from Transworld Chemicals, Inc., of Rockville, MD), and DIEA (0.87 mL, 5 mmol) were dissolved in DMF and the resulting solution stirred for a further 16 h at 25 ° C to provide the compound 7. The reaction was monitored using high pressure liquid chromatography until the reaction was complete. When the reaction was complete, piperazine 4 (0.593 g, 3 mmol) and DIC (0.568 g, 4.5 mmol) were added to the reaction mixture and the reaction mixture was allowed to stir for a temperature of about 18 h around of 25 ° C. The solvent was then removed under reduced pressure to provide a residue. The resulting residue was purified using column chromatography on silica gel eluted with a gradient of 5:95 ethyl acetate: hexane at 20:80 ethyl acetate: hexane to provide Compound Dl (a) as a solid (110 mg, 9% delivery). The identity of Compound Dl (a) was confirmed using 1H NMR and MS.
Compound Dl (a):? NMR (400 MHz CD3OD): d 1.3 (s, 9H), 1.51 and 1.58 (s, 9H), 3.35-3.40 (m, 4H), 3.43-3.48 (m, 4H), 6.85 (dd, lH), 6.95 (2, dH), 7.37 (d, 2H), 7.58 (dd, ÍH), 8.14 (dd, ÍH), 9 , 85 (s, ÍH) ppm.
MS (EI): m / z = 496 (m + l).
. 9 Example 9: Bonding or Bonding of Nifro Compounds (cyanovinylpiperazine to mGluR5
The following test can be used to demonstrate that Nitium (cyano) vinyl piperazine compounds bind or bind to mGluR5 and, therefore, are useful for thiatal or prevente, eg pain.
Cell Culture: Primary glial cell cultures are prepared from 18 day Sprague-Dawley embryo cortices. The cortices are dissected and then dissociated by means of grinding. The resulting homogeneous cell is disposed on the plate on TI 75 flasks pre-coated with poly-D-lysine ((BIOCOAT, commercially available from Becton Dickinson and Company Inc. in Franklin Lakes, NJ) in the Modified Eagle Dulbecco Medium ("DMEM," pH 7.4), buffered with 25 mM HEPES, and supplemented with 15% fetal calf serum ("FCS," commercially available from Hyclone Laboratories Inc. in Omaha, NE), and incubated at 37 ° C and 5% CO2.Following 24 hours, the FCS supplement is reduced to 10%. 'On the sixth day, oligodendrocytes and microglia are removed by strongly striking the contour of the vials One day after this purification step, secondary astiocyte cultures are established by replacing 96 TI-75 coated poly-D-lysine pxe flasks (BIOCOAT) at a density of 65,000 cells / originals in DMEM and 10% FCS. of 24 hours, the astrocytes are washed s with a serum free medium and then cultured in DMEM, without glutamate, supplemented with 0.5% FCS, 20 mM HEPES, 10 ng / mL of epidemial growth factor ("EGF"), 1 mM sodium pyrata, and IX penicillin steeptomycin at pH 7.5 for 3 to 5 days at 37 ° C and 5% CO2. The method allows the expression of mGluR5 receptor by astrocytes, as demonstrated by S. Miller et al., J. Neuroscience 15 (9): 6103-6109 (1995).
Test Protocol: After a 3 to 5 day incubation with EGF, the asteocytes are washed with 127 mM NaCl, 5 mM KCl, 2 mM MgCl2, 700 mM NaH2PO4, 2 mM CaCl2, 5 mM NaHCO3, 8 mM HEPES, 10 mM Glucose at pH 7.4 ("Assay Buffer") and loaded with Fluo-4 dye (commercially available from Molecular Probes Inc. of Eugene, OR) using 0.1 mL of Assay Buffer containing Fh? o-4 ( 3 mM final). After 90 minutes of caxga dyeing, the cells are washed twice with 0.2 mL of Assay Buffer and xesuspended in 0.1 mL of Test Buff. The plates containing the asteocytes are then transferred to a Fluorometric Image Plate Reader ("FLIPR," commercially available from Molecular Devices Coforation of Sunnyvale, CA) for calculation of calcium mobilization flux in the presence of glutamate and in the presence or absence of antagonist. After monitoring the fluorescence for 15 seconds in order to establish a baseline, DMSO solutions containing various concentrations of a Nitium Compound (cyano) vinylpiperazine diluted in Assay Buffer (0.05 mL of 4X solutions for competitive curves) are added to The cell plate and fluorescence is monitored for 2 minutes. 0.05 mL of a 4X glutamate solution (agonist) is then added to each original to provide a final concentration of glutamate in each original of 10 mM. The fluorescence of the plate is then monitored for an additional 60 seconds after the addition of the agonist. The final concentration of DMSO in the assay is 1.0%. In each experiment, the fluorescence is monitored as a function of time and the data analyzed using Microsoft Excel and GraphPad Prism. The dose-response curves are adjusted using a non-linear regression to determine the IC50 value. In each experiment, each data point is determined twice.
. 10 Example 10: In Vivo Tests for the Prevention or Treatment of Pain
Test animals: Each experiment uses rats weighing 200-260 g at the beginning of the experiment. Rats are grouped and have free access to food and water at any time, except before oral administration of a Compound
Nitro (cyano) vinyl piperazine when the food is removed 16 hours before the dose. A control group acts as a comparison for rats treated with a Compound
Nitro (cyano) vinylpiperazine. The carrier of the Compound is administered to the control group
Ñitio (cyano) vinylpiperazine. The volume of carrier administered to the control group is equal to the volume of carrier and Compound Nitium (cyano) vinylpiperazine administered to the test group. Acute Pain: In order to evaluate the actions of the Niteo (cyano) vinylpiperazine Compounds for the treatment or prevention of acute pain, the rapid tail movement test of the rat can be used. The rats are carefully restrained with the hand and tail exposed to a focused beam of radiant heat light at a point 5 cm from the tip using a fast tail movement unit (Model 7360, commercially available from Ugo Basile of Italy). The latencies of the fast tail movements are defined as the interval between the beginning of the thermal stimulus and the rapid movement of the tail. Animals that do not respond within 20 seconds are removed from the fast tail movement unit and assigned a latency delay of 20 seconds. The latencies of fast tail movements are measured immediately before (pre-treatment) and 1, 3, and 5 hours after the administration of a Nitro (cyano) vinylpiperazine Compound. The data are expressed as fast tail movement latency (s) and the maximum possible effect percentage (% MPE), that is, 20 seconds, is calculated as follows:
[(post-administration latency) - (pre-administration latency)]% MPE = "x 100
(20 s pre-management latency)
The rapid tail movement test in rats is described in F.E. D'Amoux et al, "A Method for Determining Loss of Pain Sensation," J. Pharmacol Exp. Ther. 72: 74-79 (1941). Acute pain can also be assessed by measuring the response of the animal to noxious mechanical stimulus by determining the leg withdrawal threshold ("PWT"), as described below.
Inflammatory Pain: In order to evaluate the actions of the Niteo (cyano) vinylpiperazine Compounds for the treatment or prevention of inflammatory pain, Freund's complete adjuvant inflammatory pain model ("FCA") is used. The FCA-induced inflammation of the hind paw of the rat is associated with the development of persistent inflammatory mechanical hyperalgesia and provides reliable predictions of the anti-hyperalgesic action of clinically useful analgesic drugs. (L. Bartho et al, "frrvolvement of Capsaicin-sensitive Neurons in Hyperalgesia and Enhanced, Opioid Antinociception in Inflammation," Naunyn-Schmiedeberg's Archives of Pharmacol 342: 666-670 (1990)). An intiaplanax injection of 50 μL of 50% ACF is administered to the left hind paw of each animal. 24 hours after the injection, the animal is evaluated on its response to noxious mechanical stimulus, determining the PWT, as described below. The rats are then administered a single injection of 1, 3, 10 or
mg / Kg of either a Nitium (cyano) vinylpiperazine Compound; 30 mg / Kg of a control selected from Celebrex, indomethacin or naproxen; or carrier The noxious mechanical stimulus responses are then determined 1, 3, 5 and 24 hours after their administration. The percentage of inversion of hyperalgesia for each animal is defined as:
[(PWT post administration) - (PWT pre-administiación)]% Investment = x 100
[(baseline PWT) - (PWT pre-adnninistiación)]
Neuropathic Dolox: To evaluate the actions of Compounds
Nitro (cyano) vinylpiperazine for the treatment of neuropathic pain, you can use either the Seltzer or Chung model. In the Seltzer model, the neuropathic pain model of partial ligation of the sciatic nerve is used to produce neuropathic hyperalgesia in rats. (Z. Seltzer et al, "A
Novel Behavioral Model of Neuropathic Pain Disorders Produced in Rats by Partial Sciatic
Nexve Injury, "Pain 43: 205-218 (1990).) The partial ligation of the left sciatic nerve is performed under the inhalation of enflurane / O2 anesthesia After the induction of anesthesia, the left thigh of the rat is shaved and the sciatic nerve exposed at the level of the thigh height through a small incision and is carefully isolated from the surrounding connective tissue, in a location near the teoncater just distal to the point where the semitendenous nerves of the posterior biceps branch out from the nerve common sciatic A 7-0 silk suture is inserted into the nerve with a reversible mini-needle with a 3/8 curve firmly attached so that the dorsal 1/3 to Vz of the nerve is dentin-bound. The wound is closed with a single muscle suture (4-0 nylon (Vicryl)) and vetbond tissue glue.After surgery, the wound area is dusted with antibiotic powder.The substitute-treated rats are subjected to a identical surgical procedure except that the sciatic nerve is not manipulated.
After the cirage, the animals are weighed and placed on a warm pad until they recover from anesthesia. The animals are then returned to their cages until the behavior tests begin. The animal is evaluated for its response to noxious mechanical stimulus, determining PWT, as described below, before surgery (baseline), then immediately before and 1, 3, and 5 hours after the administration of drugs to the hind leg of the animal. The hyperalgesia inversion percentage is defined as:
[(PWT post-administration) - (PWT pre-adnninistiación)]
% Investment = '- X 100
[(baseline PWT) - (PWT pre-administering)]
In the Chung model, the neuropathic pain model of spinal nerve ligation is used to produce mechanical hyperalgesia, thermal hyperalgesia and tactile allodynia in rats.
The surgery is carried out under inhalation of isoflurane / O2 anesthesia. After the induction of anesthesia, a 3 cm incision is made and the left paraspinal muscles are separated from their vertebral process at the L4 - S2 levels. The tiansversal L6 process is carefully removed with a pair of small forceps to visually identify the vertebral nerves L4 - L6. The left nerve (s) L5 (or L5 and L¿) is isolated and firmly linked with silk thread. A complete hemostasis is confirmed and the wound sutured using non-absorbent sutures, such as nylon sutures or stainless steel staples. Substituted-teared rats are subjected to an identical surgical procedure, except that the vertebral nerve (s) is not manipulated. After the cirage, the animals are weighed, given a subcutaneous (s.c.) injection of saline or lactose, the area of the wound dusted with antibiotic powder kept on a warm pad until they recover from anesthesia. The animals are then returned to their cages until the behavior test begins. The animals are evaluated for their response to noxious mechanical stimulus, determining PWT, as described below, before the cirage (baseline), then immediately prior to and 1, 3, and 5 hours after they are administered a Compound Nitium (cyano) vinylpiperazine for the animal's left rear leg. The animal can also be evaluated for its response to noxious thermal stimulus or tactile allodynia, as described below. The Chung model for neuropathic pain is described in S.H. Kim, "An Experimental Model for Peripheral Neuropathy Produced by Segmental Spinal Nerve Ligation in the Rat," Pain 50 (3): 355-363
(1992). Response to Mechanical Stimulation as Evaluation of Mechanical Hyperalgesia: The leg pressure test can be used to evaluate mechanical hyperalgesia. For this test, hind leg hindrance thresholds (PWT) to a noxious mechanical stimulus are determined using an analgesimeter (Model 7200, commercially available at Ugo Basile in Italy) as described in C. Stein, "Unilateral Inflation of the Hindpaw in Rats as a Model of Pxolonged Noxious Stimulation: Alterations in
Behavior and Nociceptive Thresholds, "Pharmacol Biochem. And Behavior 31: 451-455
(1988). The maximum weight that can be applied to the rear leg is set at 250 g and the end point is taken as the complete withdrawal of the leg. PWT is determined once for each rat at each time point and only the affected paw (ipsilateral) is tested.
Response to Thermal Stimulation as Evaluation of Thermal Hyperalgesia: The plantar test can be used to evaluate thermal hyperalgesia. For this test, withdrawal latencies of the hind paw to a noxious thermal stimulus are determined using a plantar test apparatus (commercially available at Ugo Basile of Italy) following the
technique described by K. Hargreaves et al, "A New and Semantic Method for Measuring
Thermal Nociception in Cutaneous Hyperalgesia, "Pain 32 (l): 77-88 (1988) .The maximum exposure time is set at 32 seconds in order to avoid tissue damage and any
- Direct withdrawal of the leg of the heat source is taken at this final point. Three «latencies are determined in each period of time and averaged. Only the affected leg
(ipsilateral) is tested. Tactile Allodynia Evaluation: To assess tactile allodynia, the rats are placed in transparent plexiglass compartments with a mesh floor where they are allowed to become habituated for a period of at least 15 minutes. After habituation, a series of von Frey monofilaments are placed on the plantar surface of the left paw
(operated) of each rat. The von Frey monofilament series consist of six monofilaments of increasing diameter, with the smaller diameter fiber presented first.
Five tests are conducted with each strand, each test with approximately 2 minutes of separation. Each presentation lasts a period of 4-8 seconds or until nociceptive withdrawal behavior is observed. Retraction, paw withdrawal or licking of the leg are responses considered as nociceptive behavior.
. 11 Example 11: In Vivo Tests for the Prevention or Treatment of Anxiety The elevated plus maze praeba or the probe-shock concealment test can be used to evaluate the anxiolytic activity of Nitium (cyano) vinyl piperazine compounds in rats and mice.
Praeba de laberinto Elevado Plus: The praeba of elevated plus labyrinth consists of a platform with four sleeves, two open and two closed (50x10x50 cm capped with an open roof). Rats (or mice) are placed in the center of the platform, at the intersection of the four sleeves, facing one of the closed sleeves. The time of stay in the open sleeves vs. Closed sleeves and number of open sleeves entries is recorded. This praeba is conducted before drug administration and again, after drug administration. The results of the test are expressed as the average time spent in open sleeves and the average number of open sleeves. Known anxiolytics increase both the open sleeves time and the open sleeves entry number. The elevated plus maze praeba is described in D. Treit, "Animal Models for the Study of Anti-anxiety Agents: A Reyiew," Neuroscience & Biobehavioral Reviews 9 (2): 203-222 (1985). Praeba for concealment probe-shock: For the probe-shock concealment test, the praeba apparatus consists of a plexiglass box measuring 40x30x40 cm, uniformly covered with approximately 5 cm of bedding material (cat litter absorbing odors) with a small hole at one end through which a shock probe is inserted (6.5 cm long and with a diameter of 0.5 cm). The Plexiglas discharge probe is spirally wrapped with two copper cables through which electrical current is administered. The current is set to 2 mA. Rats are habituated to the praeba apparatus for 30 minutes for 4 consecutive days without the shock probe in the box.
On the day of the test, the rats are placed in a corner of the test chamber after drug administration. The probe was not electrified until the rat touches it with its nose or front legs, at which point the rat receives a brief 2 mA discharge. The praeba period of 15 min begins once the rat receives its first discharge and the probe remains electrified for the remainder of the praeba period. The discharge induces a burial or concealment behavior on the part of the rat. After the first discharge, the length of time the rat spends spraying bed material to or above the probe with its front nose or legs (burial or concealment behavior) is measured as well as the number of discharges that the rat receives from the probe induced by contact. Known anxiolytic drugs reduce the amount of burial or concealment behavior. Also, the rate of rat reactivity to each discharge is recorded on a scale of 4 points. The total immobility time during the praeba period of 15 minutes is used as an index of general activity. The praeba of probe-shock concealment is described in D. Treit, 1985, supra.
. 12 Example 12: In Vivo Tests for the Prevention or Treatment of an Addictive Disorder
The praeba of preference of conditioned place or drug self-administration test can be used to evaluate the ability of Nitro (cyano) vinylpiperazine compounds to attenuate the gratifying properties of known drug abuse. The praeba preferably of conditioned place: The apparatus for praeba preferably of conditioned place consists of two large compartments (45 x 45 x 30 cm) made of wood with a front wall of plexiglass. These two large compartments are clearly different. Doors in the back of each compartment lead to a smaller box (36 x 18 'x 20 cm) made of wood, painted gray, with a mesh roof. The two large compartments differ in terms of shade (white vs. black), level of illumination (the plexiglass door of the white compartment is covered with aluminum foil except for a 7 x 7 cm window), texture (the white compartment has a table 3 cm thick (40 x 40 cm) with nine holes of a diameter of 5 cm equally spaced and black has a mesh floor), and controls of smell (saline in the white compartment and 1 mL of a 10 % acetic acid in the black compartment). In the days of habituation and praeba, the doors to the small box remain open, granting the free rat access to both large compartments. The first session in which a rat is placed in the apparatus is a habituation session and the entrances to the smaller gray compartment remain open giving the rat free access to both large compartments. During habituation, rats generally show no preference for either compartment.
After habituation, the rats are given 6 conditioning sessions. The rats are divided into 4 groups: carrier pre-treatment + carrier (control group), Compound Nitium (cyano) vinylpiperazine pre-treatment + carrier, pre-treatment carrier
+ Morphine, Compound Niteo (cyano) vinylpiperazine pre-treatment + morphine. During each session, the rat is injected with one of the drug combinations and confined to a compartment for 30 minutes. The next day, the rat receives a portadox training
+ carrier and is confined to the other large compartment. Each rat receives three conditioning sessions consisting of 3 combinations-drug compartments and three compartment-carrier pairs. The order of the injections and the compartment / drug pairs are counterbalanced within the groups. On the day of the test, the rats are injected, before the praeba (30 min to 1 hour), with either morphine or a carrier and the rat is placed in the apparatus, the doors to the gray compartment remain open and the rat can explore the entire apparatus for 20 min. The time that remains in each compartment is recorded. Abuse of known drugs increase the time spent in the par-dxoga compartment during the test session. If the Compound Nitium (cyano) vinylpiperazine blocks the range of preference of the place conditioned with morphine (prize), there will be no difference in the residence time on each side in rats pretreated with a Compound Nitro (cyano) vinylpiperazine and the group does not it will be different from the group of rats that were given carrier + carrier in both compartments. The information will be analyzed as the time of permanence in each compartment (pair-combination dxoga vs. pax-carrier). In general, the experiment is repeated with a minimum of 3 doses of a Niteo (cyano) vinylpiperazine Compound. Self-Administered Drug Praeba: The apparatus for self-administered drug praeba is a standard chamber commercially available as an operational conditioning chamber. Before the drug tests begin, the rats are trained to press a lever for a reward in food. Once a stable lever pressure behavior is acquired, the rats are tested to exert pressure on the lever for a drug reward. The rats are implanted with chronic residence jugular catheters for intea venous administration of compounds and allowed to recover for 7 days before the start of training. Experimental sessions are conducted daily for 5 days in 3-hour sessions. Rats are trained to self-administer a known abuse disorder, such as morphine. The rats are then presented with two levers, an "active" lever and an "inactive" lever. Pressing the active lever results in a drug infusion in a fixed ratio program of 1 (FR1) (that is, a lever pressure gives an infusion) followed by a recess period of 20 seconds (indicated by the illumination of a light above the levers). Pressing the inactive lever results in the infusion of excipients. The interpretation continues until the total number of morphine infusions stabilizes within ± 10% per session. Rats are trained to evaluate the effect of pretreatment with Niteo (cyano) vinyl piperazine compounds in the self-administration of drugs. On the day of the test, the rats are pretreated with a Compound Nitio (cyano) vinylpiperazine or excipient and then allowed to self-administer drugs, as usual. If the Nitro (cyano) vinylpiperazine Compound blocks the reward effect of morphine, the rats pretreated with the Compound Nitium (cyano) vinylpiperazine will demonstrate a lower response rate compared to the previous response rate and compared to pre-thiatal rats. with excipients. The information is analyzed according to the change in the number of drug infusions per test session (number of infusions during the test session - number of infusions during the training session).
. 13 Example 13: Functional Assay for Characterizing mGluRl Antagonist Properties Functional assays for the characterization of mGluR 1 antagonist properties are known in the art. For example, the following procedure can be used. A CHO-rat mGluRl cell line is generated using cDNA encoding the rat mGluRl receptor (M. Masu and S. Nakanishi, Nature 349: 760-765 (1991)). The cDNA encoding the mGluRl receptor can be obtained from, for example, Prof. S. Nakanishi (Kyoto, Japan). 40,000 cells / original CHO-rat mGluRl are plated on a tissue plate treated with culture tissue, 96 deposits, light background, black, COSTAR 3409 (commercially available from Fisher Scientific of Chicago, IL) and incubated in an Eagle Medium Modified Dulbecco (DMEM, pH 7.4) supplemented with glutamine, 10% FBS, 1% Pen / Stiep, and 500 μg / mL Geneticin for about 12 hours. The CHO-rat mGluRl cells are then washed and treated with an Optimem medium (commercially available from hrvitrogen, Carisbad, CA) and incubated for 1 to 4 hours before loading the cells with FLUO-4 dye. After incubation, the cell plates are washed with a loading buffer (127 mM NaCl, 5 mM KCl, 2 mM MgCl2, 700 μM, NaH2PO4, 2 mM CaCl2, 5 mM NaHCO3, 8 mM HEPES, and 10 mM glucose, pH 7.4) and incubated with 3 μM FLUO-4 in 0.1 mL of loading buffer for 90 minutes. The cells are then washed twice with 0.2 mL of loading buffer, resuspended in 0.1 mL of loading buffer, and transferred to a FLIPR for flow measurement of calcium mobilization in the presence of glutamate and in the presence or absence of a Compound
Niteo (cyano) vinylpiperazine. To measure the flow of calcium mobilization, the fluorescence is monitored for a period of 15 seconds to establish a baseline and DMSO solutions containing a variety of concentrations of a Nitro (cyano) vinylpiperazine Compound ranging from 50 μM to 0.8 nM. diluted in a bulking agent (0.05 mL of a 4X dilution) are added to cell plates and the fluorescence monitored for about 2 minutes. Then, 0.05 mL of a 4X glutamate solution (agonist) is added to each original to provide a final concentration of glutamate in each original of 10 μM and the fluorescence is monitored for about an additional 1 minute. The final concentration of DMSO in the assay is 1%. In each experiment, the fluorescence is monitored as a function of time and the data are analyzed using a non-linear regression to determine the IC50 value. In each experiment, each data point is determined twice.
. 14? Example 14: Bonding or Compounding of Nitro (cyano) vinylpiperazine Compound to VRl
Methods for demonstrating the ability of a compound to inhibit VR1 are known to those skilled in the art, for example, those methods described in U.S. Patent No. 6,239,267 to Duckworth et al .; U.S. Patent No. 6,406,908 to Mclntyre et al .; or United States Patent No.
6. 335,180 to Julius et al.
Ligación or Union of the Compound El (a) to VRl: Test Protocol
Cloning of Human VRl: Human spinal cord RNA was used
(commercially available in Clontech, Palo Alto, CA). Reverse transcription was performed on 1.0 μg of total RNA, using Reverse Transcriptase Termoscript
(commercially available from Invitrogen) and oligo dT primers as detailed in the product description. Reverse transcription reactions are incubated to
55 ° C for 1 hour, inactivated by heat at 85 ° C for 5 min, and treated with RNase H- a
37 ° C for 20 minutes. The human VR1 cDNA sequence is obtained by comparison of the human genomic sequence, prior to annotation, with the published sequence of the rat. The sequences of the intion are removed and the flanking exonic sequences are joined to generate the hypothetical human cDNA. Primers flanking the human VR1 coding region were designed as follows: primer (primer) forward,
AAGATCTTCGCTGGTTGCACACTGGGCCACA; and primer (first) back,
GAAGATCTTCGGGGACAGTGACGGTTGGATGT. VR1 PCR was carried out in a tenth of the reverse transcription reaction mixture, using Expand Long Tissue Polymers and Expand Buffer 2 in a final volume of 50 μL according to the manufacturer's instructions (Roche Applied
Sciences, Indianapolis, IN). After denaturation at 94 ° C for 2 minutes, the PCR amplification was carried out for 25 cycles at 94 ° C for 15 'seconds, 58 ° C for
seconds, and 68 ° C for 3 minutes, followed by a final incubation at 72 ° C for 7 minutes to complete the amplification. A PCR product of -2.8 kb was isolated gel using 1.0% agarose, Tris-Acetao gel containing 1.6 μg / mL crystal violet and purified with an S.N.A.P. UV-free gel purification kit (commercially available from Invitiogen). The VR1 PCR product was cloned into the pIND / V5-His-TOPO vector (commercially available from Invitiogen) according to the manufacturer's instructions. DNA preparations, restricted digestion of enzymes, and preliminary DNA sequencing were carried out according to standard protocols.
Full-length sequencing confirms the identity of human VR1. Generation of Inducible Cell Lines: Unless otherwise indicated, cell culture reagents were purchased from Life Technologies of Rockville, MD.
HEK293-EcR cells expressing the ecdysone receptor (commercially available from Invitiogen) are cultured in a Growth Medium (Dulbecco's Eagle Medium)
Modified with 10% fetal bovine serum (commercially available from HYCLONE, Logan, UT), lx penicillin streptomycin, lx glutamine, 1 mM sodium pyravate and 400 μg / mL Zeocin (commercially available from Invitiogen)). The VR1-pIND constructs are synthesized from the HEK293-EcR cell line using Fugene teasing reagent (commercially available from Roche Applied Sciences, Basel, Switzerland). After 48 hours, the cells are teased to a Selection Medium (Growth Medium containing 300 μg / mL G418 (commercially available from Invitrogen)). Approximately 3 weeks later, Zeocin / G418 resistant individual colonies are isolated and expanded. In order to identify functional clones, multiple colonies are arranged in 96-well dentio plates and expression is induced for 48 hours using a Selection Medium supplemented with 5 μM ponasterone A ("PonA") (commercially available from Invitiogen). On the day of the assay, the cells are loaded with Fluo-4 (xm calcium-sensitive dye commercially available in Molecular Probes) and the influx of CAP-mediated calcium is measured using a FLIPR, as described below. Functional clones are re-analyzed, expanded and cryopreserved. PH-Based assay: Two days prior to carrying out this assay, the cells were seeded in 96 transparent bottom black plates coated with poly-D-lysine- (commercially available in Becton-Dickinson) at 75,000 cells / originals in a medium of growth containing 5 μM PonA to induce expression. On the day of the assay, plates were washed with 0.2 mL lx Hank's Balanced Salt Solution (commercially available from Life Technologies) containing 1.6 mM CaCl2 and 20 mM HEPES, pH 7.4
("wash buffer"), and loaded using 0.1 mL of wash buffer containing Fluo-4 (3 μM final concentration, commercially available in Molecular Probes). After 1 hour, the cells were washed twice with 0.2 mL of wash buffer and resuspended in 0.05 mL lx of Hank's Balanced Salt Solution containing 3.5 mM CaCl2 and 10 mM Citrate, pH 7.4 ("test buffer"). The plates were then transferred to a FLIPR for testing. Compound El (a) was diluted in the assay buffer, and 50 mL of the resulting solution was added to the cell plates and the solution monitored for 2 minutes. The final concentration of Compound El (a) ranges from about 50 pM to about 3 μM. An agonist buffer (wash buffer flushed with IN HCl to provide a solution with a pH of 5, 5 when mixed 1: 1 with assay buffer) (0.1 mL) is then added to each original, and the plates incubated for an additional 1 minute. The data is collected on the total time course and using Excel and Graph Pad Prism. When tested according to this protocol, Compound El (a) had an IC50 of 290.7 + 67.4 nM (n = 4). Capsaicin-based assay: Two days before carrying out this assay, the cells were seeded in 96 black transparent bottom plates coated with poly-D-lysine- (50,000 cells / originals) in a growth medium containing 5 μM PonA for induce expression. On the day of the assay, the plates were washed with 0.2 mL lx of
Hank's Balanced Salt solution containing 1 mM CaCl2 and 20 mM HEPES, pH 7.4, and the loaded cells using 0.1 mL of wash buffer containing Fluo-4 (final 3 μM).
After one hour, the cells are washed twice with 0.2 mL of wash buffer and resuspended in 0.1 mL of wash buffer. The plates are transferred to a FLIPR for testing. 50 μL of Compound (a), diluted with assay buffer was added to the cell plates and incubated for 2 minutes. The final concentration of Compound El (a) ranges from about 50 pM to about 3 μM. Human VR1 was activated by the addition of 50 μL of capsaicin (400 nM), and the plates were incubated for an additional 3 minutes. The data was collected during the whole period and analyzed using Excel and GraphPad Prism. When tested according to this protocol, Compound El (a) had an IC50 of 92.2 ± 28 nM (n = 3). The results of the pH-based and capsaicin-based assay showed that Compound El (a), an illicitiative Nitro (cyano) vinylpiperazine Compound, binds or binds to and modulates human VR1 activity and, consequently, is useful for tiatar or preventing pain, Ul, an ulcer, D3D or IBS in an animal. The present invention should not be limited in scope by the specific embodiments described in the examples which are intended to illustrate some aspects of the invention and any modalities that are functionally equivalent are within the scope of this invention. Indeed, various modifications of the invention, in addition to those indicated and described in this document, will be apparent to those persons skilled in the art and are intended to be within the scope of the
Claims requested. A number of references have been cited, the descriptions of which are completely unaffected to this document by reference. 2 and a pharmaceutically acceptable vehicle.
Claims (12)
- An is Ar2 is R! is -H, -halo, -CH3, -CN, -NO2, -OCH3, -NH2, -C (halo) 3, -CH (halo) 2, or - 'CH2 (halo); each R2 is independently: (a) -halo, -OH, -NH2, -CN, or -NO2; 5 (b) - (C? -do) alkyl, - (C2-C10) alkenyl, - (C2-C10) alkynyl, - (C3-C10) cycloalkyl, - (C8-C14) bicycloalkyl, - (C8-C14) ) tricycloalkyl, - (C5-C8) cycloalkenyl, - (C8-C1) bicycloalkenyl, - (Cs-C14) tricycloalkenyl, - (3- to 7-chain) heterocycle, or - (7- to 10-chain) bicycloheterocycle, each of which is substituted or not with one or more R5 groups; or (c) -phenyl, -naphthyl, - (C14) aryl or - (5- to 10-cells) heteroaryl, each of which 0 is substituted or not with one or more Re graphers; each R3 is independently: (a) -halo, -OH, -NH2) -CN, or -NO2; (b) - (d-C10) alkyl, - (C2-C10) alkenyl, - (C2-C10) alkynyl, - (C3-C1o) cycloalkyl, - (C8- C14) bicycloalkyl, - (C8-C14) tricycloalkyl , - (C5-C10) cycloalkenyl, - (C8-C! 4) bicycloalkenyl, - (C8-C14) tricycloalkenyl, - (3- to 7-well) heterocycle, or - (7- to 10-5-well) bicycloheterocycle , each of which is substituted or not with one or more R5 staples; or (c) -phenyl, -naphthyl, - (C14) aryl or - (5- to 10-cells) heteroaryl, each of which is substituted or not with one or more Re graphers; RA is -H, -CN, -C (O) O (d-C4) alkyl, O -C (O) NH ((d-C4) alkyl); each R5 is independently -CN, -OH, - (C? -Ce) alkyl, - (C2-C6) alkenyl, - (C -0? C6) alkynyl, -halo, -N3, -NO2, -N (R7 ) 2, -CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O) 2R7; each Re is independently - (d-Ce) alkyl, - (C2-Ce) alkenyl, - (C2-C6) alkynyl, - (C3-C8) cycloalkyl, - (C5-C8) cycloalkenyl, -phenyl, - (3- to 5-carbon) heterocycle, -C (halo) 3, - CH (halo) 2, -CH 2 (halo), -CN, -OH, -halo, -N 3, -NO 2, N (R 7) 2, -CH = NR 7, -NR 7 OH, -OR 7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O) 2R7; each R is independently -H, - (d-C6) alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, - (C3-C8) cycloalkyl, - (C5-Cs) cycloalkenyl, -phenyl, - (3- to 5-capes) hetexocycle, -C (halo) 3, -CH (halo) 2, or CH 2 (halo); each Rs is independently - (d-C6) alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, - (C3-Cs) cycloalkyl, - (C5-Cs) cycloalkenyl, -phenyl, - (3 to 5 characters) heterocycle, -C (halo) 3, -CH (halo) 2, -CH2 (halo), -CN, -OH, -halo, -N3, -NO2, -N (R7) 2, -CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O) 2R7; each halo is independently -F, -Cl, -Br, or -I; m is an integer in a range from 0 to 2; n is an integer in a range from 0 to 3; p is an integer in a range from 0 to 2; q is an integer in a range from 0 to 6; r is an integer in a range from 0 to 5; and s is an integer in a range from 0 to 4.
- 2. Compound of formula (11) (U) or a pharmaceutically acceptable salt thereof, CHARACTERIZED because: An is Ax2 is Ri is -H, -halo, -CH3, -CN, -NO2, -OCH3, -NH2, -C (halo) 3, -CH (halo) 2, or CH2 (halo); each R2 is independently: (a) -halo, -OH, -NH2, -CN, or -NO2; (b) - (C? -do) alkyl, - (C2-C10) alkenyl, - (C2-C10) alkynyl, - (C3-C10) cycloalkyl, - (C8-C14) bicycloalkyl, - (C8-C14) tricycloalkyl, - (C5-C8) cycloalkenyl, - (C8-C14) bicycloalkenyl, - (C8-C1) tricycloalkenyl, - (3- to 7-well) heterocycle, or - (7- to 10-well) bicycloheterocycle, each one of which is substituted or not with one or more R5 staples; or (c) -phenyl, -naphthyl, - (C14) aryl or - (5- to 10-cells) heteroaryl, each of which is substituted or unsubstituted with one or more Re groups; each R3 is independently: (a) -halo, -OH, -NH2, -CN, or -NO2; (b) - (C? -do) alkyl, - (C2-C? 0) alkenyl, - (C2-C! 0) alkynyl, - (C3-C10) cycloalkyl, - (C8-C14) bicycloalkyl, - ( C8-C14) tricycloalkyl, - (C5-C? O) cycloalkenyl, - (C8-C14) bicycloalkenyl, - (C8-C14) tricycloalkenyl, - (3- to 7-well) heterocycle, or - (7- to 10) -colds) bicycloheterocycle, each of which is substituted or not with one or more R5 graphers; or (c) -phenyl, -naphthyl, - (C14) aryl or - (5- to 10-well) heteroaryl, each of which is substituted or not with one or more R groups; R 4 is -H, -CN, -C (O) O (CrC 4) alkyl, O -C (O) NH ((d-C 4) alkyl); each R5 is independently -CN, -OH, - (d-Ce) alkyl, - (C2-Ce) alkenyl, - (C2-C6) alkynyl-halo, -N3, -NO2, -N (R7) 2, - CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O) 2R7; each Re is independently - (d-Ce) alkyl, - (C2-Ce) alkenyl, - (C2-C6) alkynyl, - (C3-C8) cycloalkyl, - (C5-Cs) cycloalkenyl, -phenyl, - (3 - to 5-cells) heterocycle, -C (halo) 3, - CH (halo) 2, -CH2 (halo), -CN, -OH, -halo, -N3, -NO2, N (R7) 2, - CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O) 2R7; each R7 is independently -H, - (d-Ce) alkyl, - (C2-C6) alkenyl, - (C2-C6) alkynyl, - (C3-C8) cycloalkyl, - (C5-C8) cycloalkenyl, -phenyl, - (3- to 5-carbon) heterocycle, -C (halo) 3, -CH (halo) 2, or CH 2 (halo); each R8 is independently - (C1-Ce) alkyl, - (C2-C6) alkenyl, - (C2-Ce) alkynyl, - (C3-C8) cycloalkyl, - (C5-C8) cycloalkenyl, -phenyl, - (3 to 7 cells) heterocycle, -C (halo) 3, -CH (halo) 2, -CH 2 (halo), -CN, -OH, -halo, -N 3, -NO 2, -N (R 7) 2, -CH = NR7, -NR7OH, -OR7, -COR7, -C (O) OR7, -OC (O) R7, -OC (O) OR7, -SR7, -S (O) R7, or -S (O 2R7; each halo is independently -F, -Cl, -Br, or -I; m is an integer in a range from 0 to 2; n is an integer in a range from 0 to 3; p is an integer in a range from 0 to 2; q is an integer in a range from 0 to 6; r is an integer in a range from 0 to 5; and s is an integer in a range from 0 to 4.
- 3. Compound according to Claim 1 or 2, CHARACTERIZED 'because it is - H; Ax! is p or n is 0; month; R! is -halo, -CF3, or -CH3; and Ar2es
- 4. Compound according to Claim 1 or 2, CHARACTERIZED because R 4 is -H; Ax! is p or n is 0; month 1; R i is -halo, -CF3, or -CH3; R3 is methyl; and Ar2es
- 5. Compound according to any of Claims 3-4, CHARACTERIZED because r is 0 or r is 1 and Ar2 is substituted in its SAP.
- 6. Compound according to Claim 5, CHARACTERIZED in that Rs is a group -CF3 or R8 is a group - (C6C6) alkyl, preferably a tert-butyl group. or a zso-propyl group.
- 7. CHARACTERIZED composition because it comprises an effective amount of the compound or a pharmaceutically acceptable salt of the compound according to Claim 1 or 2 and a pharmaceutically acceptable carrier.
- 8. CHARACTERIZED kit because it comprises a container containing an effective amount of the compound or pharmaceutically acceptable salt of the compound according to Claim 1 or 2.
- 9. Method for preparing a composition, CHARACTERIZED because it comprises the step of mixing a compound or a pharmaceutically acceptable salt of the compound according to Claim 1 or 2 and a pharmaceutically acceptable carrier.
- 10. Use of a compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2, characterized in that it serves to prepare xm medicament for the treatment of pain, urinary incontinence, ulcer, irritable bowel syndrome or inflammatory bowel disease.
- 11. Use of a compound or a pharmaceutically acceptable salt thereof according to claim 1 or 2 characterized in that it serves to prepare xm drug to inhibit VR1 function in a cell.
- 12. Use of a compound substantially as demonstrated and illustrated in this document, CHARACTERIZED because it serves for the production of a medicament for the treatment of a condition or disease.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60/533,037 | 2003-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA06007565A true MXPA06007565A (en) | 2006-12-13 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7262194B2 (en) | Therapeutic agents useful for treating pain | |
KR100977242B1 (en) | Piperidine compounds and pharmaceutical compositions containing them | |
KR100896497B1 (en) | Therapeutic agents useful for treating pain | |
US7696208B2 (en) | Therapeutic agents useful for treating pain | |
JP4560610B2 (en) | Therapeutic piperazine compounds | |
JP4621502B2 (en) | A therapeutic agent useful for the treatment of pain | |
WO2004058754A1 (en) | Benzoazolypiperazine derivatives having mglur1- and mglur5-antagonistic activity | |
WO2005030766A1 (en) | Phenyl - carboxamide compounds useful for treating pain | |
EP1664016A2 (en) | Therapeutic agents useful for treating pain | |
ES2322907T3 (en) | USEFUL PIPERAZINAS FOR THE TREATMENT OF PAIN. | |
MXPA06007565A (en) | Piperazines useful for treating pain | |
MXPA06003214A (en) | Phenyl - carboxamide compounds useful for treating pain |